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ABSTRACT 
“The relationship between methylation and genes associated with opioid 
response in humans.” 
Poppy McLaughlin 
Opioids are used to alleviate pain however ~10–30% of the Caucasian population 
obtain ineffective pain relief and / or intolerable side effects. Genetic polymorphisms 
in opioid pharmacodynamic and pharmacokinetic important genes have been 
investigated however there has been a lack of conclusive results. Epigenetic gene 
regulation is another study field of interest. DNA methylation is a gene regulatory 
mechanism that has been associated with gene repression or expression. Thus it was 
hypothesised that variable opioid response was influenced by methylation alterations. 
The promoter region methylation of ABCB1/MDR1, CYP2D6 and OPRM1 genes were 
analysed by pyrosequencing in smoking, opioid exposed and control pilot populations. 
Genetic variations within ABCB1/MDR1, COMT, CYP2B6, CYP2D6 and OPRM1 
genes were also investigated. Tissue opioid concentrations were determined by HPLC-
MS/MS and GC-MS/MS. 
DNA methylation was influenced by chronic opioid exposure and / or the lifestyle 
associated with opioid dependency, but not by cigarette smoke exposure. An increase 
in DNA methylation was observed in the opioid exposed baby population but this was 
not indicative of development of neonatal abstinence syndrome (NAS). Associations 
between the CYP2B6*6 genotype and NAS development were found. No relationship 
was observed between gene methylation and opioid response but variants in OPRM1 
and ABCB1/MDR1 exhibited a relationship with opioid response in cancer pain. 
This investigative pilot research revealed that some genetic variants can be used as 
diagnostic markers to predict susceptibility of methadone exposed babies to NAS 
development, and others are associated with variable opioid response in a cancer 
patient population. Although DNA methylation was not observed to be a contributory 
factor to opioid response, this research has ascertained the influence of chronic opioid 
exposure on DNA methylation of various biological samples. This finding is 
significant for future studies. 
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1.0 INTRODUCTION  
Opioids have been used for centuries, either medicinally to alleviate pain or 
recreationally for their euphoric properties (Kritikos and Papadaki 1967; 
Brownstein et al. 1993; Dikotter et al. 2004; Chou et al. 2009). Despite the long 
history of opioid use / abuse, individual response to opioids is difficult to predict. One 
individual may take a dose of an opioid and obtain adequate analgesia and no side 
effects, conversely another individual on the same dose may obtain only the adverse 
effects of the opioid and none of the benefits (Galer et al. 1992; Skorpen et al. 2008). 
Clinically, and for the purpose of this study, a patient perceived score of ≤ 4 on an 
11 point scale (0 = “no pain”, 10 = “worst pain imaginable”) is considered a good 
response to opioids, as long as the side effect experienced are “none” or “a little”.  
The variable response to opioids has been explained in part by age (Wilder-Smith 
2005; Mercadante 2010), organ dysfunction (King et al. 2011; Neerkin et al. 2012), 
concurrent drug use (Nielsen et al. 2007; Gaertner et 
al. 2012; Tetrault and Fiellin 2012), prior opioid experience (Hay et al. 2008; 
Alford et al. 2013), route of opioid administration (Katz et al. 2011; Daoust et 
al. 2015), as well as genetic variations in genes associated with opioid 
pharmacokinetics (Branford et al. 2012; Somogyi et al. 2015); however these factors 
do not fully account for the variable response.   
Another factor that may contribute to variable opioid response is the epigenetic 
mechanism, DNA methylation. Gene expression is, in part, regulated by DNA 
methylation (Bell et al. 2011; Jones 2012) therefore aberrant methylation in genes 
involved in opioid pharmacokinetics may alter drug response. The aim of this study 
was to recruit pilot populations to help determine the influence of gene DNA 
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methylation on the response to opioid analgesics, as cancer patients who are prescribed 
either morphine or oxycodone do not always obtain the desired effects and on occasion 
obtain severe adverse side effects.  
As DNA methylation is a dynamic mechanism influenced by environmental exposures 
and cellular stress (Doehring et al. 2013; Hammoud et al. 2013; Nestler 2014) control 
populations to determine the effect of smoking and chronic opioid exposure 
on selected opioid genes were investigated. Female smokers and non-smokers 
between the ages of 18 and 50 were recruited from a student and staff population at 
Bournemouth University (n = 96). Once the influence of smoking was ascertained the 
effect of chronic opioid exposure on gene methylation was ascertained in 30 
methadone-prescribed opioid-dependant (MPOD) mothers, who were also smokers. 
The babies of the MPOD mothers provided a unique opportunity to determine the 
effect of in utero methadone exposure on DNA methylation of the opioid related 
genes.  
DNA methylation has been reported to be tissue specific (Davies et 
al. 2012; Sliekar et al. 2013; Lokk et al. 2014) so to determine whether methylation 
changes in peripheral tissues were relevant to gene methylation in tissues where the 
opioids exert their action or are bio-transformed, intra-individual 
tissue DNA methylation differences in blood, liver, psoas muscle and thalamus 
samples was ascertained in ~30 opioid associated deaths. Finally, taking into account 
the findings of the prior studies, the influence of DNA methylation on opioid response 
was determined using a population of opioid naive cancer patients (n = 147).  
The selected genes were the transport protein encoded by the ABCB1/MDR1 gene, the 
metabolising enzyme encoded by the CYP2D6 gene, and the µ-opioid receptor 
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encoded by the OPRM1 gene. ABCB1/MDR1, CYP2D6 and OPRM1 were chosen as 
genetic variations within these genes have been associated with variable drug response 
by previous studies (detailed in 2.1.4.6 Genetic Variations) thus it was plausible that 
gene methylation may also play a role. As genetic variations, such as single nucleotide 
polymorphisms (SNPs) have been associated with variable opioid response, mutations 
within ABCB1/MDR1, COMT (gene that encodes for the metabolising enzyme of 
endogenous opioids), CYP2B6 (gene that encodes for a xenobiotic metabolising 
enzyme), CYP2D6 and OPRM1, it was necessary to investigate these variations 
alongside the gene DNA methylation analysis.  
1.1 Study rationale  
Genetic variations have been associated with variable drug response. Warfarin is the 
common example – SNPs in CYP2C9 and VKORC1 and demographic characteristics 
enable appropriate doses to be prescribed. The Human Genome Project was 
established to map the human genome to gain a better understanding of genes in the 
body. Following its completion in 2003 it was hoped that individuals could be 
prescribed selected drugs at appropriate doses based upon their genetic traits. For 
disorders caused by single gene-defects, such as clotting disorders this has been 
achieved, as with warfarin (Feero et al. 2010; Brenner 2012). However the majority 
of diseases are polygenic which makes predicting drug response more difficult 
(Motulsky and Qi 2006). Not only are multiple genes involved but also body mass 
index (BMI), diet, exercise, concomitant drug use and the epigenetic mechanism DNA 
methylation has been shown to influence the response of drugs, such as tamoxifen. 
Therefore the effect of ABCB1/MDR1, CYP2D6 and OPRM1 methylation on opioid 
response, in conjunction with commonly investigated SNPs was investigated.  
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1.2 Study aim  
The aim of this work was to explore the DNA methylation on the ABCB1/MDR1, 
CYP2D6 and OPRM1 genes to determine whether DNA methylation affected response 
to opioid analgesics.  
1.2.1 Objectives  
 Determine the effect of smoke exposure on DNA methylation of ABCB1/MDR1, 
CYP2D6 and OPRM1 in buccal DNA of female adults.  
 Determine the effect of chronic opioid exposure on DNA methylation of 
ABCB1/MDR1, CYP2D6 and OPRM1 in buccal DNA of female adults and new-
born babies exposed to opioids in utero.  
 Determine the effect of drug dose, mother plasma methadone 
concentrations, gene methylation and polymorphisms on the development 
of neonatal abstinence syndrome (NAS). 
 Determine the methylation profile of ABCB1/MDR1, CYP2D6 and OPRM1 in 
blood, liver, muscle and thalamus samples obtained from opioid exposed and 
opioid naïve adults.  
 Determine the methylation status (and genotype) of opioid responding and opioid 
non-responding cancer patients. 
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2.0   LITERATURE REVIEW 
Genetic and epigenetic variations of the P-glycoprotein transporter (encoded by 
ABCB1/MDR1), the CYP2D6 opioid metabolising enzyme and the µ-opioid receptor 
gene (OPRM1) were investigated in relation to opioid response. In addition, genetic 
variations were also investigated in the COMT and CYP2B6 metabolising enzyme 
genes. To understand the importance of these genes, an introduction to opioids is 
provided including opioid pharmacodynamics and pharmacokinetics. 
2.1 Opioids 
The term “opioid” refers to any chemical with a morphine-like structure and activity 
that exerts its action via opioid receptors (Martin 1967). Activation of the opioid 
receptors, mu (µ), delta (δ) and kappa (ϰ) results in analgesia and decreased 
gastrointestinal (GI) motility; hence the historic use of opioids as a remedy for the 
relief of pain and diarrhoea (Pasternak and Pan 2013). The efficiency of analgesia and 
euphoria, as well as the occurrence and severity of side effects experienced varies 
between different opioids and routes of opioid administration (Benyamin et al. 2008; 
Wolff et al. 2012; Mori et al. 2013; Daoust et al. 2015). 
Substrates of opioid receptors include 1) naturally occurring alkaloids obtained from 
the unripe seed capsules of the opium poppy (Papaver somniferum), 2) semi-synthetic 
drugs, 3) fully synthetic drugs and, 4) endogenous opioid peptides (Trescot et al. 
2008). The earliest known record of the poppy plant being used and cultivated for its 
pharmacological properties dates back to c.4500 BC (Norn et al. 2005; Gussow et al. 
2013). However the first naturally occurring pharmacologically active alkaloid was 
not isolated from raw opium until 1805. This alkaloid was named morphine after 
Morpheus, the Greek god of sleep (Sertürner 1817) and was first sold commercially 
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by Merck in 1827. The profound addictive qualities of morphine were soon realised 
and the search for non-addictive alternatives began (Pasternak and Pan 2013).  
The discovery of morphine led to the identification of other alkaloids within opium, 
the most predominant alkaloids (after morphine) being codeine, noscapine, papaverine 
and thebaine (Spinella 2001). In an attempt to develop drugs with the analgesic 
properties of the opium but without the adverse side effects and addictive properties, 
the chemical structures of the alkaloids were modified producing a wide range of semi-
synthetic opioids such as diamorphine, oxycodone, oxymorphone, buprenorphine and 
naloxone (Rosenblum et al. 2008) (Figure 2-1). Ironically diamorphine, AKA heroin, 
was initially marketed as the opioid to treat morphine addiction; however heroin has 
a quicker onset of opioid action and shorter duration of effects resulting in greater 
addiction (Twycross 1973; Olivieri et al. 1986; Katz et al. 2007).  
During the 20th century numerous fully synthetic opioids were developed for use as 
analgesics but with less abuse / dependence potential (Armstrong et al. 2009; Pathan 
and Williams 2012). Similarly to the semi-synthetic opioids, the majority of synthetic 
opioids have equivalent, or greater abuse potential as the archetypal opioid morphine; 
e.g. meperidine (pethidine), ketobemidone and tramadol (Trescot et al. 2008). 
Synthetic opioids, e.g. methadone and buprenorphine have slower onset of action and 
longer duration and as such are currently used to treat opioid withdrawal (Silverman 
2015a; 2015b); but these opioids can also be misused (Cicero et al. 2014).  
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Figure 2-1. Structures of naturally occurring alkaloids, semi-synthetic and synthetic opioids 
Morphine and codeine are naturally occurring alkaloids; heroin, oxycodone and oxymorphone, 
buprenorphine and naloxone are semi-synthetic opioids; tramadol and methadone are fully synthetic 
opioids. Chemical structures obtained from ChemSpider (http://www.chemspider.com/). 
 
Morphine Codeine 
Oxymorphone Heroin Oxycodone 
Buprenorphine Naloxone 
Tramadol Methadone 
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The current guidelines, suggested by the World Health Organisation (WHO), to 
alleviate pain depends on the extent of the pain.  A pain relief step ladder (Figure 2-2) 
directs the pharmacological management of pain from the use of non-opioids (e.g. 
paracetamol and aspirin) for mild pain (Step I), adding weak opioids (e.g. codeine) for 
moderate pain (Step II), and using regular strong opioids such as morphine, 
oxycodone, hydromorphone, fentanyl and alfentanil for moderate to severe pain (Step 
III) (WHO 1986; WHO 1996). Traditionally morphine is the prototype analgesic to 
alleviate pain because of its availability, cost and familiarity (Hanks et al. 2001; 
Caraceni et al. 2012). However alternative Step III opioids, e.g. oxycodone and 
hydromorphone have similar efficacy and tolerability profiles (Reid et al. 2006; 
Wiffen and McQuay 2007; Hanna and Thipphawong 2008; Caraceni et al. 2011) so 
are plausible first-line analgesics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2. World Health Organisation (WHO) pain step ladder 
WHO proposed the use of non-opioid analgesics for the relief of mild pain, Step I; mild opioids in 
conjunction with non-opioids for mild pain that cannot be relieved by non-opioid analgesics alone, Step 
II; strong opioids in conjunction with non-opioids if necessary to relieve severe pain, Step III. Figure 
obtained from Davis et al. (2007). 
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2.1.1 Opioid adverse effects 
Alongside the advantageous properties of opioids, adverse side effects have been 
reported throughout history, as have the effects of inappropriate dosing 
(Emmanuel and Tschirc 1923; Tamsen et al. 1979; EAPC 1996; Argoff 2010). For 
example, up to 30% of cancer patients on oral morphine for pain are known as 
“morphine non-responders” (Cherny et al. 2001; Ross et al. 2005; Oertel et al. 2006). 
These “morphine non-responders” present in a number of different ways (Mercadante 
and Bruera 2006):  
 Patients who achieve good analgesia but with intolerable side-effects. 
 Patients who do not achieve good analgesia because of dose-limiting side-
effects. 
 Patients who do not achieve good analgesia but do not experience side-effects 
either, despite escalating morphine doses. 
Although most work in this area had been carried out in patients on morphine, inter-
individual variation in response to other strong opioids for pain relief also exists. 
Emerging evidence suggests that there may be two broad groups of opioid non-
responders: 
 Patients who do not achieve an adequate clinical response to the initial opioid 
shortly after initiation, when the opioid dose is relatively low, reflecting that 
not all drugs are efficacious in all patients. “Heterogeneity of treatment effects” 
is seen with most pharmaceutical medications and may be explained in part by 
individual pharmacokinetic or pharmacodynamic factors. 
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 Patients who appear to become non-responsive to the initial opioid at either 
higher doses or after chronic opioid therapy. This may be attributable to the 
development of physical tolerance to the initial opioid (Slatkin 2009). 
Recognition of this substantial inter-individual variation in response to morphine for 
pain relief has resulted in the emergence of "opioid switching" as a clinical manoeuvre 
to redress the balance between analgesia and side-effects. If patients are considered to 
be “non-responders” to the initial opioid, it is common clinical practice to switch them 
to an alternative strong opioid (Quigley et al. 2003; Dale et al. 2011).  
Common opioid side effects include constipation, nausea, vomiting, dry mouth, 
drowsiness, pruritus and dizziness that can have an adverse effect on quality of life 
(Benyamin et al. 2008; Pizzi et al. 2012). Classic µ-opioid receptor agonists such as 
morphine and oxycodone induce nausea and vomiting in approximately 15-30% of 
chronic or acute pain patients (Cherny et al. 2001; Kalso et al. 2004; Moore and 
McQuay 2005). Nausea and vomiting are considered the least desirable side effects of 
opioids from a patient’s perspective (Strassels et al. 2005). The precise mechanism of 
nausea / vomiting induction is unknown however activation of the µ-opioid receptor 
is postulated to be a predominant factor as naloxone, a µ-opioid receptor antagonist, 
can alleviate nausea (Smith and Laufer 2014). Severity of side effects influences 
opioid continuation as an analgesic and fear of side effects can lead to under-dosing 
and inadequate analgesia (Morley-Forster et al. 2003; Arnold 2004; Bhamb et al. 
2006; Benyamin et al. 2008).  
2.1.1.1 Opioid tolerance 
Individuals can be, or can become tolerant to opioids as a result of predetermining 
genetics or acquired through repeated opioid exposure, respectively (Collett 1998; 
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Cepeda-Benito et al. 2005). Tolerance can be a result of pharmacokinetic changes such 
as the up-regulation of metabolic processes by a drug that stimulates its own 
elimination from the body or as a result of pharmacodynamics, when responses within 
the neural system are altered by drugs (Hassan et al. 2013). As a result of the 
development of tolerance, increasing doses of opioids are required to obtain effective 
analgesia (Angst and Clark 2006; Benyamin et al. 2008; Chu et al. 2008). The 
occurrence of tolerance has been shown to be dependent upon the method of 
administration (repeated or continuous) and the efficacy of the opioid on the µ-opioid 
receptor (Pawar et al. 2007; Kumar et al. 2008; Madia et al. 2009). It has been 
postulated that agonists that cause µ-opioid receptor internalisation produce less 
behavioural tolerance than low efficacy agonists (Williams et al. 2013). Morphine is 
a low-efficacy agonist of the µ-opioid receptor and as such tolerance is more likely to 
occur than following administration of high-efficacy agonists, e.g. DAMGO, 
sufentanil, etorphine, methadone (Stevens and Yaksh 1989; Duttaroy and Yoburn 
1995; Madia et al. 2009; Enquist et al. 2012).  
2.1.1.2 Opioid dependence 
Prolonged opioid exposure can lead to physical dependence for the drug (Benyamin 
et al. 2008) and arises in virtually all chronically opioid exposed individuals 
(Ballantyne 2007). Abrupt cessation of drug results in unpleasant withdrawal 
symptoms (Angst and Clark 2006; Kauer and Malenka 2007; Drdla et al. 2009; Heinl 
et al. 2011) and therefore opioid users consume more drug to avoid the prospect of 
withdrawal symptoms (Juurlink and Dhalla 2012). Additionally opioid users may 
consume opioids for their pleasurable effects caused by stimulation of reward centres 
in the brain (Juurlink and Dhalla 2012). Prolonged dependence to chronic opioid 
exposure can cause neurochemical and structural neuronal changes that cause 
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hypersensitivity in the brain’s reward system (Tetrault and Fiellin 2012). This 
hypersensitivity causes the individual to crave more opioid and leads to compulsive 
drug-seeking and drug-taking behaviour (Cami and Farrer 2003). To reduce the 
symptoms of opioid withdrawal, tapering strategies are employed. A slower rate of 
tapering has been demonstrated to reduce the symptoms of opioid withdrawal, e.g. 
initially a 10% reduction per week followed by a 25-50% reduction in opioid (Chou 
et al. 2009). Treatments for opioid dependence include long acting µ-opioid receptor 
agonists such as methadone and buprenorphine, and the antagonist naltrexone that 
block opioid induced euphoria and stabilise drug seeking behaviour (Tetrault and 
Fiellin 2012).  
2.1.2 Opioid pharmacodynamics 
Morphine and other clinically used exogenous opioids preferentially bind to the µ-
opioid receptor and have poor affinity towards δ and ϰ receptors (Börner et al. 2008). 
Therefore, the µ-opioid receptor is the main focus for the remainder of the thesis.  
2.1.2.1 µ-Opioid receptor distribution 
Opioids exert their pharmacological effects by binding to receptors primarily in the 
brain and spinal cord but also in peripheral tissues (Oertel et al. 2008). Various brain 
regions involved in sensory and motor function and central control of nociceptive 
transmission have opioid receptors at their neurons (McDonald and Lambert 2005). 
The expression and distribution of µ-opioid receptors varies between different organs. 
Peripheral organs containing opioid receptors include heart, lungs, liver, gastro-
intestinal (GI) tract (stomach, duodenum, jejunum, ileum and colon) and reproductive 
tracts (Wittert et al. 1996; Villemagne et al. 2002; Bigliardi-Qi et al. 2004; Holzer 
2004; Gray et al. 2005). In addition the µ-opioid receptor is also expressed in immune 
cells such as macrophages and lymphocytes (Bidlack 2000; Vousooghi et al. 2009). 
13 
 
The stimulation of peripherally located receptors, whilst playing a small role in the 
analgesic effect of opioids, are mostly associated with producing the side effects of 
opioids such as reduced GI motility (McDonald and Lambert 2005; Holzer 2012). 
2.1.2.2 µ-Opioid receptor structure 
The µ-opioid receptor is a member of the G-protein-coupled receptor (GPCR) 
superfamily. The µ-opioid receptor is encoded by the OPRM1 located on 6q24-q25 
(Figure 2-3). The receptor consists of seven transmembrane domains, an extracellular 
N-terminus with several glycosylation sites, three intracellular loops, 3 extracellular 
loops and an intracellular C-terminus (Figure 2-3). Exon 1 codes for the first 
transmembrane domain, and exon 2 and 3 code for the second through to seventh 
transmembrane domains (Pasternak 2004) (Figure 2-4).  
 
 
Figure 2-3. Diagrammatic representation of the µ-opioid receptor  
The µ-opioid receptor consists of 7 transmembrane domains that span the cell membrane. N-terminus 
resides in the extracellular space whereas the C-terminus is in the intracellular space. Extracellular loops 
in orange; intracellular loops in blue; TM = transmembrane domain. 
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Figure 2-4. Chromosomal location of OPRM1 and layout of coding exons 
 
2.1.2.3 µ-Opioid receptor signal transduction 
Once opioids interact with the receptor, an intracellular cascade of chemical reactions 
takes place. The binding of a µ-opioid receptor agonist, such as morphine or 
methadone causes a receptor conformational change that stimulates the disassociation 
of guanosine diphosphate (GDP) from the coupled G-protein. The GDP is readily 
replaced by guanosine-5'-triphosphate (GTP) and the G-protein separates into two 
components, α subunit and the β,γ subunit, that stimulate intracellular changes. 
Coupled to µ-opioid receptor is the pertussis toxin sensitive protypical G 
heterotrimeric protein (Gi/Go) that inhibits adenylate cyclase activity, modulates 
neurotransmitter release via ion channel alterations and stimulates signal transduction 
pathways via secondary messengers  (Mostany et al. 2008; Al-Hasani and Bruchas 
2011) (Figure 2-5).  
 
 
Exon                1                                               2                            3                                              4                  
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Figure 2-5. Summary of opioid receptor signalling 
Inactive opioid receptors (a) are coupled to a G-protein made up of three subunits (α, β,γ). In an inactive 
state the receptor is in an open conformation free to bind opioids, calcium channels (yellow and red 
rectangles) are open enabling calcium (Ca2+) to enter the cell and potassium channels (red rectangles) 
are closed inhibiting the extracellular release of potassium (K+). When an opioid (purple hexagon) binds 
the conformation of the receptor alters stimulating the release and disassociation of the coupled G-
protein and simultaneous conversion of GDP to GTP. The disassociated G-protein stimulates the release 
of potassium from the cells and inhibits the entry of calcium into the cell effectively hyperpolarising 
the cell membrane. The hyperpolarisation inhibits the release of neurotransmitters. The disassociated 
G-protein also inhibits the cAMP pathway and activates MAPK signalling pathways. 
 
 
The G-protein subunits inhibit N-type and P/Q type calcium channels and activate 
potassium channels preventing calcium ions entering the intracellular region and 
allowing potassium ions into the extracellular region, respectively (Currie and Fox 
1997; Zamponi and Snutch 2002; Altier and Zamponi 2004; Pérez-Garci et al. 2013). 
The change in ion concentrations causes cellular membrane hyperpolarisation that 
decreases the release of neurotransmitters such as glutamate, acetylcholine, 
norepinephrine, serotonin and substance P. The reduction of neurotransmitters in the 
synaptic cleft reduces the excitability of the nociceptive pathways and brain regions 
involved in pain perception producing an analgesic effect (Oertel and Lotsch 2008). 
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The disassociated G-protein also inhibits adenylyl cyclase activity and therefore the 
cAMP dependant pathway. The Gαi subunit stimulates mitogen-activated protein 
kinases (MAPK) pathways within 5-10 minutes of agonist binding. The MAPK 
pathways are fundamental for cell proliferation, differentiation, channel 
phosphorylation, apoptosis and transcription factor regulation (Raman et al. 2007). 
Members of the MAPK family include: extracellular signal-related kinases 1 and 2 
(ERK1/2), c-Jun N-terminal kinases (JNK1-3) and p38 (α, β, γ, δ) stress kinases. The 
ERK1/2 cascade is the most commonly studied opioid-induced MAPK pathway (Al-
Hasani and Bruchas 2011). Opioid stimulated ERK1/2 pathways modulate and direct 
cell fate determination in embryonic stem cells (Kim et al. 2006; Hahn et al. 2010) 
and inhibit axon/dendrite and synapse formation in astrocytes (Ikeda et al. 2010). 
Activation of the JNK pathway results in increased gene expression of c-Jun which is 
a component of the transcription factor, activator protein-1 (AP-1). The p38 pathway 
is important for response to chemical stimulus and cell proliferation and has been 
shown to play a role in neuropathic pain response (Watkins et al. 2001; Xu et al. 2007).  
2.1.2.4 µ-Opioid receptor desensitisation, recycling, degradation 
Simultaneously to the ion channel modulations, adenylyl cyclase inhibition and 
stimulation of MAPK pathways; the intracellular domain of the µ-opioid receptor 
undergoes G-protein receptor kinase (GRK)-dependent phosphorylation (Figure 2-6). 
GRK phosphorylation is rapid, saturating the receptor in less than 20 seconds 
(Williams et al. 2013) producing binding sites for arrestin molecules (β-arrestin 1 and 
β-arrestin 2). These arrestin molecules bind to the receptor resulting in desensitisation 
as the G-protein binding sites are blocked. Blocking of the G-protein binding sites 
inhibits the µ-receptor intracellular activity, therefore adenylyl cyclase is no longer 
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inhibited, ion channels are not modulated and associated signalling cascades are not 
continued (Dang et al. 2012; Williams et al. 2013).  
 
 
 
 
 
 
 
Figure 2-6. Ligand-specific signalling complexes 
Different opioids affect the signalling and trafficking of opioid receptors. Morphine, a low internalising 
opioid is postulated to desensitise the receptor via β-arrestin 2 and PKC-dependant pathway; whereas 
DAMGO, a high internalising agonist recruits GRK2, β-arrestin 1 and 2, and p38 MAPKs.  Figure 
obtained from Pradhan et al. (2012). 
 
Non-GRKs such as JNK, PKC and p38 MAPK can also phosphorylate the µ-receptor 
(Koch and Hollt 2008). The recruitment of phosphorylating agents is postulated to be 
ligand specific. For example morphine is thought to desensitise the µ receptor via β-
arrestin 2 and PKC-dependant pathways, whereas DAMGO recruits GRK2, β-arrestin 
1 and 2, and p38 MAPKs (Tan et al. 2009a; Groer et al. 2011; Pradhan et al. 2012). 
The desensitisation process is reversed by cellular phosphatases upon removal of the 
agonist. However, after continued exposure to opioids (hours to weeks), µ-receptor 
desensitisation becomes enhanced and the re-sensitisation process impaired leading to 
a lack of agonist responsiveness and development of tolerance (Dang et al. 2012; 
Williams et al. 2013). 
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The phosphorylating agents recruited by the different opioids can alter the receptor’s 
fate. For example as mentioned above, morphine desensitises the receptor via β-
arrestin 2 and PKC-dependant pathway whereas DAMGO and fentanyl phosphorylate 
the receptor more than morphine by GRK2, β-arrestin 1 and 2, and p38 MAPK (Tan 
et al. 2009a; Groer et al. 2011; Pradhan et al. 2012). The binding of GRK2, β-arrestin 
1 and 2, and p38 MAPK complex results in receptor conformational changes enabling 
receptor internalisation, therefore DAMGO and fentanyl have better opioid 
internalisation than morphine (Evans 2004; Kelly et al. 2008). In addition, the opioid 
receptor–arrestin complex is not inactive; the complex stimulates signal transduction 
cascades such as mitogen-activated protein kinase (MAPK) pathways (Lefkowitz and 
Shenoy 2005), as discussed in 2.1.2.3 µ-Opioid receptor signal transduction.  
Knock-in mice expressing a mutant µ-opioid receptor were able to internalise and had 
increased morphine analgesia and reward effects, reduced tolerance, dependence and 
addictive behaviour (Kim et al. 2008; Berger and Whistler 2011). Effects remained 
unchanged in wild-type and mutant mice exposed to methadone (Kim et al. 2008). 
Methadone already has high internalisation properties so analgesic efficacy and 
duration were unchanged, whereas morphine that has poor internalisation properties 
has increased analgesic effect with facilitated internalisation (Pradhan et al. 2012). 
Abuse potential and tolerance towards morphine may in part be due to lack of receptor 
internalisation (Whistler et al. 1999; Finn and Whistler 2001; Koch et al. 2005). 
Agonists of receptor internalisation therefore represent valuable molecular targets for 
more effective analgesics (Berger and Whistler 2010).  
2.1.2.5 µ-Opioid receptor subtypes 
Although clinically used opioids such as morphine, oxycodone and methadone 
preferentially bind to the same receptor (µ), the mechanism of action is different for 
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these different opioids (Crews et al. 1993; Mercadante 1999). In the event of an 
adverse response, a switch to an alternative µ-opioid receptor agonist can alleviate the 
negative effect even though the same receptor is being activated. In addition, 
individuals can develop tolerance to one opioid after prolonged exposure but have 
incomplete cross-tolerance to other opioids (Pasternak 2004; Riley et al. 2006; Dumas 
and Pollack 2008). 
Clinical experiences have reflected the different responses to opioids observed in 
animal studies. CXBK mice with a low number of opioid receptors do not obtain 
analgesic activity from morphine; however their analgesic response to M6G and 
fentanyl is not affected (Rossi et al. 1996; Chang et al. 1998). Also mice tolerant to 
morphine have complete cross-tolerance to codeine but obtain normal analgesic 
response to M6G, heroin and fentanyl (Rossi et al. 1996). A possible explanation of 
this variation in opioid response is the existence of µ receptor subtypes (review by 
Cox et al. 2015).  
Subtypes of the µ-opioid receptor were suggested in the 1980s with the use of opioid 
antagonists (Pasternak et al. 1980; Wolozin and Pasternak 1981). The µ-receptor 
antagonist naloxonazine binds irreversibly and reversibly to the subtypes named µ1 
and µ2 respectively (Hahn and Pasternak 1982; Chaijale et al. 2013). The presence of 
naloxonazine blocked the analgesic effects of morphine but not the side effects which 
suggested that analgesia was achieved through the µ1 subtype, and side effects via the 
µ2 subtype (Ling et al. 1985; Paul and Pasternak 1988; Andoh et al. 2008). However 
knockout of the individual subtypes eliminates all the effects associated with the µ-
receptor implying there was only one µ-receptor gene (Kitchen et al. 1997; Simonin 
et al. 2001; Weibel et al. 2013). Therefore, rather than the existence of µ-receptor 
subtypes Dietis et al. (2011) suggested that, 1) splice variants, 2) receptor 
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dimerization, and 3) receptor-protein complexes contribute to variable opioid 
response. 
2.1.2.5.1 Receptor splice variants 
Three major splice variants can occur in the µ-opioid receptor increasing protein 
diversity (Figure 2-7): 
1) Full-length (7 transmembrane domains) with 3’ splice variant 
This variant has the same 7 transmembrane domains as the wild type receptor (Figure 
2-3) and so has the same opioid-binding pocket. However a splicing at the C-terminal 
yields a unique amino acid sequence that alters agonist-induced G-protein coupling, 
receptor phosphorylation, internalisation and postendocytic sorting (Abbadie and 
Pasternak 2001; Tanowitz et al. 2008; Pasternak 2014).  
2) Truncated variant (6 transmembrane domains) 
The truncated variant lacks exon 1 which encodes the first transmembrane domain 
therefore the variant has only 6 transmembrane domains (Pasternak 2014). The 
expression of this splice variant is controlled by the exon 11 promoter (Pan et al. 2009; 
Majumdar et al. 2012). Mouse knockout studies have shown that the analgesic effect 
of morphine is completely lost when exon 1 is disrupted but full analgesic response 
can be obtained with heroin and M6G if dose is increased. Lack of exon 11 
significantly reduces heroin and M6G activity but not morphine or methadone 
(Schuller et al. 1999; Pan et al. 2009; Xu et al. 2013). 
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3) Single transmembrane domain 
With the loss of exon 2 or the loss of exon 2 and 3 only a single transmembrane domain 
is produced. They do not bind opioids directly however modulate opioid activity by 
increasing expression of the full-length 7 transmembrane variants through a chaperone 
like action (Xu et al. 2013; Pasternak 2014). 
The binding affinities of endogenous and exogenous opioids to the splice variants have 
been investigated and different binding efficiencies and potency of effects have been 
observed. However, the efficiency of binding is not related to potency as opioids that 
have similar binding properties can have very different potencies (Bolan et al. 2004; 
Pasternak 2004; Xu et al. 2009).  
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Figure 2-7. Schematic of the human OPRM1 gene and the MOR-1 splice variants  
Exons and introns are shown by boxes and horizontal lines, respectively. Exons are numbered in the 
order in which they were identified. The approximate sizes of introns (in kb) are indicated. The locations 
of the promoters upstream of exons 11 and 1are indicated. Image adapted from Andersen et al. (2013) 
and Xu et al. (2013). 
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2.1.3 Opioid pharmacokinetics 
2.1.3.1 Absorption and bioavailability 
For opioids to exert their effects they must first enter the systemic circulation and 
permeate blood-tissue membranes to reach the opioid receptors (Figure 2-8). The 
concentration and speed at which the opioid reaches its target sites depends on the 
route of administration, the physiology of the opioid and the extent of first pass 
metabolism. The most common route of opioid administration to alleviate pain is 
orally (Leppert et al. 2013) as it is considered non-invasive, easy to administer and 
has a high patient acceptance (Linardi et al. 2012). However, it is one of the routes 
with the poorest bioavailability, i.e. the proportion of opioid that enters the systemic 
circulation able to exert its effects.  
The poor bioavailability results from incomplete absorption and first pass metabolism. 
Orally administered opioids must first dissolute, cross the gastrointestinal epithelial 
membrane and enter the hepatic portal vein that flows to the liver. The rate of 
absorption through the epithelial membrane is limited by the opioids ionisation, 
lipophilicity and formulation. Morphine, oxycodone and methadone are weak bases, 
pKa 8.0, 8.9 and 8.9 respectively (Moffat et al. 2011), that disassociate into ionised 
(BH+) and non-ionised (B) fractions, the proportions of which depend on the 
surrounding pH. In the stomach, that has a pH of ~2, opioids are highly ionised so are 
poorly absorbed. The pH of the small intestine however is more alkaline increasing 
the proportion of non-ionised fraction. The non-ionised opioids are more lipid soluble 
so can diffuse across the epithelial membrane down a concentration gradient.  
The lipophilicity of an opioid is measured by their octanol-water partition ratio that 
measures the solubility of the opioid in two immiscible phases, i.e. octanol and water. 
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Opioids with a high octanol-water partition ratio are hydrophobic and therefore cross 
the epithelial membrane more readily than opioids with a low octanol-water partition 
ratio. For example morphine and fentanyl have similar pKa values (pH at which the 
proportion of BH+ = B), 8.0 and 8.4 respectively. However fentanyl has a much higher 
octanol-water partition ratio than morphine (Log P = 2.3 and -0.1, respectively (Moffat 
et al. 2011)), which is postulated to explain the shorter time taken for fentanyl to exert 
its effects compared to morphine (Aronoff et al. 2005). Oxycodone and methadone 
have higher octanol-water partition ratios than morphine, 0.7 and 2.1 respectively 
(Moffat et al. 2011).  
The formulations of the opioid preparations can also affect the rate of absorption. 
Morphine is available in immediate release (IR) or sustained release (SR) 
formulations. The sustained release formulations have polymer coatings that encase 
the morphine (capsules) or trap the morphine within the pores of a hydrophilic polymer 
matrix (tablets). For the morphine to be released from the tablets and capsules the GI 
fluids must first breakdown the hydrophilic layers delaying drug absorption and 
therefore prolonging pharmacological response (Amabile and Bowman 2006). 
Opioids in solution have the fastest rate of absorption, followed by drug emulsions, 
suspensions, capsules, tablets, coated tablets, enteric coated tablets and finally 
sustained release tablets.  
Even once the opioid is released from formulation, not all of the absorbed opioid will 
enter the systemic circulation as a result of drug efflux from the enterocytes by P-
glycoproteins (P-gp) and first-pass metabolism that occurs in the gut wall and 
primarily the liver (Smith 2009). Morphine, oxycodone, fentanyl and methadone are 
substrates of P-gp efflux (Henthorn et al. 1999; Dagenais et al. 2004; Hamabe et al. 
2006; Hassan et al. 2007; Ortega et al. 2007; Hassan et al. 2009a, 2009b; Fujita-
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Hamabe et al. 2012) however the extent of interaction with the P-gp varies between 
opioids (Dagenais et al. 2004; Metcalf et al. 2014). Hassan et al. (2009a) incubated 
morphine analogs with a known excess of ATP and recombinant human P-gp. 
Morphine had greater ATP consumption than etorphine and codeine, but all 3 opioids 
had greater ATP consumption than the control demonstrating that they were P-gp 
substrates (Hassan et al. 2009a).  
The opioid antagonists, naloxone and naltrexone however are classified as P-gp non-
substrates (Hassan et al. 2009a). Despite absorption of naloxone and naltrexone not 
being inhibited by P-gp efflux they have poorer bioavailability than the P-gp substrates 
morphine, oxycodone and methadone as a result of extensive hepatic metabolism. 
Approximately 2% of naloxone and naltrexone enters the systemic circulation 
following oral administration (Smith et al. 2012; Goonoo et al. 2014) whereas the 
average bioavailability of morphine, oxycodone and methadone is ~30%, ~60% and 
~75% respectively (Poyhia and Kalso 1992; Hanks et al. 2001; Eap et al. 2002; Moffat 
et al. 2011; Pathan and Williams 2012).  
Opioids that are administered intravenously however have 100% bioavailability as the 
opioid is injected directly into the systemic circulation (Figure 2-8). Sublingual, 
intramuscular, subcutaneous, transdermal (patches and gels), intranasal and rectal (by-
passes 50% of first-pass metabolism) administration of opioids have greater 
bioavailability than oral routes but do not have complete bioavailability as their 
absorption is limited by the ionisation and lipophilicity of the opioid (Narang and 
Sharma 2011; Inui et al. 2012; Krishnamurthy et al. 2012; Leppert et al. 2013; Patel 
et al. 2014). 
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Figure 2-8. Vascular pathway of drugs absorbed from various systemic routes of administration 
and sites of first pass metabolism 
Total drug absorbed orally is subjected to first pass metabolism in intestinal wall and liver, while 
approximately half of that absorbed from the rectum passes through the liver. Drug entering from any 
systemic route is exposed to first pass metabolism in lungs, but its extent is minor for most drugs. Image 
obtained from Tripathi (2013, p. 7).  
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2.1.3.2 Metabolism 
Metabolism is a process of detoxification that converts a drug into a hydrophilic form 
enabling its excretion from the body. The primary site of opioid metabolism is in the 
liver where high densities of phase I and phase II enzymes are situated. CYP enzymes 
are phase I enzymes that metabolise opioids by oxidation and hydrolysis. Phase II 
enzymes metabolise opioids through conjugation with hydrophilic substances, the 
most common of which being glucuronic acid. The process of glucuronidation is 
undertaken by UGT enzymes. Opioids can undergo phase I metabolism, phase II 
metabolism or both. The products formed can be pharmacologically inactive or active, 
and some of the active metabolites can be more potent than the parent compound 
(Smith 2009), e.g. oxymorphone is more potent than oxycodone. 
2.1.3.2.1 Morphine 
Morphine is metabolised to the potent analgesic morphine-6-glucuronide (M6G) and 
non-analgesic morphine-3-glucuronide (M3G) by UGT2B7, and UGT2B7 and 
UGT1A3 respectively (Figure 2-9) (Christrup 1997; Coffman et al. 1997; Green et al. 
1998). M3G is the major metabolite (45-55%), whereas 10-15% of morphine is 
metabolised to M6G and 5% is metabolised to the minor metabolites normorphine, 
normorphine 6-glucuronide, morphine-3, 6-diglucuronide, morphine ethereal sulfate 
and hydromorphone are also formed (Christrup 1997; Coffman et al. 1997; Cone et 
al. 2008; McDonough et al. 2008; Smith 2009). 
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Figure 2-9. Metabolism pathways of morphine 
Morphine is metabolised to the analgesically inactive metabolite M3G and the potent analgesic M6G, 
as well as minor metabolites. 
 
2.1.3.2.2 Oxycodone 
Oxycodone is a substrate for phase I CYP enzymes. CYP3A4 and CYP3A5 metabolise 
oxycodone to the major metabolite noroxycodone that has no analgesic activity 
(Figure 2-10). A small proportion of oxycodone is metabolised by CYP2D6 to 
oxymorphone that is a potent analgesic (Lalovic et al. 2004; Lalovic et al. 2006; Smith 
2009). Oxymorphone is inactivated by glucuronidation (Smith 2009). 
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Figure 2-10. Metabolism pathways of oxycodone 
Oxycodone is metabolised to the analgesically inactive metabolite noroxycodone and the potent 
analgesic oxymorphone. 
 
2.1.3.2.3 Methadone 
Methadone has no active metabolites; instead it undergoes N-demethylation by 
CYP3A4, CYP2B6, CYP2C19, CYP2D6 and CYP2C8 to the inactive metabolites 2-
ethyl-1, 5-dimethyl-3, 3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3, 3-
diphenylpyrroline (EDMP)(Figure 2-11) (Kharasch et al. 2004; Totah et al. 2008; 
Chang et al. 2011; Kharasch and Stubbert 2013). 
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Figure 2-11. Metabolism pathways of methadone 
Methadone is metabolised EDDP and EDMP by CYP450 enzymes. 
 
2.1.3.3 Distribution 
Opioids that enter the systemic circulation are transported around the body to organs 
to exert their pharmacological effects, to be stored, to be metabolised and to be 
excreted. The rate of blood flow to a tissue, the volume of the tissue and presence of 
protective barriers influence opioid distribution. Drugs are distributed first to the liver, 
kidneys, lungs, heart and brain that have a good blood supply, then to adipose tissues, 
bones and teeth that have a lesser blood supply (Sanders et al. 2011, p. 287). However 
the concentration and rate at which opioids distribute into tissues such as the brain, 
cerebrospinal fluid, placenta and the vitreous humor is influenced by protective 
barriers. The blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier 
(BCSFB) lack pores or gaps between the endothelial cells and has an additional 
continuous basement membrane consisting of astrocytes that modulate tissue 
EDMP 
CH2CH3 
EDMP 
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EDDP 
CHCH3 
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permeability (Redzic 2011; Tournier et al. 2011). These barriers also contain 
transporters and enzymes that impede the free diffusion of drugs from blood into the 
brain and CSF (Redzic 2011). In particular, the P-gp ATP-binding cassette 
B1/multiple drug resistance 1 (ABCB1/MDR1) transports morphine, oxycodone and 
methadone from the endothelial cells back into systemic circulation (Wyman and 
Bultman 2004; Dumas and Pollack 2008; Hassan et al. 2009b).  
The occurrence and rate of tissue penetration is dependent upon the physiology of the 
opioid, e.g. ionisation and lipophilicity, as discussed above (2.1.3.1 Absorption and 
bioavailability). Additionally the extent of opioid-protein binding influences tissue 
distribution. The protein bound fraction of opioid, be it within the plasma or binding 
to proteins within opioid permeable tissues, is too large to diffuse through cell 
membranes therefore inhibiting distribution. However a constant ratio between protein 
bound and unbound opioid is maintained within the plasma and between the tissues 
(Figure 2-12). When unbound (free fraction) opioid is redistributed into the tissues, 
metabolised or excreted, bound drug disassociates from plasma proteins to maintain 
the ratio (Lehman-McKeeman 2013, p. 169).  
The ratio varies between different opioids, for example 15-35% of morphine is protein 
bound, predominately to albumin (Leow et al. 1993; Ederoth et al. 2004), oxycodone 
is 45% protein bound (Gallego et al. 2007) and methadone is highly bound to α1-acid 
glycoprotein (70-87%) (Kharasch et al. 2009; Parmar and Parmar 2013). The greater 
the extent of protein binding, the longer the delay in onset of action and the longer the 
duration of drug action is observed. The action of methadone, which is highly protein 
bound, is experienced 30-60 minutes following administration and may last up to 48 
hours whereas the action of immediate release formulations of morphine and 
oxycodone occur after 15-30 minutes and last 4-6 hours.  
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Figure 2-12. Schematic depiction of free drug movement through blood-tissue membranes 
Only free drug can pass through blood-tissue membranes. However, as the concentration of free drug 
decreases (through metabolism, distribution and excretion) the ratio of free drug and protein bound drug 
is maintained by the disassociation of drug from proteins. This disassociation provides free drug that 
can pass through membranes. Image adapted from Tripathi (2013, p. 10). 
 
2.1.3.4 Elimination 
Opioids are removed from the body primarily through kidney secretion but also via 
the bile. Through the kidneys ~10% of the original dose of morphine, oxycodone and 
methadone is excreted as unchanged drug and the remainder as metabolites (Moffat et 
al. 2011). Following filtration from the glomerulus into the convoluted tubules of the 
kidney nephrons, opioids can be reabsorbed into the peritubular capillaries leading to 
the renal vein (Sim 2015). The proportion of opioids excreted via the kidneys is 
dependent upon urinary pH and the ionisation of the opioid. The reabsorption of 
morphine, oxycodone and methadone rises with increasing urine alkalinity (Nilsson et 
al. 1982). The increased reabsorption reduces the plasma clearance rate thereby 
increasing the half-life of the opioid prolonging its duration of effects. In addition to 
renal absorption, the prolonged effects of opioids are also attributable to the 
reabsorption of opioid from the gastrointestinal tract, referred to as enterohepatic 
circulation (Hanks and Wand 1989). 
2.1.4 Factors that influence opioid response 
Inter-individual variation in response to opioids may be a result of factors such as age, 
gender, disease and lifestyle that affect the pharmacodynamic and pharmacokinetic 
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properties of a drug. A recent study of over 2000 patients suggested that psychological 
issues and sleep deprivation may also play a role in opioid response (Knudsen et al. 
2011). To date no clinical factors (with the exception of renal impairment) have been 
identified which can be used prospectively to predict opioid response in this cohort. 
Therefore there is a growing interest in the possibility that an individual’s genetic 
makeup may influence opioid response. 
2.1.4.1 Age and opioid response 
Individuals greater than 60 - 70 are more sensitive to analgesics as a result of age 
related changes in pharmacokinetics and pharmacodynamics (Mercadante and Acuri 
2007). Normal pharmacological changes associated with aging include slowing of the 
GI, reduction in total body water content and fat-free mass and decreased glomerular 
filtration and hepatic flow (Chau et al. 2008; Reisner 2011; Mercadante 2010). As a 
result of these pharmacological changes the absorption of opioids and elimination is 
reduced resulting in extended duration or action of drug (Mercadante 2010). 
The opioid response in neonates is also different from older children and adults as a 
result of changes in body composition, liver mass, metabolic activity, renal function 
and CNS structure and function (Marsh et al. 1998; Tayman et al. 2011). The rate of 
drug absorption via enteral routes in neonates is slower than that of adults as a result 
of reduced rate of gastric emptying, slower GI transit time and reduced intestinal 
surface area (Dumont and Rudolph 1994; Carlos et al. 1997; Menard 2004). The rate 
of distribution however is increased because neonates have a higher body water 
percentage than adults increasing the volume of distribution of hydrophilic drugs 
(Kearns et al. 2003; Rakhmanina and van der Anker 2006). Neonates also have a larger 
fraction of free drug as the quantity of plasma proteins in neonate blood is less than 
that in an adult (Kearns et al. 2003). The quantity of free drug influences the clearance 
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rate, volume of distribution and half-life of the drug. Additionally protective tissue 
barriers, such as the BBB are not completely matured and therefore are permeable to 
drugs (Mahmood 2008). Biotransformation of drugs is also less than that of adults as 
the presence and activity of UGT enzymes and CYP450 enzymes is reduced in 
neonates (de Wildt et al. 1999; Gow et al. 2001; Johnson et al. 2001; Hines and 
McCarver 2002; Hines 2008). Finally, neonate kidneys are anatomically and 
functionally immature and therefore their elimination rate is lower than that of adults 
(Yared and Ichikawa 1994; Hua et al. 1997; Kearns 2003). As a result of reduced 
absorption rate, reduced elimination and greater distribution of drug to target sites, 
neonates experience extended duration of drug action (Tayman et al. 2011). 
2.1.4.2 Organ dysfunction 
Opioids such as morphine and oxycodone are excreted via the kidneys, therefore in 
individuals with renal impairment drug accumulation can occur causing opioid 
sensitivity (Murphy 2005; Johnson 2007; Neerkin et al. 2012). The extent of renal 
impairment influences the choice of opioid as well as the recommended dose. King et 
al. (2011) undertook a systematic review of the literature and concluded that opioids 
such as fentanyl, afentanil and methadone are the least likely to cause harm whereas 
morphine causes toxicity in renal impairment (King et al. 2011).  
2.1.4.3 Choice, dose and route of opioid administration 
The choice of opioid, dose and route of administration alters the rate and duration of 
analgesic/euphoric effect and influences the occurrence and severity of side effects 
(Benyamin et al. 2008; Wolff et al. 2012; Mori et al. 2013; Daoust et al. 2015). For 
example between 0.3-1.5 mg of IV administered hydromorphone, oxymorphone and 
buprenorphine are required to achieve the same analgesic effect as 10mg of IV 
morphine, whereas higher doses of IV meperidine (75mg) are needed (Vallejo et al. 
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2011). The route of drug administration influences the peak effect of the drug; the peak 
effect of IM/SC morphine occurs 45-90 minutes following administration whereas the 
effects of IV morphine are experienced more rapidly (15-30 minutes) and orally 
administered morphine effects have a slower onset of action (2-4 hours) (Lugo and 
Kern 2002). 
2.1.4.4 Drug-drug interactions 
Drug-drug interactions (DDIs) can alter the intended pharmacokinetic (absorption, 
distribution, metabolism and elimination) and pharmacodynamic (desired effects and 
side effects) properties of a drug (Gaertner et al. 2012). The DDIs can either enhance 
or decrease opioid effect, primarily by modulating opioid metabolism and therefore 
influencing their elimination rate (Maurer and Bartkowski 1993; Overholser and 
Foster 2011). DDIs are more frequent amongst opioids that are metabolised by phase 
I CYP450 enzymes as CYP enzymes are also involved in the metabolism of ~50% of 
drugs (Overholser and Foster 2011). As such DDIs are more frequent with methadone, 
oxycodone and codeine use than for morphine which is metabolised by phase II 
conjugation enzymes. 
Opioid response can be enhanced by CYP inhibitors such as telithromycin, 
itraconazole, ketoconazole and ritonavir that prevent the metabolism of oxycodone 
and methadone. The decreased metabolism results in increased opioid exposure 
causing greater opioid effect (Hagelberg et al. 2009; Nieminen et al. 2010a; Samer et 
al. 2010; Gronlund et al. 2010; 2011a, 2011b; Kummer et al. 2011). Alternatively 
CYP450 inducers (rifampin, St John’s wort) can increase the rate of opioid 
metabolism by stimulating transcription factors that upregulate the expression of CYP 
enzymes. The increased CYP presence accelerates the rate of opioid clearance (Ferrari 
36 
 
et al. 2004; Nieminen et al. 2009, 2010b; McCance-Katz et al. 2010; Rowland and 
Tozer 2010). 
2.1.4.5 Prior opioid experience 
Opioid dependant individuals require higher and more frequent doses of analgesics to 
obtain adequate pain relief than opioid naive populations (Alford et al. 2013). For 
example, methadone maintained patients required higher than normal doses of 
morphine to obtain analgesia (Doverty et al. 2001; Athanasos et al. 2006) and showed 
significant tolerance to remifantanil (Hay et al. 2008). The increased opioid dose is 
thought, in part, to be a result of an increased sensitivity to pain (Hay et al. 2009; 
Wachholtz et al. 2015). Additionally ineffective analgesia may also be obtained from 
the development of complete cross-tolerance between different opioids (Athanasos et 
al.  2006; Compton et al. 2012; Wachholtz et al. 2015). 
2.1.4.6 Genetic variations 
Understanding the implications of genetic variations has the potential to enhance 
clinical outcomes (Argoff 2010). For example, genetic and clinical data can already 
be used to accurately predict an individual’s response to irinotecan, ababcavir and 
warfarin (Higashi et al. 2002; Innocenti et al. 2004; Limdi et al. 2008; Mallal et al. 
2008; Schwarz et al. 2008). This use of genetic data to prescribe medication is termed 
“personalised medicine” as it allows the drug with the best efficacy and side effect 
profile for that individual to be prescribed first time, rather than prescribed by 
traditional methods such as clinicians experience or trial-by-error (Argoff 2010). This 
facilitates prospective decision making regarding choice of the correct dose of the 
correct drug for a given patient and reduces subsequent side-effects. Thus in a number 
of different areas of medicine including oncology and haematology, 
pharmacogenomics has revolutionised drug prescribing.  
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2.1.4.6.1 OPRM1 polymorphisms 
Despite there being >100 polymorphisms, the most studied SNP in OPRM1 is the 
118A>G that has a 10-15% minor allele frequency within the Caucasian population 
(Stamer and Stuber 2007) and a much higher frequency of 47% in Asian populations 
(Ono et al. 2009). The 118A>G polymorphism causes an amino acid exchange at 
position 40 of the µ-opioid receptor, from asparagine (Asn; N) to aspartic acid (Asp; 
D) (N40D) deleting a putative N-glycosylation site in the extracellular receptor region 
(Huang et al. 2012). The loss of the N-glycosylation site has been implicated in 
addiction vulnerability (Kroslak et al. 2007; Nagaya et al. 2012), clinical drug 
overdose vulnerability (Manini et al. 2013) and conflicting evidence exists concerning 
the effect of 118A>G on response to opioids.  
Morphine consumption in a population of Taiwanese patients (n = 120) following knee 
replacement surgery was greater in 118GG patients (40.4 ± 22 mg) than 118AA 
patients (25.3 ± 15.5 mg) (Chou et al. 2006a). The observation of greater morphine 
consumption in 118GG patients post-surgery was replicated in female populations of 
Taiwanese (n = 80) and Chinese (n = 588) patients (Chou et al. 2006b; Sia et al. 2008). 
However ethnicity is postulated to influence morphine requirements as Malay (n = 
241) and Indian (n = 137) populations showed no difference in morphine consumption 
in a study undertaken by Tan et al. (2009b) whereas the Chinese subgroup (n = 620) 
did. Similarly a lack of association between the 118A>G polymorphism and post-
surgery morphine consumption in a population of Black and White subjects was 
reported by Coulbault et al. (2006). 
Conflicting evidence for opioid response in acute and chronic pain in association with 
the 118A>G polymorphism have also been reported. Ross et al. (2005) reported no 
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relationship between 118A>G and morphine response in a Caucasian cancer 
population (n = 162). However patients homozygous for the variant allele (118GG) 
have been associated with poorer response to morphine and requirement of increased 
morphine to achieve adequate pain control compared to 118AA counterparts (Klepstad 
et al. 2004; Campa et al. 2008). Conversely Janicki et al. (2006) found that the minor 
G allele was less common in chronic opioid patients requiring higher doses of opioid 
analgesics than homozygous wild type.  
A meta-analysis published in 2009 (Walter and Lotsch 2009) and further summary 
published in 2013 (Walter et al. 2013) discourages the use of 118A>G as a solitary 
marker of clinical relevance but emphasises its importance as part of a complex system 
that underlies response to analgesics. The effect of a combination of polymorphisms 
was illustrated by Hayashida et al. (2008) who observed that individuals carrying a 
118G allele-containing haplotype required more opioids to obtain the same analgesia 
as carriers of other haplotypes. The association of the 118G allele-containing 
haplotype was more significantly associated with opioid requirements than analysing 
118A>G polymorphism by itself (Hayashida et al. 2008). 
2.1.4.6.2 CYP450 and COMT polymorphisms 
CYP2D6 is a highly polymorphic gene, the genetic variations of which can be 
categorised into different phenotypes; poor metabolisers (PMs), extensive 
metabolisers (EMs) and ultra-rapid metabolisers (UMs). PMs have two non-functional 
alleles (e.g. CYP2D6*4/*4 or *4/*6) that cannot metabolise substrates resulting in the 
risk of adverse events, whereas UMs have three or more functional alleles (e.g. 
CYP2D6*1XN) that rapidly metabolise substrates leading to poor drug response (de 
Leon et al. 2006). Post-surgery patients with CYP2D6 PM status treated with codeine 
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and tramadol had decreased analgesia (Persson et al. 1995; Stamer et al. 2003). Both 
codeine and tramadol undertake their pharmacological action via their metabolites and 
as such individuals with non-functioning CYP2D6 alleles obtain less analgesia. At the 
other extreme, individuals carrying CYP2D6 UM status have high plasma morphine 
concentrations following codeine administration and therefore experience greater 
sedation (Kirchheiner et al. 2007). Oxycodone is also a substrate for CYP2D6 however 
polymorphisms in CYP2D6 have not been associated with pharmacodynamic changes 
in oxycodone response despite CYP2D6 polymorphisms causing pharmacokinetic 
alterations (Andreassen et al. 2012). Inhibition of both CYP2D6 and CYP3A4 however 
not only increased oxycodone plasma concentrations but also increased drowsiness 
and deterioration of performance of healthy subjects compared to healthy subjects 
taking a placebo (Gronlund et al. 2010) suggesting that altered oxycodone response is 
dependent upon both CYP2D6 and CYP3A4. 
Like CYP2D6, CYP2B6 is highly polymorphic (Zanger and Klein 2013) and the 
polymorphisms influence the expression of the metabolic enzymes. For example 
CYP2B6*5 (1459C>T, R487C), *6 (516G>T, Q172H; 785A>G, K262R) and *18 
(983T>C, I328T) cause reduced expression of the CYP2B6 enzyme compared to the 
wild type that influence opioid activity (Turpeinen and Zanger 2012; Zanger and Klein 
2013). Of particular interest is CYP2B6*6 that has been shown to be associated with 
higher steady state plasma methadone concentrations (Crettol et al. 2005, 2006; Eap 
et al. 2007; Wang et al. 2011), requirement for lower methadone doses (Hung et al. 
2011; Levran et al. 2013a) and longer clearance rate of methadone (Kharasch et al. 
2014). 
Catechol-O-methyltransferase (encoded by the COMT gene) is responsible for 
conjugating endogenous opioids such as dopamine and norepinephrine. These 
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endogenous opioids are instrumental in pain relief and genetic variations in COMT 
have been associated with pain perception, opioid response, dependence and addiction 
(Diatchenko et al. 2005, 2006; Dai et al. 2010; Lee and Lee 2011; de Gregori et al. 
2013). In particular, the SNP 472A>G (rs4680) that codes for a Val158Met 
substitution is responsible for reducing COMT activity by decreasing its 
thermostability (Lotta et al. 1995; Rakvag et al. 2005; Oosterhuis et al. 2008). Patients 
that carry the Met/Met genotype have been reported to require less morphine than Val 
carriers following surgery and when used to alleviate cancer related pain (Rakvag et 
al. 2005; Reyes-Gibby et al. 2007; de Gregori et al. 2013).  
Alongside the 472A>G polymorphism, three SNPs create haplotypes that have been 
associated with increased median doses of morphine and patients’ having greater pain 
sensitivity, -98A>G, 408C>G and 186C>T of COMT (Diatchenko et al. 2005; Rakvag 
et al. 2008). The side effects of morphine have also been reported to be less in carriers 
of variant alleles within COMT. For example, nausea was decreased in 158Met carriers 
following surgery (Kolesnikov et al. 2011) and drowsiness and confusion was 
decreased in cancer patients with the variant allele at -4873A>G (rs740603) (Ross et 
al. 2008).  
2.1.4.6.3 Transport protein polymorphisms 
The metabolites as well as parent drug rely on transport proteins such as P-
glycoproteins (P-gp) to reach their sites of action. Variations within the P-gp encoded 
by the ABCB1/MDR1 gene has shown to significantly influence the bioavailability of 
many opioids (Coller et al. 2006; Campa et al. 2008). According to the National Centre 
for Biotechnology Information (NCBI) there are more than 50 SNPs in the coding 
region of the human transport gene ABCB1/MDR1 (Fung and Gottesman 2009). The 
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majority of the SNPs are located within the intracellular regions, with only 3 SNPs 
located in the extracellular loop, 4 SNPs within 2 of the transmembrane domains (T9 
and T12) and of those SNPs none change the glycosylation or phosphorylation sites, 
or the ATP binding domains (Fung and Gottesman 2009).  Genetic variations within 
in ABCB1/MDR1, specifically 1236C>T, 2677G>T and 3435C>T have been 
associated with not only variable analgesic efficacy to morphine and oxycodone but 
also variable degrees of adverse effects (Campa et al. 2008; Ross et al. 2008; Fujita et 
al. 2010; Zwisler et al.  2010).
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2.2 DNA methylation 
DNA methylation is an important gene regulatory epigenetic mechanism essential for 
mammalian development and genome stability (Jaenisch and Bird 2003; Jones and 
Liang 2009; Smith and Meissner 2013). It is classified as an epigenetic mechanism 
because unlike genetic variations such as single nucleotide polymorphisms, repeats, 
insertions or deletes, the sequence of DNA bases remains unaltered as illustrated in 
Figure 2-13. Instead methyl groups are covalently bound to the DNA which influences 
whether or not DNA is transcribed and subsequently translated into proteins or non-
coding/ribosomal/transfer RNA. The epigenetic patterns in the genome are referred to 
as the epigenome and unlike the genome, the epigenome is variable and dynamic, 
responding to environmental influences and cellular stress (Hammoud et al. 2013). 
 
 
 
 
 
 
 
 
Figure 2-13. Genetic variations and DNA methylation 
Genetic variations alter the underlying DNA sequence (variant highlighted by dashed box); single 
nucleotide polymorphism (SNP) = a base change from the reference sequence, deletion = deleted base, 
insertion = additional base, and repeat = repeated sequence. Epigenetic mechanisms such as DNA 
methylation do not alter the underlying DNA sequence; instead methyl groups (CH3) are added to the 
DNA. A = adenosine; C = cytosine; G = guanine; T = thymine. 
 
Reference DNA Sequence 
 
Single Nucleotide Polymorphism 
 
Deletion 
 
Insertion  
 
Repeat 
 
 
DNA Methylation 
A      C      G      T       C      G       T      A 
A      C       G      T       C      G       T      A 
CH3 CH3 
A      C      G       T       T      G       T      A 
A       C     G       T       C      G       T      A 
A      C      G       T       C      G      G       T     A 
A      C      G       A      C       G     T       C      G       T      A 
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Methylation occurs at the 5 carbon of the DNA base cytosine (Figure 2-14). This 
process is undertaken by a group of enzymes called DNA methyltransferases 
(DNMTs). The DNMTs achieve methylation by enveloping a cytosine base that has 
been flipped out from the DNA helix. A covalent bond forms between the enzyme and 
substrate base which causes an increased negative charge at position 5- of the cytosine. 
To neutralise the charge, a methyl group donated from S-adenosyl-methionine (SAM) 
is added to C5 which in turn causes the cleavage of the covalent bond between the 
enzyme and the substrate base freeing the DNMT to methylate additional cytosine 
bases (Jeltsch 2002; Goll and Bestor 2005).  
 
 
 
 
 
Figure 2-14. Positioning of methyl group on a cytosine base 
A methyl group (CH3) donated from S-adenosyl-methionine (SAM) is covalently bonded to the 5 
carbon on the cytosine base; a process facilitated by DNA methyltransferase (DNMT). SAH = S-
adenosyl-homocysteine. 
 
In mammalian genomes, methylation predominately occurs when cytosine and 
guanine bases fall in succession within the DNA sequence; referred to as CpG 
dinucleotides, CpGs (Kim et al. 2010a). Methylation can also occur at CpH 
dinucleotides (where H = adenosine [A] / cytosine [C] / thymine [T]) however CpH 
methylation has only been observed in mammalian oocytes, pluripotent embryonic 
stem cells and mature neurons (Lister et al. 2009; Xie et al. 2012; Lister et al. 2013; 
Shirane et al. 2013) and is absent in somatic tissue (Ramsahoye et al. 2000; Ziller et 
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al. 2011). Unlike CpGs which demonstrate cell-type-specific methylation (Lister et al. 
2009), CpH methylation has great inter-individual variability and are therefore not 
thought to have a gene regulatory function (Medvedeva et al. 2014). As the function 
of CpH methylation is unknown the focus of this study will be CpG methylation. 
In the adult human genome the majority, ~60-90%, of CpG sites are methylated (Puig 
& Agrelo 2012; Smith and Meissner 2013), however the distribution of CpGs, and 
their methylation status is uneven within the genome (Figure 2-15). Approximately 
99% of the human genome has a CpG deficit, in intronic and intergenic regions for 
example, and the CpGs in these regions are mostly methylated. However ~1% of the 
human genome has clusters of CpG sites, particularly in promoter regions near 
transcription start sites, and these CpG sites are largely unmethylated (Deaton & Bird 
2011). The lack of CpG homogeneity throughout the genome is as a result of the 
instability of methylated-cytosine that deaminates to thymine (Weber et al. 2007; 
Cohen et al. 2011).  
 
 
 
 
 
Figure 2-15. Distribution of methylated and unmethylated CpGs within the mammalian genome 
Unmethylated CpGs (empty lollipops) and hemi-methylated CpGs (half lollipops) cluster within 
promoter regions of coding regions (blue rectangles), termed CpG islands, and near enhancer sequences 
(purple hexagon). If the island is methylated then transcription factors can bind and the gene can be 
expressed. However, if the CpG island is methylated (filled lollipop), e.g. islands associated with 
imprinted genes (orange rectangles), then transcription factors cannot bind and the gene is silenced. 
Throughout the rest of the genome CpGs are sparse and generally methylated silencing repeat elements 
within the DNA (red squares). Figure adapted from Baubec and Schubeler 2014.  
 
CpG island CpG island 
CpG density 
5mC percentage 100% 
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2.2.1 Functions of DNA methylation 
The arrangement and methylation status of CpG sites within the genome is important 
since DNA methylation influences whether DNA is transcribed or repressed. For 
example, intergenic and intronic regions that were thought to contain “junk” DNA 
actually contain potentially harmful transposable / repetitive elements such as SINE, 
LINE, DNA transposons and simple repeats that can act as functional genome 
reshapers (Han & Boeke 2005; Beauregard et al. 2008; Goodier & Kazazian 2008; Su 
et al. 2012). If the CpGs repressing these repetitive elements become hypomethylated 
it can cause genomic instability leading to genetic disorders and cancer (Kato et al. 
2007; Daskalos et al. 2009; Choi et al. 2009; Baccarelli et al. 2010; Xie et al. 2010). 
One such disorder is immunodeficiency, centromeric instability, and facial anomaly 
(ICF) syndrome that occurs when pericentromeric repeats are not repressed. Lack of 
repression is a result of missense mutations in the DNA methyltransferase, DNMT3b. 
As the pericentromeric repeats are not repressed they cause rearrangements near the 
centromeres leading to the affected individuals being susceptible to infectious diseases 
and having facial abnormalities (Gopalakrishnan et al. 2009).  
Methylation is also fundamental for long term repression and silencing of genes on 
the inactive X chromosome (Splinter et al. 2011). During the embryonic stages of 
female mammalian development, one X chromosome undergoes region wide 
inactivation by a cis-acting non-coding RNA, Xist. This inactivation is shortly 
followed by recruitment of proteins and a change in chromatin structure brought about 
by DNA methylation that inhibits transcription factor access to the DNA (Payer and 
Lee 2008). If both of the X chromosomes were active then twice the number of genes 
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associated with the X chromosome would be produced compared to males resulting in 
metabolic imbalance (Gartler & Goldman 2001).  
As well as maintaining the inactivation of the X chromosome, methylation is 
important for establishing and maintaining imprinted genes (Miranda & Jones 2007; 
Bartolomei 2009; Ferguson-Smith 2011). The rule for the majority of genes is that 
both alleles, the paternal allele and the maternal allele, are expressed equally. 
However, when genes are imprinted only one of the parental alleles are expressed. For 
example, the insulin-like growth factor II (IGF2) is only expressed from the paternal 
allele (Pedone et al. 1999) as the maternal allele is repressed by DNA methylation. 
Failure to maintain gene imprinting can lead to numerous developmental defects such 
as Prader-Willi syndrome (Gillessen-Kaesbach et al. 1995), Beckwith-Widemann 
syndrome (Kubota et al. 1994) and Angelman syndrome (Das et al. 1997).  
Although other epigenetic modifications such as histone modifications can alter 
chromatin structure and gene expression, they are reversible so long-term gene 
inactivation is not maintained (Shi et al. 2004; Takeuchi et al. 2006). McGarvey et al. 
(2006) demonstrated that artificially reversing histone modifications did not alter gene 
expression if the promoter region was highly methylated. However, active in vitro 
demethylation of promoter regions does activate a gene (Kaminskas et al. 2005) 
despite the presence of other chromatin / gene altering modifications suggesting 
methylation is the predominant controlling factor.  
DNA methylation is also fundamental in cellular differentiation that enables 
organisms to exist. During embryogenesis essential methylation programming occurs 
that determine which genes are expressed, as well as determining cell fate (Christensen 
et al. 2009; Huang & Fan 2010). To understand the influence of DNA methylation on 
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cellular differentiation, Laurent et al. (2010) compared the methylation profile of 
different cells: an undifferentiated cell; human embryonic stem cell, and differentiated 
cells; a fibroblastic derivative of the human embryonic stem cell, neonatal fibroblasts 
and a fully differentiated adult monocyte. Their study found that embryonic stem cells 
had higher global methylation in comparison to fibroblasts and monocytes, however 
genes associated with pluripotency and development had less methylation in 
embryonic cells than differentiated cells. For example, the POU5F1 / OCT4 gene that 
encodes for a transcription factor important for embryonic development has less 
methylation within the transcription start site in embryonic cells than the differentiated 
cells. This lack of methylation within the transcription start site allows the necessary 
transcription of the gene for embryogenesis, but becomes increasingly methylated 
during differentiation when the transcription factor is not as functionally important for 
cell development.  
Similarly, HOX genes that are responsible for the orientation and basic structure of an 
organism are less methylated during embryogenesis allowing appropriate anatomical 
arrangement and are more methylated in differentiated cells. Different methylation 
patterns are also seen in different tissue samples. For example, CpG sites in adult and 
infant blood are typically more methylated than CpG sites in tissues such as placenta, 
brain and kidney (Christensen et al. 2009). A study conducted by Byun et al. (2009) 
discovered that one particular locus, MST1R, was heavily methylated in the brain 
compared to other tissues. This particular gene encodes for a receptor that is involved 
with the development of epithelial tissue and bone that is less in demand in brain tissue 
than other tissues (Byun et al. 2009).  
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2.2.2 DNA methyltransferases (DNMTs) 
There are four members in the DNMT family, three enzymes that actively undertake 
DNA methylation, DNMT1, DNMT3A and DNMT3B (Goll and Bestor 2005), and 
DNMT3L, a protein that shares homology with DNMT3A and DNMT3B but lacks 
catalytic activity (Gowher et al. 2006; Kareta et al. 2006). The domains of the DNMTs 
cause a preference for either de novo methylation (establishment of new methylation 
patterns, during germ development for example) or for maintenance methylation 
(maintaining methylation patterns following DNA replication). DNMT1, DNMT3A 
and DNMT3B contain a large N-terminal catalytic domain and smaller C-terminal 
domain. The localisation of the DNMT in the nucleus and interaction with other 
proteins, DNA and chromatin is regulated by domains within the N-terminal. The C-
terminal is the enzymatically active domain responsible for the transfer of the methyl 
group to the 5 carbon of cytosine (Jeltsch 2002).  
DNMT3L, although not catalytically active is also required for DNA methylation. 
DNMT3L is unable to bind SAM and has very weak affinity for DNA (Gowher et al. 
2006; Kareta et al. 2006) however has been shown to co-localise and stimulate the 
activity of DNMT3A and DNMT3B in vivo (Chedin et al. 2002; Chen et al. 2005a; 
Jia et al. 2007) and in vitro (Suetake et al. 2004; Gowher et al. 2006; Kareta et al. 
2006). DNMT3L-knockout mouse studies have shown that DNMT3L is important for 
establishing methylation on imprinted genes. Without DNMT3L, de novo methylation 
does not occur in the germline resulting in mouse sterility (Bourc’his and Bestor 2004; 
O’Doherty et al. 2011).  
2.2.2.1 De novo methylation and maintenance methylation 
The different DNMTs methylate cytosines at various periods in cell development. 
DNMT3A and DNMT3B are more prevalent during germ cell development when new 
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methylation patterns are established, de novo methylation (Figure 2-16a). Whereas 
DNMT1 is the primary DNMT for maintaining methylation patterns following DNA 
replication (Kim et al. 2009) as illustrated in figure 2-16b. However all of the DNMTs 
are involved in both de novo and maintenance methylation to some extent (Riggs and 
Xiong 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-16. Functions of DNMTs 
a) DNMT3A and DNMT3B are prevalent during cell development to induce de novo methylation 
patterns. b) During cell replication, DNMT1 is more prevalent as it has a preference for hemi-
methylated DNA; c) without the presence of DNMT1 the DNA passively demethylates causing cell 
abnormalities; d) active demethylation by enzymes such as TET (figure taken from Wu & Zhang 2010). 
 
 
Once the methylation patterns have been established and the DNA undergoes 
replication, DNMT1 quickly methylates the newly synthesised DNA strand preserving 
the methylation pattern of the parent strand (Kim et al. 2009) (Figure 2-16b). DNMT1 
a) 
b) 
c) 
d) 
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is considered to be the major maintenance methyltransferase as it has a preference for 
hemi-methylated DNA (Pradhan et al. 1999). Transcription of DNMT1 occurs mostly 
during the S-phase of the cell cycle (Robertson et al. 2000) when it is most needed to 
methylate newly generated hemi-methylated DNA. DNMT1 achieves this by 
occupying a position at the replication fork from which it can methylate the CpG 
dinucleotides before the chromatin reassembles (Jurkowska et al. 2011). DNMT1 has 
domains that can interact with the DNA polymerase processivity factor, proliferating 
cell nuclear antigen (PCNA)- interacting binding partner, NP95 (Chuang et al. 1997) 
which would ensure its localisation to the replication fork (Arand et al. 2012). NP95 
specifically attracts DNMT1 to the parental methylated strand orientating the enzyme 
and its activity to the newly synthesised, unmethylated strand (Bostick et al. 2007; 
Sharif et al. 2007). Disruption of DNMT1-PCNA interaction only causes a small 
change in methylation (Egger et al. 2006; Schermelleh et al. 2007). The ubiquitin-like 
PHD and RING finger domain containing protein (UHRF1) could also fulfil a similar 
function (Bostick et al. 2007; Arita et al. 2008; Avvakumov et al. 2008). DNMT1 may 
be recruited by UHRF1 to hemi-methylated sites in DNA even after replication 
(Bostick et al. 2007; Arita et al. 2008; Avvakumov et al. 2008; Jones and Liang 2009). 
DNMT1 however is not efficient so de novo methylation by DNMT3a and DNMT3b 
helps re-establish the precursor methylation pattern (Jeong  et al. 2009; Starkweather 
& Pair 2011). DNMT3A and 3B are anchored to nucleosomes, presumably to 
methylated regions, and do not read the methylation but are proposed to methylate 
sites missed by DNMT1 during DNA replication (Jeong et al. 2009). Mice lacking 
DNMT3A and DNMT3B have up to 30% of CpG sites hemimethylated in repeat 
regions, and embryonic cells gradually lose DNA methylation with each cell division 
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(Liang et al. 2002; Chen et al. 2003). The passive demethylation results in abnormal 
cell development (Wu & Zhang 2010).  
2.2.3 Mechanism of gene regulation by DNA methylation 
The exact mechanism by which CpG methylation inhibits gene transcription is 
unclear; but possible suggested mechanisms include: 
1. Direct blocking of transcription factor binding sites (TFBS). 
The addition of methyl groups to the CpG dinucleotides, in or surrounding, 
transcription factor binding sites can interrupt the recognition sequence to which 
transcription factors bind (Klose and Bird 2006; Maunakea et al. 2010). There are 
~1400 transcription factors in the mammalian genome (Vaquerizas et al. 2009) 
however the sensitivity of these transcription factors to DNA methylation have only 
been tested in a minority (Medvedeva et al. 2014). The transcription factors listed in 
Table 2-1 have CpG dinucleotides within their recognition motifs and the majority of 
transcription factors are adversely affected when these CpGs are methylated. 
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Table 2-1. Impact of methylated DNA on transcription factor binding site recognition 
Transcription Factor Effect of methylation on 
transcriptional activity 
Reference 
Aryl hydrocarbon 
receptor (AhR) 
Inhibitory Shen and Whitlock 1989 
Sudheer et al. 2010 
Activator protein 1 (AP-
1) 
Inhibitory Comb and Goodman 1990 
Ng et al. 2013 
cAMP response element 
binding protein (CREB) 
Inhibitory Iguchi and Schaffner 1989 
Kim et al. 2007 
Wen et al. 2010 
Specificity protein 1 
(Sp1) 
Inhibitory 
 
 
No effect 
Macleod et al. 1994 
Lal et al. 2009 
Wang et al. 2010 
Harrington et al. 1988; Holler et 
al. 1988 
E2F E2F1-5 and E2F2 = Inhibitory; 
E2F2-5 = no effect 
Campanero et al. 2000 
Cdc2 Inhibitory Campanero et al. 2000 
YY1 Inhibitory Kim et al. 2003 
n-Myc Inhibitory Perini et al. 2005 
NGFI-A Inhibitory Weaver et al. 2007 
c-myc Inhibitory Prendergast et al. 1991 
CTFC Inhibitory Bell and Felsenfeld 2000 
Renaud et al. 2007 
Wang et al. 2012 
P120(ctn_-binding 
partner Kaiso 
No effect; however greater affinity 
for unmethylated binding sites. 
Daniel et al. 2002 
USF1 No effect Prendergast et al. 1991 
TFE3 No effect Prendergast et al. 1991 
 
For example, the transcription factor n-Myc is prevented from binding to the 
promoters of the epidermal growth factor receptor (EGFR) and caspase-8 protein 
(CASP8) if the E-box (CACGTG) is methylated (Perini et al. 2005). In vitro 
experiments have shown that the binding activity of Yin Yang 1 (YY1) is repressed if 
the YY1-binding site (CCAT / ATGG) in the paternally-expressed gene 3 protein 
(PEG3) is methylated (Kim et al. 2003). However the effect of methylation on Sp1 
transcription factor binding is variable. Some authors have found that SP1 is not 
affected by DNA methylation (Harrington et al. 1988; Holler et al. 1988) whereas 
others have demonstrated that Sp1 binding may be affected by methylation of specific 
CpGs within the Sp1 binding motif (Clark et al. 1997) or affected by hypermethylation 
surrounding the Sp1 binding site (Zhu et al. 2003).  
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The positioning of transcription factor (TF) motifs effects the level of methylation as 
TF motifs <1000bp from transcription start sites had significantly less methylation 
than TF motifs >1000bp from transcription start sites (Eckhardt et al. 2006). TF motifs 
near transcription start sites of development and housekeeping genes are 
hypomethylated to enable normal growth. When these CpG islands become 
methylated the transcription of the respective gene is inhibited resulting in gene 
silencing (Jones & Baylin 2002). Experiments have been undertaken that illustrate the 
repression of gene expression by artificial methylation (reviewed in Jurkowska & 
Jeltsch 2010), as well as the restoration of gene expression by demethylating 
endogenously methylated DNA regions using DNA methyltransferase inhibitors 
(Baylin 2005; reviewed in Kelly et al. 2010). This is not the case for all genes, for 
example, genes with high CpG density are hypomethylated and repressed if the CpG 
island becomes hypermethylated (Weber et al. 2007; Meissner et al. 2008), however 
genes with intermediate CpG density acquire differentiation-dependant 
hypermethylation and are repressed with hypermethylation (Maatouk et al. 2006; 
Weber et al. 2007; Farthing et al. 2008; Meissner et al. 2008; Borgel et al. 2010), 
whereas low CpG density promoters which are generally hypermethylated remain 
transcriptionally active regardless of methylation state (Weber et al. 2007; Meissner 
et al. 2008).  
2. Indirect blocking of transcription factor binding sites. 
a. Methyl-CpG binding protein complexes block transcription factor 
binding sites. 
Methylated CpGs recruit proteins that contain a methyl-CpG binding domain (MBD), 
methyl-CpG binding zinc finger domains, and SET and RING Associated (SRA) 
domains (Figure 2-17). Proteins with MBD that bind to methylated DNA include 
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MeCP2, MBD1, MBD2 and MBD4 (Klose and Bird 2006). Kaiso, ZBTB4 and 
ZBTB38 contain zinc finger domains and UHRF1 and UHFR2 have SRA domains. 
When these proteins bind they, and their associated co-repressor complexes, may 
block transcription factor binding (Nan et al. 1998; Jones et al. 1998; Sharif et al. 
2007; Quenneville et al. 2011).  
 
Figure 2-17. Proteins recruited to methylated CpGs 
BTB = Broad complex, Tramtrack, Bric and brac; CTD = chromatin compaction; CXXC ZF = cysteine 
rich unmethylated-CpG-binding zinc finger; glycolase = DNA glycolase activity; MBD = methyl 
binding domain; mZF = methyl-CpG-binding zinc fingers; PHD = plant homeodomain finger domain; 
SRA = SET and RING associated domain; RING = really interesting new gene finger domain; TRD = 
transcriptional repression domain; TTD = tandem tudor domain; Ubl = ubiquitin-like domain. Image 
taken from Fournier et al. 2012.  
 
 
b. Alteration of chromatin / nucleosome configuration  
The proteins complexes formed by MeCP2, MBD1, MBD2 and MBD4 can also 
silence gene expression by altering the formation of the chromatin (Tate and Bird 
1993). The MBD proteins recruit histone deacetylases (HDAC) and / or DNA 
methyltransferases (DNMTs) that remove an acetyl group and / or add a methyl group 
to H3 and H4 histone tails, respectively. Acetyl groups on histone tails is associated 
55 
 
with open chromatin, euchromatin that allows access to the transcription machinery. 
The removal of acetyl groups and addition of methyl groups creates an inaccessible 
chromatin configuration, heterochromatin, that inhibits transcriptional activity 
(Kimura and Shiota 2003; Fuks et al. 2003; Klose and Bird 2006; Bogdanovic and 
Veenstra 2009). Furthermore, CpG methylation can contribute to gene transcription 
repression by forming a more rigid and compact nucleosome conformation, wrapping 
the DNA tighter around the histone and changing the topology of nucleosomal DNA 
limiting access of the underlying DNA to transcription factors (Choy et al. 2010; Lee 
and Lee 2011). 
2.2.4 Factors that influence DNA methylation 
2.2.4.1 Diet 
Epigenetic mechanisms, although inherently stable, can be affected by nutrition, 
exposure to drugs / chemicals and age (Barres & Zierath 2011). The most widely used 
example to illustrate the effect of nutrition on DNA methylation is the Apis mellifera 
(Honeybee). Worker and queen bees begin life as genetically identical larvae, 
however, the larvae that are fed royal jelly become queen bees and those that are not 
fed royal jelly become worker bees (Kucharski et al. 2008). Specifically, the protein 
royalactin has been proposed as the factor that induces queen / worker bee 
differentiation, as bees fed with purified royalactin had an increased body size and 
ovary development (Kamakura 2011).  
In human populations, deficiencies in nutrients essential for DNA methylation cause 
aberrant methylation profiles (Sharp et al. 2008). These nutrients include folate, 
choline, vitamin B6, vitamin B12 and methionine that are modulated by one-carbon 
metabolism (Figure 2-18). Folate, methionine and choline are methyl group donors, 
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and vitamin B6 and vitamin B12 facilitate the methyl group donation. From methionine, 
S-adenosylmethionine (SAM) is synthesised which donates its methyl group to 
cytosine, facilitated by DNMTs. The loss of the methyl group reduces SAM to S-
adenosylhomocysteine (SAH). An accumulation of SAH results in methylation 
inhibition as the synthesis of SAH from homocysteine is favourable over the 
hydrolysation of SAH to homocysteine. Therefore there is no homocysteine to accept 
a methyl group from folate or choline to form methionine, and no SAM is synthesised 
resulting in no DNA methylation (Chmurzynska 2010).  
Figure 2-18. Simplified version of one-carbon metabolism showing some major metabolic 
intermediates, cofactors and dietary sources of methyl groups 
Methionine, choline and folate are the major donors of methyl groups for DNA methylation however a 
number of enzymes and vitamins are necessary for successful methyl group donation; enzymes are 
written in red and italics, essential vitamins are inside ellipses. Information to create figure obtained 
from Mason (2003) and Chmurzynska (2010). 
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5-methyl-
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Without the donation of methyl groups from these factors, or the cofactors that 
facilitate methyl group donation, methylation cannot take place (Sharp et al. 2008). 
As normal DNA methylation is not maintained, repetitive elements within intronic and 
intergenic regions, as well as oncogenes can become available for transcription (Choi 
& Mason 2000; Wilson et al. 2007) and genes critical for tumour repression and 
growth regulatory genes become repressed promoting and progressing carcinogenesis 
(Sharp et al. 2008). Studies carried out using mice and rats on various methyl donor 
group deficient diets demonstrate the impact on genome methylation status (Powell et 
al. 2005; Pogribny et al. 2006; Huang et al. 2008; Pogribny et al. 2009). A global loss 
of DNA methylation was reported as well as hypermethylation of promoter regions.  
These abnormal methylation patterns were reversible if the rodents were returned to 
methyl-sufficient diets within a relatively short time period, but the longer the rodents 
were methyl-deficient, the more likely the abnormal methylation would remain 
contributing to the progression of the cancer (Pogribny et al. 2009). A review by Kim 
(2003) concluded that the dose of folate and the stage of the disease in which folate is 
taken are important as folate supplementation during the initial stages of cancer can 
be beneficial, but later in cancer development can act as a cancer catalyst. It is 
commonly known that human cancer patients experience a loss of appetite during the 
advanced stages of their disease (Halliday et al. 2012) so may not intake the necessary 
nutrients for DNA methylation maintenance. However, the addition of nutrient 
supplements to cancer patients’ treatment does not always change the outcome of the 
cancer for the better (Andreeva et al. 2012) and may even increase the chance of 
prostate cancer in men (review by Wien et al. 2012).  
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2.2.4.2 Age 
Age also has an impact on DNA methylation status (Christensen et al. 2009). 
Maintenance of DNA methylation profiles deteriorate with age (Li et al. 2010) so 
DNA regions typically hypermethylated become hypomethylated, and 
hypomethylated promoter regions become hypermethylated. This results in the 
expression of genes that are normally silenced and the repression of previously 
expressed genes (Richardson 2003). Mechanisms that are thought to cause these 
aberrant methylation profiles include; altered expression of DNMTs, increased plasma 
concentrations of homocysteine (de Bree et al. 2005) and less efficient DNA repair 
(Gorbunova et al. 2007).  
2.2.4.3 Environmental and drug exposures  
Exposure to trace metals within the environment have also been reported to alter 
normal methylation patterns. These metals can alter the DNA methylation by 
interfering with metabolism of methinonine / folate (Rowling et al. 2002); by 
competing for the intracellular methyl group inhibiting its use for DNA methylation 
(Sutherland & Costa 2003); or by directly inhibiting the methyltransferases (Cox 
1985; Takiguchi et al. 2003).  
For arsenic to be metabolised, a methyl group must be donated which directly 
competes with the DNA methylation process for the SAM molecule. When arsenic 
was introduced into the diet of rats, DNA from liver tissue was hypomethylated (Davis 
et al. 2000), this outcome was supported by Chen et al. (2004) and Reichard et al. 
(2007), however they also reported gene-specific hypermethylation. Exposure to 
nickel can trigger de novo methylation of tumor suppressor genes making it a potent 
environmental carcinogen (Cangul et al. 2002). When Lee et al. (1995) exposed 
Escherichia coli gtp gene to nickel the transfected gene was inactivated. Cadmium 
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also causes genome-wide demethylation, and one method in which it achieves this is 
by inhibiting methyltransferases (Takiguchi et al. 2003).  It has been speculated that 
these metals alter DNA methylation by metal induced oxidative stress.  
The reactive oxygen species (ROS) produced by the metals interfere with the 
DNMT:DNA interaction resulting in no methylation (Baccarelli and Bollati 2009). In 
response to ROS, the body produces the antioxidant glutathione (GSH) (Schwartz et 
al. 2005; Chahine et al. 2007). GSH is produced from homocysteine that is 
fundamental in the one-carbon metabolism pathway. The redirection of homocysteine 
for GSH production causes a decreased availability of methyl donors and therefore 
DNA hypomethylation (Hitchler and Domann 2009). In addition, ROS can directly 
damage the DNA reducing the binding affinity of methyl-CpG binding proteins 
(MBPs) that recruit DNA methyltransferases (DNMTs) to methylate the DNA 
(Valinluck et al. 2004; Baccarelli and Bollati 2009). 
A study by Bollati et al. (2007) reported that prolonged exposure to airborne benzene 
can alter methylation patterns. They found that the benzene exposed individuals had a 
global loss of DNA methylation and hypermethylation of gene-specific methylation. 
Exposure to benzene has been associated with an increased risk of acute myelogenus 
leukaemia (Bird et al. 2005). 
Alongside accidental exposures to trace metals and air pollutants, substances we 
choose to consume can affect DNA methylation. Alcohol has been found to alter the 
DNA methylation patterns in several tissues including liver, oesophagus, colon and 
uterus tissue. These alterations lead to genetic and phenotypic changes (Zhou et al. 
2011b). Alcohol achieves these genetic changes via two methods; directly affecting 
the methyl donors and inhibiting enzymes (methionine synthase and methionine 
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adenosyltransferase) important for one-carbon metabolism (Mason and Choi 2005). 
Christensen et al. (2010) suggest that alcohol’s disruption of the one-carbon 
metabolism is the mechanism that makes it carcinogenic.  
Drugs such as cannabis and opioids are also thought to alter methylation by stimulating 
DNMT activity through G-protein-coupled receptor-mediated cascade pathways 
(Paradisi et al. 2008; Doehring et al. 2013). The effect of drug exposure on the 
epigenome, specifically gene alterations made in the reward, motivations and pleasure 
centres of the brain are postulated to play a role in the development of addiction, 
dependence and tolerance (Kalivas et al. 2005; Hyman et al. 2006; Koob and Kreek 
2007).  
Acute cocaine exposure was observed to increase the expression of DNMT3a and 3b 
in the nucleus accumbens (NAc) and stimulate MeCP2 binding causing 
hypermethylation of the protein phosphatase-1 catalytic subunit (PP1c) promoter. 
Pharmacological inhibition of DNMT activity resulted in attenuated down regulation 
of PP1c in the NAc and delayed the development of cocaine induced behavioural 
sensitization (Anier et al. 2010). Therefore, alterations to OPRM1 methylation may 
influence the analgesic effects of opioids and could play a role in the development of 
tolerance. 
2.2.4.4 Smoking 
Tobacco exposure has been associated with mortalities through causing numerous 
cancers, cardiovascular and metabolic diseases and respiratory diseases (Centres for 
Disease Control and Prevention 2011). These diseases are instigated by the chemicals 
within tobacco smoke such as carcinogens, nicotine and carbon monoxide that can 
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damage DNA and alter epigenetic mechanisms such as DNA methylation (Lee and 
Pausova 2013).  
Exposure to cigarette smoke is considered one of the most influential factors for 
modifying DNA methylation patterns (Breitling et al. 2011; Lee and Pausova 2013; 
Shenker et al. 2013; Zeilinger et al. 2013). Possible mechanisms for cigarette smoke 
mediated DNA methylation alterations are shown in Figure 2-19, as summarised by 
Lee and Pausova (2013). Carcinogen induced double-stranded DNA breakage results 
in the recruitment of DNMT1 that has been suggested to alter the normal methylation 
profile (Mortusewicz et al. 2005). The recruited DNMT1 methylates CpG sites 
adjacent to the DNA repair site regardless of the CpG site’s previous methylation 
status (Cuozzo et al. 2007).  
Secondly, activation of the nicotine acetylcholine receptor increases intracellular 
calcium; the calcium increase leads to downstream stimulation of the transcription 
factor cAMP response element-binding protein that can alter gene expression (Shen 
and Yakel 2009). Via this pathway it has been suggested that DNMT1 expression is 
down-regulated in cortical and hippocampal GABAergic neurons resulting in 
hypomethylation and subsequent reduced expression of genes such as GAD67 (Satta 
et al. 2008).  
Thirdly, cigarette smoke exposure can modulate the expression and activity of DNA-
binding proteins, e.g. Sp1 and PEA3 (Mercer et al. 2009; Di et al. 2012; Wallace et 
al. 2012; Shin et al. 2015). Cigarette smoke exposure has been observed to increase 
Sp1 protein expression in lung epithelial cells resulting in increased transcription of 
the MUC5AC gene that is the major inducible mucus gene in the airway (Di et al. 
2012).  
62 
 
Fourthly, the carbon monoxide within cigarette smoke decreases cellular oxygen 
content (Jensen et al. 1991), to which gene regulatory hypoxia-inducible factors 
(HIFs) respond (Majmundar et al. 2010). These transcription factors regulate enzymes 
that facilitate the synthesis of methyl donors thereby altering DNA methylation (Avila 
et al. 1998; Liu et al. 2011). Hypoxia has also been observed to alter the expression of 
DNMT1 and DNMT3a (Liu et al. 2011). 
Figure 2-19. Mechanisms by which smoking effects DNA methylation  
Cigarette smoke has been shown to modulate DNA methyltransferase 1 (DNMT1) content, both at the 
transcript and protein level, and enzymatic activity separately in different cell types. Double stranded 
DNA breaks may be induced by cigarette smoke, which subsequently recruits DNMT1 adjacent to the 
repair site. DNA binding proteins, such as Sp1, are activated by cigarette smoke and protect CpG sites 
from de novo methylation. In the context of prenatal exposure, cigarette smoke induces hypoxia in the 
embryo, which in turn modulates methyl group availability. Image obtained from Lee and Pausova 
(2013). 
 
 
In vivo and in vitro experiments have shown that smoke exposure can alter DNA 
methylation. For example, repetitive elements within the genome such as LINE and 
AluYb8 are hypomethylated in diseased tissues of smokers (current or former) 
compared to non-smokers (Smith et al. 2007; Furniss et al. 2008). Global 
hypomethylation was also reported in cord serum DNA and buccal swabs of infants 
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exposed to prenatal smoke exposure (Breton et al. 2009; Guerrero-Preston et al. 2010). 
Hypomethylation of repetitive elements is associated with genomic instability leading 
to genetic mutations, insertions and deletions (Cordaux and Batzer 2009).  
The genomic instability and resulting genomic mutations have been implicated in 
disease development. For example, infants exposed to prenatal smoke exposure have 
a greater susceptibility of developing diseases such as asthma (Wang and Pinkerton 
2008), cancer (Filippini et al. 2000), obesity (Toschke et al. 2003; Sharma et al. 2008), 
type II diabetes (Montgomery and Ekbom 2002). 
In addition to global hypomethylation, the extent of methylation at specific CpG loci 
varies between smoke and non-smoke exposed individuals. CpGs within genes 
associated with tumour suppression (APC, CDH13, p16, RAR-beta, RASSF1A), 
genomic stability (MGMT), or xenobiotic metabolism (GSTP1) or transportation 
(ABCB1/MDR1) are hypermethylated in smokers compared to non-smokers 
suggesting less gene expression (Zöchbauer‐Müller et al. 2003; Enokida et al. 2006; 
Liu et al. 2010). However, genes associated with coagulation (F2RL3) and 
inflammation (GPR15) are hypomethylated in smokers (Breitling et al. 2011; Wan et 
al. 2012). The varying methylation of different genes suggests that tobacco smoke 
targets specific genes for hypermethylation and hypomethylation (Vaissiere et al. 
2009).  
2.2.5 DNA methylation and opioid genes 
Although there are currently no direct links between methylation status of opioid 
related genes and opioid response, studies have been carried out that research the 
methylation status of opioid genes in relation to stage of disease, contribution to 
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disease progression, susceptibility to drug addiction and use of the methylation level 
as a biomarker for drug resistance (not opioids).  
The expression of OPRM1 is affected by DNA methylation. Embryonic P19 cells do 
not express the µ-opioid receptor as the promoter region of the OPRM1 gene is heavily 
methylated. Once cells become differentiated, the promoter region is hypomethylated 
allowing expression of the gene. To further illustrate that DNA methylation is a 
prominent factor for OPRM1 expression, the P19 cells were artificially demethylated 
and OPRM1 was expressed (Hwang et al. 2007; Hwang et al. 2010). The majority of 
authors who have analysed OPRM1 have focused on the promoter region of the gene. 
Within this region there are reported to be a number of transcription factors (Sp1, AP-
1, NFkB, Stat6, IL-4) and 3 nucleosomes (Hwang et al. 2007; Hwang et al. 2010). In 
vitro experiments infecting hybrid T and B cells with Simian immunodeficiency virus 
(SIV) showed that SIV induced methylation of Sp1 transcription binding sites 
inhibited the expression of OPRM1 (Liu et al. 2009). Therefore, methylation of CpG 
sites within the regions that contain the motifs for the transcription factors and 
nucleosomes are of importance. Variable OPRM1 methylation levels have been 
reported between different ethnicities (Nielsen et al. 2010), former drug users and non-
drug users (Nielsen et al. 2009) and ischemic cells and non-ischemic cells (Formisano 
et al. 2007) in human studies, and social (Hao et al. 2011) and diet (Vucetic et al. 
2010) factors in rats. 
The majority of studies that analyse the P-glycoprotein opioid transport protein 
(ABCB1/MDR1 gene) are concerned with the methylation level at different stages of 
cancers such as colon and breast cancer. As cancer progresses, the ABCB1/MDR1 gene 
becomes more methylated (Enokida et al. 2004; Muggerud et al. 2010). However, 
Dejeux et al. (2010) found that hypomethylation within the promoter region of the 
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gene was correlated with progressive disease and that the level of methylation could 
indicate the patient’s drug response. This opinion was supported by Boettcher et al. 
(2010) who found that the ABCB1/MDR1 was hypomethylated in breast and ovarian 
carcinoma and the resulting increase in gene expression could be an indicator of 
resistance to doxorubicin, a cancer chemotherapy drug. 
With regards to studies involving opioid metabolising enzymes, there are few studies 
relating to the phase I metabolising enzymes important for oxycodone and methadone 
metabolism. However, the importance of studying these enzymes has been noted. 
Ingelman-Sundberg et al. (2007) located CpG islands within the genes and speculated 
that methylated CpG sites may play a role in gene expression.  Kim et al. (2010b) 
found methylated sites within the CYP2D6 gene but this methylation was not 
associated with drug response to tamoxifen. 
2.2.6 DNA Methylation analysis 
Numerous methods have been employed to analyse the methylation profile of a DNA 
sample (summarised in Laird et al. 2010). The initial step of methylation analysis is 
to distinguish between methylated cytosines and unmethylated cytosines (Johansson 
2008). To achieve this, the DNA can be enzyme digested, bisulfite converted or 
undergo affinity enrichment pre-treatment. The literature has shown (Nielsen et al. 
2009, Chrobov et al. 2010) that methylation at specific CpG loci correlate with drug 
response. Therefore, affinity enrichment pre-treatments would not be appropriate for 
this study as they determine the average methylation status of a defined region. 
Bisulfite conversion and restriction enzymes allow the methylation status of particular 
loci to be determined.  
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Bisulfite conversion was the first method developed to distinguish between the two 
cytosine states (Frommer et al. 1992). The unmethylated cytosine is converted to 
uracil by addition of bisulfite across cytosine’s 5-6 double bond. Hydrolytic 
deamination of the unmethylated cytosine produces a bisulphate uracil derivative that 
undergoes alkali treatment to remove the sulfonate group resulting in uracil (Clark et 
al. 1994) (Figure 2-20). Following bisulfite pre-treatment the uracil bases are 
converted to thymine during PCR amplification whereas the methylated cytosines 
remain as cytosines. The DNA sequence can then be determined by gel separation 
following direct sequencing (also known as Sanger bisulfite sequencing) or capillary 
electrophoresis (bisulfite conversion sequencing). Alternatively the bisulfite 
converted sample can be sequenced by pyrosequencing.  
 
 
 
 
 
 
During pyrosequencing nucleotide bases are added to the single stranded DNA one at 
a time. Once a nucleotide is incorporated into the complimentary DNA strand 
pyrophosphate (PPi) is released. ATP sulfurylase converts PPi to ATP which in turn 
converts luciferase to oxyluciferase. Oxyluciferase produces light proportional to the 
amount of ATP produced which represented in a pyrogram as a peak. Any 
unincorporated bases are degraded by apyrase before the next nucleotide is added and 
Figure 2-20. Process of bisulfite conversion 
Figure taken from EpiMark Bisulfite Conversion Kit technical reference, available at 
http://www.neb.com/nebecomm/tech_reference/epigenetics/Bisulfite_Conversion.asp#.UJAy228mQo8 
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the process begins again (Figure 2-21). Methylated cytosines are indicated as cytosine, 
and unmethylated cytosines are indicated by a thymine. Fundamentally, the 
methylated sites are detected the way in which a C/T SNP would be identified. 
Pyrosequencing is not the cheapest method of analysis but the sample preparation is 
relatively quick and easy compared to direct sequencing.  
 
 
 
 
 
 
 
 
 
 
Figure 2-21. Mechanism of pyrosequencing 
Sequencing primers anneal to single stranded DNA and aided by polymerase complimentary 
nucleotides are added to synthesised DNA. Nucleotides are added to the single stranded DNA 
sequentially; if that nucleotide is next in the sequence then it is incorporated into the DNA which 
releases pyrophosphatase. Via ATP sulfyrase, pyrophosphatase is converted to ATP that converts 
luciferase to oxyluciferase resulting in the production of light. This light is captured by a CCD camera 
and the intensity of the light is directly proportional to the number of nucleotides incorporated into the 
newly synthesised DNA sequence. Any unused nucleotides are broken down by apyrase and the next 
nucleotide is added to the DNA mix (image available at 
http://www.omicsonline.com/ArchiveJCSB/2009/February/03/Images/JCSB2.74Figure1.htm). 
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3.0  GENERIC METHODS 
To determine the effect of ABCB1/MDR1, CYP2D6 and OPRM1 gene DNA 
methylation, in conjunction with commonly investigated genetic variations, on 
response to opioid analgesics a population of cancer patients requiring morphine or 
oxycodone for pain relief were recruited. First though the influence of smoking and 
opioid exposure on gene DNA methylation was established in a population of smokers 
and non-smokers, and in a population of former-heroin dependant women and their 
babies. Gene DNA methylation has also been shown to be tissue dependant so 
methylation of ABCB1/MDR1, CYP2D6 and OPRM1 in various tissues were 
investigated.  
3.1 Ethical considerations and patient recruitment 
As the populations for each of the exploratory studies consisted of human volunteers, 
ethical approval was obtained to ensure that the outcomes of the project outweighed 
any adverse effects on the participants. The ethical processes for each population and 
recruitment process are detailed below. 
3.1.1 Does smoking affect buccal DNA methylation? 
DNA methylation is known to be affected by age, lifestyle, environmental exposures, 
smoking and diet. To determine the effect of smoking on the DNA methylation on 
CYP2D6 and OPRM1 in buccal cells a population of Caucasian smokers and non-
smokers were recruited by the PhD candidate. A protocol was written (Appendix A 
1.0) by the PhD candidate and Ethical approval sought and obtained from 
Bournemouth University Science, Technology and Health Research Ethics panel. 
Women on Bournemouth University campus grounds were approached and were 
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asked whether they would like to participate in a study concerning the influence of 
smoking on DNA. The women were eligible to participate in the study if they were 
between the ages of 18 and 50 and were not exposed to regular opioid use. If the 
women met the criteria they were asked to read a participant information sheet 
(Appendix A 1.1) and sign a consent form (Appendix A 1.2). The women were asked 
to provide their age (as methylation has been shown to alter with age), smoking status 
and whether or not they took opioids on a regular basis (Appendix A 1.3). Following 
completion of the consent form and questionnaire oral swabs were collected by the 
PhD candidate as described in section 3.2.1.1 Oral swabs. 
3.1.2 Methadone-prescribed opioid-dependant mothers and their new-
born babies 
To determine the effect of in utero drug exposure on the methylation of targeted opioid 
genes, buccal swabs from a population of pregnant former-heroin addicts on 
methadone maintenance treatment programmes and their babies were analysed. The 
protocol, ethics submission and collection of buccal DNA were undertaken by Dr 
Helen Mactier and Dr Cheryl Gillis at Glasgow Royal Infirmary. All methadone-
presribed opioid-dependent (MPOD) mothers delivering after 36 completed weeks’ 
gestation in a single large inner-city maternity unit in Glasgow were eligible to 
participate in this study. Potential subjects were identified within the first few days 
after delivery. The mothers had been managed within an established multidisciplinary 
service for women with substance misuse problems; antenatal care included ongoing 
methadone maintenance provided in collaboration with social work and addiction 
services and tailored to symptoms. Sufficient methadone was prescribed to eliminate 
physical withdrawals, with the aim of reducing towards the lowest acceptable dose of 
71 
 
methadone prior to delivery. Following written, informed consent demographic data 
included maternal age and prescribed dose of methadone at delivery, as well as infant 
gestation, birth weight and duration of hospital stay. All babies were nursed in the 
postnatal ward with their mothers and NAS was managed according to protocol with 
twice daily scoring using a local version of the Lipsitz scoring system (Lipsitz 1975). 
Those infants scoring 5 or more on two consecutive occasions despite consoling and/or 
with poor feeding or ongoing weight loss after 5 days were commenced on oral 
morphine at 60 µg/kg six times daily. This dose could be escalated to 80 µg/kg six 
times daily if the baby remained symptomatic, otherwise oral morphine was weaned 
daily by 10 µg/kg/dose. If NAS symptoms were not controlled by oral morphine, 
phenobarbititone was added to the treatment regime. 
The control population of non-opioid-dependant mothers comprised 17 smoking 
mother-baby dyads from similar postcodes to the MPOD mothers, and 15 non-
smoking mother-baby dyads from more affluent areas of Glasgow as assessed by the 
DEPCAT scale. The DEPCAT scale is derived from the Carstairs and Morris index of 
deprivation that amalgamates areas into four groups (DEPCAT 1-2 = affluent, 3-4 = 
intermediate, 5 = deprived, 6-7 = very deprived) based on level of overcrowding, male 
unemployment, car ownership and the proportion of people in households in social 
class 4 or 5 (NHS Lothian).  
Oral swabs were obtained from the mothers and babies within 24-48 hours of delivery 
as described in 3.2.2.1 Oral swabs. Plasma samples were obtained from the MPOD 
mothers as detailed in 3.2.2.2 Plasma samples within 24 hours of delivery. 
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3.1.3 Tissue specific DNA methylation 
3.1.3.1 Dundee blood and tissue samples 
To help ascertain the effect that frequent opioid use has on DNA methylation of opioid 
important genes, post-mortem samples from deaths associated with heroin overdose, 
as decided by the resident pathologists, were obtained from Sir James Black Mortuary, 
Dundee. Tissue samples were collected as described in section 3.2.3.  
For comparison to the opioid exposed population, blood samples from a control non-
drug using Dundonian population were obtained. Opioid naivety was determined by 
toxicological screening and drug / medical history.  Ethical approval was not required 
as the results of the genetic analysis formed part of the medico-legal examiners 
investigation. Following genetic analysis, reports were written and incorporated into 
the pathologists report. 
3.1.3.2 Edinburgh tissue samples 
Non-opioid exposed tissue samples were required to ascertain the “normal” 
methylation of opioid related genes in liver, psoas muscle and thalamus. To achieve 
this the Edinburgh Tissue and Brain Bank was approached to provide liver, psoas 
muscle and thalamus from non-opioid exposed individuals. To obtain the samples a 
“tissue user request form” was completed and the management group of the tissue 
bank decided whether or not the proposed project was worthy of using their samples. 
To obtain the tissue samples from Edinburgh tissue bank a MTA was set up. 
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3.1.4 Pilot trial: Personalising opioid therapy for cancer pain relief 
3.1.4.1 Royal Bournemouth, Christchurch and Poole Hospitals 
To determine the effect of methylation and SNPs on opioid response, an opioid naïve 
population requiring either morphine or oxycodone were recruited from Royal 
Bournemouth Hospital, the MacMillan Unit, Forest Holme and Poole Hospital. To 
gain ethical approval, the PhD candidate wrote a protocol and supporting documents 
(Appendix B 1.0) and submitted them to the South Berkshire B Ethics Committee via 
the Integrated Research Application Service.  
Eligibility for study participation was determined by lead clinician of each patient 
following the criteria detailed in the inclusion / exclusion document (Appendix B 1.1). 
The reasons for why patients could not be recruited into the study were recorded so 
that recruitment rate could be increased in future studies. Those patients that were 
eligible to participate in the study were provided with a patient information sheet and 
consent form (Appendix B 1.2 and B 1.3) and were approached by the PhD candidate.  
The patients were also asked if they would be willing to allow a member of the 
research team to visit them at their homes to discuss the study; if yes the patient was 
asked to sign a home visit permission form (Appendix B 1.4). The patient was given 
at least 24 hours to consider participating in the study before being asked to sign the 
consent form. If the patient chose not to participate, they were asked to provide a 
reason to help with future recruitment rate; but were under no obligation to give a 
reason if they chose not to.  
When morphine or oxycodone use was imminent, baseline date was collected. This 
information included a demographic questionnaire (Appendix B 1.5), pain 
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questionnaire (Appendix B 1.7), side effect questionnaire (Appendix B 1.8), 
constipation assessment (Appendix B 1.9), and opioid history record (Appendix B 
1.10).  
Within 24 hours of the first opioid dose the patient was asked to complete a pain 
questionnaire and side effect questionnaire; these questionnaires were repeated on 
alternate days from initial dose. Once the patient was considered a morphine / 
oxycodone responder or non-responder they were asked to complete the pain, side 
effect and constipation questionnaire and provide blood and oral fluid samples. One 
blood sample and oral swab were obtained for genetic analyses and one blood sample 
and oral fluid sample were obtained for metabolite analysis. If the patient did not 
respond to their first-line opioid and they were switched to an alternative opioid the 
reason for the opioid switch was recorded in Appendix B 1.11 and biological samples 
were collected. If the patients were switched to either morphine or oxycodone then the 
patients were asked the same questions at the same time intervals as their first-line 
opioid. 
Patients were considered stable on an opioid when their average pain over the last 24 
hours was 4 or less for at least 2 days, and side effects experiences were either “none 
at all” or “a little”. Responses of >4 on the pain questionnaire, and “quite a bit” and 
“very much” responses on the side effect questionnaire constituted an opioid non-
responder. If the initial opioid was ineffective, and the patients were switched to the 
alternative study opioid (either morphine or oxycodone) the patient continued to 
participate in the study. Once the patient reached a stable or switch time point blood 
samples were taken for toxicological analysis, and methylation and SNP analyses. In 
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addition, buccal swabs were obtained from a subset of cancer patients to determine the 
suitability of buccal swabs over blood for genetic and epigenetic analysis. Buccal swab 
DNA collection is less invasive and has a gentler collection procedure so would be 
more comfortable for the cancer patients who undergo innumerable tests and blood 
collections.       
From the participating Bournemouth and Christchurch, and Poole NHS Foundation 
trusts 21 patients diagnosed with cancer requiring either morphine or oxycodone gave 
informed consent to participate in the study. Of the 21 patients, 18 patients saw the 
study through to completion providing pain and side effect questionnaire responses at 
the designated intervals and blood samples at the end of the study. Buccal swabs were 
obtained from 17 of the 18 patients who completed the study as the buccal collection 
devices were not ready when the first patient was recruited. The three patients that 
agreed to participate but did not complete the study withdrew for a number of reasons; 
1) did not complete the questionnaire responses at the designated time points, 2) failed 
to provide blood and buccal swabs in a timely manner and, 3) felt daunted by the 
number of healthcare professionals contacting them throughout their treatment so 
decided against study participation. 
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If patient withdraws from study complete Appendix B1.16                   *Poppy’s Contact number: 07900968185 
Alternate days 
from initial 
dose 
Stable opioid dose 
obtained? 
 
IDENTIFY CANCER PATIENTS WHO 
MAY REQUIRE A STEP III OPIOID IN 
THE FUTURE THAT FIT THE 
INCLUSION / EXCLUSION CRITERIA 
Clinical Team  
Resources: Appendix B1.1 
 
Does the patient fit 
the inclusion 
criteria? 
 
No 
Yes 
GIVE THE PATIENT A “PATIENT INFORMATION SHEET” and 
“CONSENT FORM” 
Clinical Team  Resources: Appendix B1.2 & B1.3 
 
RECORD WHY THE PATIENT DOES NOT SUIT THE CRITERIA IN THE 
“MISSED PARTICPANTS” DOCUMENT 
Clinical Team            Resources: Appendix B1.14 
 
After 24 hours… 
Has the patient agreed to 
participate? 
 
No 
RECORD WHY THE PATIENT DOES NOT WANT TO PARTICIPATE (IF REASON GIVEN 
FREELY) IN THE “MISSED PARTICPANTS” DOCUMENT 
Clinical Team  Resources: Appendix B1.14 
 
Yes 
SEND “GP LETTER”; REMINDER IN ELECTRONIC FILE; PUT “REMINDER OF STUDY 
PARTICIPATION” INTO PATIENTS FILE; GIVE PATIENT A “PATIENT REMINDER CARD”; 
Poppy*  Resources: Appendix B1.4, B1.19 & B1.20 
 
Step III opioid use 
imminent/started? 
 
Yes 
COLLECT BASELINE DATA 
Poppy* Resources: Appendix B1.5, B1.6, B1.7, B1.8, B1.9, 
B1.10 & B1.12 
 
COLLECT QUESTIONNAIRE INFORMATION 
WITHIN 24 HOURS; UPDATE DIARY WITH 
PATIENT ALTERNATE DAYS 
Poppy*  Resources: Appendix B1.7, B1.8, B1.10 & 
B1.12 
 
COLLECT QUESTIONNAIRE 
INFORMATION  
Poppy*  Resources: Appendix B1.7, 
B1.8, B1.10 & B1.12 
 
Yes 
No 
RECORD THE REASON FOR OPIOID SWITCH IN “CRITERIA 
FOR ALTERNATIVE OPIOID”  
Clinical Team Resources: Appendix B1.11 
 
Switched to oxycodone/morphine? 
Yes 
COLLECT BLOOD AND ORAL FLUID 
FOR TOXICOLOGY 
Poppy* Resources: Appendix B1.13 & 
B1.21 
No 
COLLECT QUESTIONNAIRE INFORMATION; COLLECT 
BLOOD AND ORAL FLUID FOR DNA ANALYSIS AND 
TOXICOLOGY (Just toxicology if patient is on second Step III 
opioid) 
Poppy* Resources: Appendix B1.7, B1.8, B1.9, B1.10, B1.12, 
B1.13 & B1.21 
 
End of Study 
 
Figure 3-1. Flow diagram of pharmacogenetic study 
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3.1.4.2 Royal Marsden Hospital 
A collaboration was formed between Royal Marsden Hospital and Bournemouth 
University to increase the study population size. Plasma samples and pain and side 
effect responses were obtained from 129 patients by Dr Joy Ross and her team at Royal 
Marsden Hospital.  
To analyse the plasma samples a material transfer agreement (MTA) was arranged. 
This document allowed the samples to be transferred from the donor site (Royal 
Marsden Hospital), to the site of analysis (Randox Laboratories, N. Ireland for 
toxicology analysis and Royal Bournemouth Hospital for methylation analysis by the 
PhD candidate, and LCG Genomics for SNP analysis). 
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3.2 Sample collection 
The tissue type selected for genetic, epigenetic and toxicological analysis varied 
between the different populations studied because of sample availability, ease of 
collection as well as ethical limitations (range of tissues obtained are listed in Table 3-
1). For example, only buccal cells were obtained from drug and non-drug exposed 
babies as the use of buccal swabs is a relatively non-invasive and pain free DNA 
collection method suitable for babies. DNA from each population was analysed for 
SNPs and DNA methylation in all samples collected. 
In addition to genetic analyses, samples from five of the populations underwent 
toxicological analysis (relevant populations emphasised in italics in Table 3-1). The 
concentrations of opioids were determined in blood or plasma samples.  
Table 3-1. Tissue samples collected from each study population for genetic, epigenetic and 
toxicological analyses 
Study Population 
Buccal 
swab 
Whole 
blood 
Plasma Liver Thalamus 
Psoas 
Muscle 
Mothers: Methadone / 
non-drug exposed  
Yes  Yes*    
Babies: Methadone / non-
drug exposed  
Yes      
Cancer patients: RBH, PH Yes Yes     
Cancer patients: RMH   Yes    
Methadone / non-opioid 
deaths 
 Yes     
Heroin deaths  Yes  Yes Yes Yes 
Non-drug exposed tissues    Yes Yes Yes 
Smokers / non-smokers Yes      
Breast cancer survivors  Yes     
Key: * = Plasma samples only obtained from the methadone exposed mothers; RBH = Royal 
Bournemouth Hospital; RMH = Royal Marsden Hospital; PH = Poole Hospital; italics = populations 
whose blood or plasma samples were also analysed for drug concentrations. 
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3.2.1 Does smoking affect buccal DNA methylation? 
3.2.1.1 Oral swabs 
Buccal DNA from smokers and non-smokers were collected by the PhD student using 
Catch-AllTM sample collection swabs (Cambio Ltd, Cambridge). The Catch-AllTM 
swabs consist of a cotton bud-like collector encapsulated within a hard case for ease 
of storage. Using this swab, epithelial cells from the inner cheeks are collected from 
which genomic DNA can be extracted. 
Prior to collection of the epithelial cells from buccal tissues, subjects were requested 
to rinse their mouths twice with water. Both inner cheeks of the subject were swabbed 
by the researcher, firmly rolling the collector up to 20 times over the entire cheek. 
Swabs were allowed to air dry for 15-20 minutes and then stored at -20°C in the 
original packaging. For longer term storage the swabs were stored at -70°C.  
3.2.2 Methadone-prescribed opioid-dependant mothers and their new-
born babies 
3.2.2.1 Oral swabs 
Mother and baby buccal DNA samples were collected by the Glasgow Royal Infirmary 
Team. Samples were stored as described in section 3.2.1.1 and when batches of 20 
DNA samples were obtained the samples were posted to Bournemouth University on 
dry ice to be analysed by the PhD candidate. 
3.2.2.2 Plasma samples 
The Glasgow Royal Infirmary Team obtained ~3mL venous blood samples from each 
mother, spun down the sample and collected the plasma portion. Plasma samples were 
stored at -70°C before being sent to Imperial College, London, on dry ice for drug 
analysis.  
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3.2.3 Tissue specific DNA methylation 
3.2.3.1 Blood samples 
Post-mortem blood was collected from the ligated femoral vein by pathologists at Sir 
James Black Mortuary in Dundee. For drug analysis blood was collected in tubes 
containing sodium fluoride and potassium oxalate preservative (BD Vacutainer®, 
New Jersey). Samples were stored at -70°C before undergoing toxicological screening 
by the staff at the Centre of Forensic and Legal Medicine, Dundee. Blood samples 
from 43 post-mortems associated with heroin toxicity were obtained for toxicological 
analyses as were 41 blood samples from non-drug related post-mortems. 
3.2.3.2 Tissue samples 
Tissue samples were collected by pathologists at Sir James Black Mortuary (Dundee) 
from heroin associated deaths as part of the routine post-mortem procedure. The 
primary purpose of the tissue samples was to ascertain the distribution of opioids in 
different tissues post-mortem therefore the right lobe of the liver sample was collected, 
the point furthest from the central cavity and stomach where drug accumulation may 
occur. A small sample of psoas major muscle was collected from near the spine once 
the cadaver’s organs were eviscerated. In addition to the liver and muscle a small 
sample of thalamus was obtained. Complete tissue sets (blood, liver, psoas muscle and 
thalamus) were obtained from 30 heroin associated post-mortems. 
Liver, psoas muscle and thalamus from opioid naïve individuals, as determined by 
drug screening and case history, were collected and stored by the Edinburgh Brain and 
Tissue Bank. The frozen samples were transported to Royal Bournemouth Hospital on 
dry ice where they were analysed by the PhD candidate. 
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3.2.4 Pilot trial: Personalising opioid therapy for cancer pain relief 
3.2.4.1 Oral swabs 
The PhD candidate collected the oral swabs from cancer patients at Royal 
Bournemouth Hospital and Poole Hospital as described in 3.2.1.1. 
3.2.4.2 Blood samples 
Peripheral blood samples were obtained by phlebotomists and clinicians at Royal 
Bournemouth Hospital, Poole Hospital and Royal Marsden Hospital. Blood intended 
for genetic analysis was collected in purple topped tubes containing EDTA. For drug 
analysis blood was collected in tubes containing sodium fluoride and potassium 
oxalate preservative (BD Vacutainer®, New Jersey). Samples were stored at -70°C 
before undergoing opioid analysis at Randox laboratories (analysis undertaken by PhD 
candidate), methylation analysis at Royal Bournemouth hospital (analysis undertaken 
by PhD candidate) or SNP analysis (analysis undertaken by LGC Genomics).
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3.3 Toxicological analysis 
3.3.1 Methadone-prescribed opioid-dependant mothers 
Plasma samples from 18 of the methadone-prescribed opioid-dependant mothers were 
analysed for methadone and its metabolite 2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine (EDDP) by the PhD candidate at the Toxicology Unit, Imperial 
College, London. Drugs were isolated from 1mL of plasma using liquid-liquid 
extraction. Deionised water (3mL), 1mL of internal standard (Clomipramined3), 
0.15mL 0.880 ammonia solution and 6mL of diethyl ether was added to the plasma 
samples. The samples were capped, agitated (10 minutes) and centrifuged (5 minutes, 
500g). The organic layer was removed and added to a glass tube containing 5mL 0.1M 
hydrochloric acid. Tubes were agitated (10 minutes), centrifuged (5 minutes, 500 x g) 
and the organic layer discarded. 0.15mL 0.880 ammonia solution and 5mL of diethyl 
ether were added to the glass tube and agitated (10 minutes) and centrifuged (5 
minutes, 500 x g) for a final time. The organic layer was carefully pipetted into a glass 
tube and left to evaporate overnight.  
For detection by gas chromatography mass spectrometry analysis the extracted drugs 
were reconstituted in 0.035mL acetonitrile. A Hewlett Packard 6890 gas 
chromatograph linked to a 5973 mass spectrometer was used to detect the analytes of 
interest. The oven temperature started at 80°C and was ramped to 310°C at a rate of 
16°C/minute with a total run time of 30 minutes per sample. A splitless injector at a 
temperature of 280°C was used with helium as the carrier gas. Compounds of interest 
were separated using a Restek Rxi-5ms capillary column (30m x 5mm, 0.25µm) at a 
carrier gas flow rate of 1mL/minute.  
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3.3.2 Tissue specific DNA methylation 
3.3.2.1 Determination of methadone – opioid overdoses 
Blood samples from deaths associated with methadone toxicity were analysed by the 
toxicologists at the Forensic and Legal Department at Dundee University. The 
methadone was extracted from the blood sample using liquid-liquid extraction. To 
0.5mL of blood sample 0.5mL internal standard was added (desipramine) and vortex 
mixed. Chlorobutane (5mL) was added to each sample, agitated and centrifuged for 5 
minutes at 1500 x g. The chlorobutane layer was pipetted carefully into a clean tube 
and 0.1mL of 0.05M sulphuric acid was added to each tube. The sample was agitated 
and centrifuged again for 5 minutes at 1500 x g. Following centrifugation the 
chlorobutane layer was aspirated carefully and the remaining sulphuric acid layer 
containing any drug was transferred into HPLC vials for analysis.  
The 43 blood samples obtained from opioid associated deaths were analysed for a 
range of drugs by the Forensic and Legal Medicine department, Dundee. The drugs 
screened for included alprazolam, amitriptyline and metabolite, amphetamine, 
citalopram, diazepam, fluoxetine and metabolite, gabapentin, methadone and 
metabolite, mirtazapine, morphine and metabolites, naloxone, oxazepam, oxycodone, 
paracetamol, phenazepam, procyclidine, quetiapine and metabolite, quinine, 
temazepam and tramadol. 
3.3.2.2 Determination of morphine – opioid overdoses 
Blood samples (150 µL) were diluted with 150 µL equine plasma and spiked with 50 
µL of Morphined3 and 50 L of M3Gd3 (IS). After vortexing, 1mL of 0.5 M ammonium 
carbonate solution was added to each sample, and extracted according to the procedure 
in Taylor and Elliott (2009). Briefly solid phase extraction columns (Bond Elut C18, 
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6 mL, Varian) were conditioned using 2 mL methanol followed by 2 mL water and 
then 1 mL 0.5 M ammonium carbonate buffer. Diluted and spiked samples were 
loaded onto the column and allowed to elute at a rate of ~1 mL/min. The columns were 
washed with 5 mL of 0.005 M ammonium carbonate buffer and air dried under vacuum 
for 5 minutes. Drugs were eluted using 1 mL 70:30 acetonitrile:water. The evaporated 
eluent was reconstituted with 100 µL of freshly made LC-MS mobile phase (96% 
phase A: 4% phase B), transferred into a HPLC vial and analysed.  
A 1200 Agilent HPLC system interfaced with an Applied Biosystem 3200 Q TRAP 
triple-quadrupole linear ion trap mass spectrometer (AB Applied Biosystem, Foster 
City,  CA, USA) equipped with an electrospray ionization source (ESI) was used to 
analyse all the samples. Separation of all analytes was accomplished using a 
Phenomenex Synergi 4µ Polar-RP 80A Column (150 mm × 2 mm × 4µm) protected 
by a Phenomenex Security Guard column (Macclesfield, UK). Mobile Phase A 
consisted of a 1mM ammonium formate and 0.1% formic acid solution (around pH 
2.7). Mobile Phase B was a 50% acetonitrile solution with 1mM ammonium formate 
and 0.1% formic acid (around pH 3.8).   
3.3.3 Pilot trial: Personalising opioid therapy for cancer pain relief 
To determine the concentration of morphine / oxycodone and their metabolites in 
blood and plasma samples a solid phase extraction followed by HPLC-MS/MS method 
developed by Randox Laboratories was used. Cancer patient blood or plasma samples 
were transported to County Antrim and analysed using the method described below.  
Samples were prepared for HPLC-MS/MS analysis by adding 1.5mL 2% phosphoric 
acid in phosphate buffer to 500µL of plasma/blood. Blood samples were centrifuged 
for 3 minutes at 1000 x g. SPE columns (Isolute®, Biotage) were conditioned using 
85 
 
2mL methanol and 2mL distilled water. The sample (0.5mL) was loaded onto the SPE 
column and allowed to flow through at a rate of 1mL/min. Columns were subsequently 
washed using 2mL of 0.1M hydrochloric acid followed by 2mL of methanol. The 
columns were air dried for 10 minutes before elution using 2mL 5% ammonia in 
methanol. Eluates were dried down under nitrogen and reconstituted in 200µL 
deionised water. 
To separate the analytes of interest a 1200 Series HPLC coupled with an Ion Trap 
6320 Mass Spectrometer (Agilent Technologies) was used. Separation of the 
compounds was achieved using a Phenomenex column (150 x 3mm; 5µm) kept at 
50°C. Drugs were eluted using a gradient elution of 100% mobile phase A (0.1% 
formic acid v/v in water) to 100% mobile phase B (0.1% formic acid in methanol) at 
a flow rate of 0.75mL/minute.
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3.4 SNP and gene duplication/deletion analysis 
3.4.1 DNA extraction 
3.4.1.1 DNA from buccal swabs 
DNA was extracted from the oral swabs by immersing the swab in an Eppendorf 
containing 500µL of QuickExtract DNA solution (Cambio Ltd., Cambridge). The 
swab was pressed firmly against the side of the Eppendorf tube at least 5 times 
ensuring the majority of the liquid containing the buccal cells remained in the tube. 
Each Eppendorf tube was vortex mixed for 10 seconds and incubated for 1 minute at 
65°C. Following incubation the samples were vortex mixed for 15 seconds and 
incubated again at 98°C for 2 minutes. Finally the extracted DNA was vortexed for 15 
seconds and stored at -70°C until further analysis.  
3.4.1.2 DNA from blood and tissue 
DNA was extracted from blood and tissue samples using the Qiagen DNeasy® Blood 
& Tissue kit. The kit contains prepared reagents that are added to samples in sequence. 
The reagents include proteinase K and four buffers; AL, AW1, AW2 and AE. 
Proteinase K enables cell lysis to release the DNA; buffers AL, AW1 and AW2 are 
used to purify the DNA and buffer AE is an elution buffer.  
To extract DNA from blood samples, cells from 100µL of blood were first lysed using 
20µL proteinase K and volume made up to 220µL using phosphate buffer solution. 
200µL of buffer AL was added and samples were thoroughly vortex mixed ensuring 
a homogeneous solution and incubated at 56°C for 10 minutes. Ethanol (200µL) was 
added to each sample and vortex mixed. The entire sample was transferred to a 
DNeasy mini spin column that was placed inside a 2mL collection tube. Following 
centrifugation (1 minute at 300 x g) the flow-through collected was discarded and 
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500µL of buffer AW1 was added to each tube. The DNeasy mini spin columns were 
centrifuged again and waste discarded. 500µL of buffer AW2 was added and 
centrifuged for 3 minutes at 6000 x g to dry and alleviate any interfering residual 
ethanol from the DNeasy membrane. The DNeasy mini spin columns were transferred 
to clean Eppendorf tubes and 50µL of buffer AE was added directly onto the DNeasy 
membrane. The samples were incubated for 15 minutes at room temperature and 
centrifuged for 1 minute at 300 x g to elute the DNA. 
To extract DNA from the tissue samples an additional sample preparation method was 
necessary. Frozen tissue samples (25mg) were cut into small sections and 180µL of 
ATL buffer and 20µL of proteinase K was added to each tube. The samples were then 
left to incubate overnight at 56°C. Once the samples were completely lysed 200µL 
buffer AL was added and extracted following the same method as the blood samples. 
3.4.1.3 DNA from plasma 
DNA was extracted from plasma using the QIAmp DNA mini kit (Qiagen). The 
extraction method was similar to that employed for extracting DNA from blood and 
tissue samples (section 3.4.1.2); the only differences being that instead of 100µL of 
sample being added, 200µL of plasma was mixed with the proteinase K and no 
phosphate buffer was added.  
3.4.2 DNA quantification 
Each extracted DNA sample was quantified using the NanoDrop 1000 
Spectrophotometer. A 1µL sample was aliquotted from the stock solution onto the 
NanoDrop 1000 pedestal that contains the end of a fibre optic cable (the receiving 
fibre). The sampling arm that contains the source fibre optic cable was then placed 
over the sample and light passed from the source fibre to the receiving fibre. The 
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amount of light of absorbed by the sample was compared to the light absorbance of a 
water control sample and the quantity of DNA was recorded. 
3.4.3 DNA preparation and packaging for LGC 
To determine the genotypes of individuals at 13 different SNP sites extracted genomic 
DNA was analysed by LGC genomics (SNPs detailed in Table 3-2 and their locations 
illustrated in Figures 3-2 to 3-6). The SNPs chosen for analysis were based upon 
previous research, summarised in section 2.1.4.6. In addition, methadone, heroin and 
oxycodone samples were analysed for CYP2D6 deletions and duplications (Table 3-
3) using a Hy-beacon assay. An external company rather than in-house analysis was 
used is it was more cost effective. As the SNP aspect of this research project was not 
novel, it was felt that the use of an external company was justifiable.  
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Table 3-2. Table of SNPs analysed by LGC genomics 
SNP ID Sequence 
NCBI Frequency 
(Caucasian) 
Synonymous / Non-
synonymous 
ABCB1 
1236C>T 
rs1128503 
TCCTGGTAGATCTTGAAGGG 
[C/T] 
CTGAACCTGAAGGTGCAGA 
C = 0.55 
T = 0.45 
Synonymous 
Glycine 
ABCB1  
2677G>T 
rs2032582 
TAAGAAAGAACTAGAAGGT 
[G/T] 
CTGGGAAGGTGAGTCAAAC 
G = 0.53 
T = 0.47 
Non-synonymous 
Serine>Threonine 
ABCB1 
3435C>T 
rs1045642 
TGGTGTCACAGGAAGAGAT 
[C/T] 
GTGAGGGCAGCAAAGGAGG 
C = 0.43 
T = 0.57 
Synonymous 
Isoleucine 
COMT  
-98A>G 
rs6269 
TCTGAACCTTGCCCCTCTGC 
[A/G] 
AACACAAGGGGGCGATGGT 
A = 0.51 
G = 0.49 
 
COMT  
186C>T 
rs4633 
AGCAGCGCATCCTGAACCA 
[C/T] 
GTGCTGCAGCATGCGGAGC 
C = 0.48 
T = 0.52 
Synonymous 
Histidine 
COMT 
408C>G  
rs4818 
TGTCACCAGGGGCGAGGCT 
[C/G] 
ATCACCATCGAGATCAACC 
C = 0.56 
G = 0.44 
Synonymous 
Leucine 
COMT 
472A>G  
rs4680 
GATGGTGGATTTCGCTGGC 
[A/G] 
TGAAGGACAAGGTGTGCAT 
A = 0.52 
G = 0.48 
Non-synonymous 
Valine>Methionine 
CYP2B6 
516G>T 
rs3745274 
GGACCCCACCTTCCTCTTCCA 
[G/T] 
TCCATTACCGCCAACATCATC 
G = 0.73 
T = 0.27 
Non-Synonymous 
Glutamine>Histidine 
CYP2B6 
785A>G 
rs2279343 
CCTGGACCCCAGCGCCCCCA 
[A/G] 
GGACCTCATCGACACCTACC 
A = 0.79 
G = 0.21 
Non-Synonymous 
Lysine>Arginine 
CYP2D6 
1707T>delT  
rs5030655 
CAAGAAGTCGCTGGAGCAG 
[T/-] 
GGGTGACCGAGGAGGCCGC 
T = 0.99 
deleted T = 0.01 
Non-Synonymous 
Tryptophan>Glycine 
CYP2D6 
1845G>A 
rs3892097 
ACCCGCATCTCCCACCCCCA 
[G/A] 
GACGCCCCTTTCGCCCCAAC 
G = 0.76 
A = 0.24 
 
CYP2D6 
2459A/delA 
rs35742686 
TGAGCTGCTAACTGAGCAC 
[A/-] 
GGATGACCTGGGACCCAGC 
A = 0.99 
deleted A = 0.01 
Non-Synonymous 
Arginine>Glycine 
OPRM1 
118A>G  
rs1799971 
ACTTGTCCCACTTAGATGGC 
[A/G] 
ACCTGTCCGACCCATGCGGT 
A = 0.85 
G = 0.15 
Non-Synonymous 
Asparagine>Aspartic 
Acid 
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Figure 3-2. Location of 1236C>T, 2677G>T/A and 3435C>T SNPs in relation to the 28 exons that 
code for the ABCB1/MDR1 transport protein  
The polymorphisms are labelled by their reference SNP number (rs), position in the gene in relation to 
the ATG start codon, the nucleotide base change (A =  adenine, C = cytosine, G = guanine, T = 
thymine) and whether or not the polymorphism results in an amino acid substitution; Syn. = 
synonymous – amino acid unchanged, Non-Syn. = non-synonymous – amino acid substitution. Boxes 
represent coding exons, black line indicates intronic regions (image adapted from Meletiadis et al. 
2006).  
 
 
 
 
 
Figure 3-3. Location of -98A>G, 186C>T, 408C>G and 472G>A SNPs in relation to the 6 exons 
that code for the COMT metabolising enzyme 
The polymorphisms are labelled by their reference SNP number (rs), position in the gene in relation to 
the ATG start codon, the nucleotide base change (A =  adenine, C = cytosine, G = guanine, T = 
thymine) and whether or not the polymorphism results in an amino acid substitution; Syn. = 
synonymous – amino acid unchanged, Non-Syn. = non-synonymous – amino acid substitution. Boxes 
represent coding exons, black line indicates intronic regions (image adapted from Rakvåg et al. 2008). 
 
 
 
 
Figure 3-4. Location of 516G>T and 785A>G SNPs in relation to the 9 exons that code for the 
CYP2B6 metabolising enzyme 
The polymorphisms are labelled by their reference SNP number (rs), position in the gene in relation to 
the ATG start codon, the nucleotide base change (A =  adenine, C = cytosine, G = guanine, T = 
thymine) and whether or not the polymorphism results in an amino acid substitution; Non-Syn. = non-
synonymous – amino acid substitution. Boxes represent coding exons, black line indicates intronic 
regions (image adapted from Jacob et al. 2004). 
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Figure 3-5. Location of 1707T>delT, 1846G>A and 2459A>delA SNPs in relation to the 9 exons 
that code for the CYP2D6 metabolising enzyme  
The polymorphisms are labelled by their reference SNP number (rs), position in the gene in relation to 
the ATG start codon, the nucleotide base change (A =  adenine, C = cytosine, G = guanine, T = 
thymine) and whether or not the polymorphism results in an amino acid substitution; Non-Syn. = non-
synonymous – amino acid substitution. Boxes represent coding exons, black line indicates intronic 
regions (image adapted from Sistonen et al. 2007). 
 
 
 
 
Figure 3-6. Location of 118A>G SNP in relation to the 4 exons that code for the µ-opioid receptor  
The polymorphism is labelled by its reference SNP number (rs), position in the gene in relation to the 
ATG start codon, the nucleotide base change (A =  adenine, G = guanine) and whether or not the 
polymorphism results in an amino acid substitution. Non-Syn. = non-synonymous – amino acid 
substitution. Boxes represent coding exons, black line indicates intronic regions (image adapted from 
Zhang et al. 2006). 
 
Table 3-3. Table of CYP2D6 variants analysed using Hy-Beacons assay 
CYP2D6 variant Number of copies Function 
*1/*1 Two copies 
Normal 
*1/*5 One copy 
*1xN More than two copies Increased 
*5/*5 CYP2D6 deleted Decreased 
 
3.4.3.1 DNA quantity and volume 
DNA samples were standardised to approximately 5 ng/µL using a Nanodrop 1000 
spectrophotometer. For analysis of the 13 SNPs and CYP2D6 deletions and 
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duplications a minimum volume of 40 µL was required. The samples, volumes and 
quantities of DNA samples sent to LGC are listed in Appendix C1.0. 
3.4.3.2 Packaging, transportation 
The 380 samples (MPOD mothers and their babies, n = 40; opioid naïve mothers and 
their babies, n = 64; heroin associated deaths, n = 43; methadone associated deaths, n 
= 77; RBH, FH and MU cancer patients, n = 18; RMH cancer patients, n =128; and 10 
control samples) were transported to LGC in four 96 well plates, each plate with an 
empty well as a negative template control. To ensure that no samples leaked during 
transportation the 96 well plates were sealed using foil seals (purchased from Fisher 
Scientific) and frozen at -70˚C. The frozen samples were transported on dry ice to 
LGC genomics using Davies International courier service.
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3.5 DNA methylation analysis 
3.5.1 Pyrosequencing method - trial 
Pyrosequencing was undertaken by the PhD candidate at Royal Bournemouth hospital, 
Molecular Pathology department using their Pyromark Q24 pyrosequencer (Qiagen).  
The gene chosen for preliminary investigation was OPRM1. This gene was chosen as 
it contains a high density of CpG dinucleotides within the promoter region and exon 
1 (Figure 3-7) and has been shown to have variable methylation between different 
ethnicities (Nielsen et al. 2010) and individuals’ exposure to drugs (Nielsen et al. 
2009; Chorbov et al. 2010).  
TCCTTGGATCGCTTTGCGCAAAATCCACCCCTTTTCCCTCCTCCCTCCCTTCCAGCCTCCGAATCCCGCATGGCCCACGCTCCCCTCCTGCAGC
GGTGCGGGGCAGGTGATGAGCCTCTGTGAACTACTAAGGTGGGAGGGGGCTATACGCAGAGGAGAATGTCAGATGCTCAGCTCGGTCCC
CTCCGCCTGACGCTCCTCTCTGTCTCAGCCAGGACTGGTTTCTGTAAGAAACAGCAGGAGCTGTGGCAGCGGCGAAAGGAAGCGGCTGAG
GCGCTTGGAACCCGAAAAGTCTCGGTGCTCCTGGCTACCTCGCACAGCGGTGCCCGCCCGGCCGTCAGTACCATGGACAGCAGCGCTGC
CCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCAAGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACT
TAGATGGCAACCTGTCCGACCCATGCGGTCCGAACCGCACCGACCTGGGCGGGAGAGACAGCCTGTGCCCTCCGACCGGCAGTCCCTCCA
TGATCACG 
Figure 3-7. CpG sites located in the promoter region and exon 1 of OPRM1 
CG represent potential variable methylation sites, CG show sites that have been previously researched 
and have shown variation between populations (information gathered from Nielsen et al. 2008, Nielsen 
et al. 2010 and Chorbov et al. 2011). Yellow highlight indicates the OPRM1 start codon.  
 
3.5.1.1 Primer design 
Eight CpG dinucleotides were selected from the promoter region and exon 1 of 
OPRM1 and their analysis was divided into two assays; 5 CpGs within the promoter 
region of OPRM1 and 3 CpGs in exon 1 (Figure 3-8).  
 
 
 
 
Figure 3-8. Promoter region and exon 1 of OPRM1 with CG regions of interest indicated  
Promoter region -32, -25, -18-, 14, -10; Exon 1 +12, +23, +27; bp: base pairs 
 
Exon 1  
+12 to +27bp 
Promoter region -
32 to -10bp 
  EXON 1 
94 
 
To design the primers for bisulfite treated DNA, PSQ Assay Design software 
(Biotage) and MethPrimer (available online) were used. The DNA sequence was 
obtained from UCSC genome browser (http://genome.ucsc.edu/). To emulate the 
effect of bisulfite treatment the DNA sequence was pasted into a Microsoft Word 
document and all CpG dinucleotides within the sequence were changed to YG; all 
remaining “C” bases converted to “T”. The region of interest was then pasted into the 
primer design software and suitable primers were suggested. Initially primers without 
biotin tags were ordered and tested to verify that the correct DNA sequence was 
amplified. Once suitable PCR products were obtained the biotin labelled primers were 
ordered (Table 3-4). 
Primers were obtained from Eurofins mwg|operon and reconstituted with water using 
the concentrations listed in the table below to make a final primer concentration of 
100µmol/µL (Table ). 
Table 3-4. OPRM1 primers; reconstitution and optimum annealing temperature 
Primer Name Sequence 
H2O 
(µL) 
Optimum 
annealing 
temp. (°C) 
OPRMpy -30 to -7 F GGATTGGTTTTTGTAAGAAATAGTA 253 53.5 
OPRMpy -30 to -7 R CTAAAAACAACCCTACTATCCATAATAC 226 59.3 
OPRMpy +12 to +27 F GGATTGGTTTTTGTAAGAAATAGTA 252 54.8 
OPRMpy +12 to +27 R CTAAAAACAACCCTACTATCCATAATAC 211 53.8 
OPRMpy -30 -7 R BIO 
Bio-
CTAAAAACAACCCTACTATCCATAATA 
499 59.3 
OPRMpy +12 +27 BIO Bio-GGATTGGTTTTTGTAAGAAATAGTA 512 54.8 
OPRMpy -30 -7 Seq AGTTTAGGTGTTTTTGGTTA 361 Na 
OPRMpy +12 +27 Seq CCAAAACATCAATACAATTA 510 Na 
 
3.5.1.2 Bisulfite conversion 
DNA was bisulfite converted using EZ-96 DNA Methylation-GoldTM Kit (Zymo 
Research). CT conversion reagent (130µL) was added to the supplied 96 well 
95 
 
conversion plate. To each well a 20µL aliquot of DNA (~25ng/µL) was added and 
incubated at 98°C for 10 minutes followed by 64°C for 2.5 hours.  Binding buffer 
(600µL) was pipetted into the wells of the Zymo-SpinTM I-96 binding plate and DNA 
was transferred from the conversion plate to the binding plate. Samples were 
centrifuged for 5 minutes at 3000 x g and the waste was discarded. The M-wash buffer 
(400µL) was then added and plate centrifuged for 5 minutes at 3000 x g. M-
desulphonation buffer (200µL) was added to each well and left to stand for 20 minutes 
at room temperature. Following centrifugation, two wash steps using the M-wash 
buffer (400 µL) were undertaken, one with a centrifuge time of 5 minutes and the 
second with a centrifuge time of 10 minutes (3000 x g). The binding plate was placed 
on top of the elution plate and 15µL of M-Elution Buffer was added directly to each 
membrane. The plate was left to stand for 5 minutes before the DNA was eluted by 
centrifuging the plates for 3 minutes at 3000 x g. 
3.5.1.3 PCR optimisation 
To amplify the regions of interest 1µL of bisulfite converted DNA was amplified 
following the protocol in Table 3-5. The success of the PCR amplification was 
determined by gel electrophoresis. A 1.5% gel was made using agarose and 1 x Tris-
acetate-EDTA buffer (TAE; Thermo Scientific). PCR products were visualised using 
1µL loading buffer (Gel Stain Red, Biotium). 
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Table 3-5. Sample preparation of bisulfite converted DNA for PCR amplification 
 Volume (μL) 
PCR H20 19.1 
Buffer x10 2.5 
dNTPs 2.0 
Bisulfite converted DNA 1.0 
Forward primer 0.1 
Reverse primer 0.1 
GoTaq polymerase 0.2 
 
To obtain the best PCR product each primer set underwent PCR at 6 different 
temperatures using a Veriti Thermocycler. The temperature ranged from 50°C to 
62°C. If faint bands were obtained the number of cycles was increased from 35 to 40 
cycles. The temperature program is summarised in Figure 3-9. 
 
 
 
 
Figure 3-9. Temperature program for amplification of samples for sequencing 
 
 Examination of PCR reaction by gel electrophoresis 
The success of the PCR amplification was determined by gel electrophoresis. A 1.5% 
gel was made using agarose and 1xTAE buffer. PCR products were visualised using 
1µL loading buffer (Gel Stain Red). Figure 3-10 illustrates that 62°C was too hot for 
both primer sets as the presence of PCR product was faint and inconsistent in the 5 
DNA samples amplified (Figure 3-10). 50°C was not hot enough for the +12 primer 
set as there was evidence of non-specific products. The optimum temperature for the 
72°C 72°C 
30 sec 
30 sec 95°C 
30 sec 
35 cycles 
∞ 
7 min 
10 min 
95°C 
50-62°C 
4°C 
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50ᵒC 
54ᵒC 
54ᵒC 
56ᵒC 58ᵒC 60ᵒC 62ᵒC 
a) +12 Primers 
b) -30 Primers 
56ᵒC 58ᵒC 60ᵒC 62ᵒC 
Figure 3-10. OPRM1 +12 and -30 PCR optimisation 
Five bisulfite converted genomic DNA samples and a PCR blank were amplified for two regions of the 
OPRM1 gene at a range of temperatures (50°C to 62°C). a) Gel obtained for the +12 primer set, b) gel 
obtained for the -30 primer set. Although the DNA ladder was smeared as a result of overloading, the 
amplicon sizes were as predicted. 
+12 primer set was 58°C as a vivid PCR product with no smear was produced. The 
optimal temperature for the -30 primer set was 50°C, however at all of the 
temperatures the -30 primer set produced a secondary product.  
 
 
 
 
 
 
 
 
The secondary product obtained using the -30 primer set was alleviated when the PCR 
product was cleaned using SureClean implying that there was an excess of primers 
within the PCR reaction (Figure 3-11). 
 
 
 
 Primer concentration optimisation 
To relieve the -30 primer set of excess primers 16 replicates were carried out, each of 
which had varying F and/or R primer concentrations. Much less PCR product was 
obtained when the lowest concentration (0.05µM) of each primer was utilised as 
Figure 3-11. SureClean purification of OPRM1 -30 primer set 
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designated by bands that were very faint (Figure 3-12, a). As the primer concentration 
increased more PCR product was replicated; however, there was also greater 
formation of secondary product. In general less secondary product was produced when 
0.05 or 0.1µM of F primer was added suggesting that excess F primer causes the 
secondary product (Figure 3-12, a, b, e, f, i, j, m, n). Of the 16 different combinations 
of F and R primer concentrations 0.05µM of F primer and 0.2µM of R primer gave 
the cleanest and brightest PCR product and the faintest secondary product (Figure 3-
12, i). 
 
 
 
 
Figure 3-12. -30 primer concentration optimisation 
A genomic DNA sample was amplified using the following concentrations of forward (F) and reverse 
(R) primers to amplify the -30 to -7bp of OPRM1: a) F:0.05µM, R:0.05µM; b) F: 0.1µM, R: 0.05µM; 
c) F: 0.2µM, R: 0.05µM; d) F: 0.4µM, R: 0.05µM; e) F: 0.05µM, R: 0.1µM; f) F: 0.1µM, R: 0.1µM; 
g) F: 0.2µM, R: 0.1µM; h) F: 0.4µM, R: 0.1µM; i) F: 0.05µM, R: 0.2µM; j) F: 0.1µM, R: 0.2µM; k) 
F: 0.2µM, R: 0.2µM; l) F: 0.4µM, R: 0.2µM; m) F: 0.05µM, R: 0.4µM; n) F: 0.1µM, R: 0.4µM; o) F: 
0.2µM, R: 0.4µM; p) F: 0.4µM, R: 0.4µM. 
 
3.5.1.4 ABI310 genetic analyser 
To ensure that the correct PCR product was amplified the replicated DNA was purified 
and subjected to sequencing using the ABI310 (Life Technologies). The PCR product 
was alleviated of excess PCR products using SureClean (Bioline). SureClean (15µL) 
was added to 15µL of PCR product. The samples were shaken for 1 minute and left to 
stand for 10 minutes. Following centrifugation the supernatant was carefully decanted 
leaving the DNA pellet in the bottom of the tube. To the pellet was added 100µL of 
a    b     c     d    e          f      g    h      i     j                 k     l    m    n     o    p 
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70% ethanol. Samples were shaken for 1 minute using a vortex mixer and centrifuged 
for 10 minutes. The supernatant was decanted and remaining pellet left to air dry. The 
DNA was resuspended in 10µL of water. 
F and R primers were diluted to make a stock solution of 3.3µM. Either the F or R 
primer (1µL) was added to a 0.5µL cleaned PCR product. BigDye (2µL; Life 
Technologies), Sequencing buffer (4µL; Life Technologies) and 12.5µL of water were 
also added to each sample. All samples were then placed in the Thermocycler and 
underwent the following temperature program (Figure 3-13): 
 
 
 
Figure 3-13. Incubation temperature program 
Samples were incubated 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 2 minutes for 25 
cycles, the temperature was then lowered to 4°C. 
 
An aliquot of the sample, 20µL, was added to 50µL 100% ethanol and 2µL sodium 
acetate buffer solution. Following a 1 minute vortex the samples were centrifuged for 
30 minutes. During this 30 minute window the sequencer was prepared for analysis. 
Fresh buffer, water and POP polymer (Life Technologies) were prepared if necessary 
and the sample list created. After centrifugation the supernatant was decanted and 
100µL 70% ethanol was added to the residue and centrifuged for 10 minutes. The 
ethanol was decanted and the residue left to air dry before 20µL deionised formamide 
was added and transferred to sequencing tubes. Denaturation was carried out by 
incubating the tubes for 2 minutes at 94°C and then placing them in an ice bucket for 
~1 minute before loading onto the sequencer.  
50°C 
25 cycles 
 
2 min 
10 
sec 
 
 96°C 
60°C  
4°C 
5 sec 
∞ 
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3.5.1.5 Pyrosequencing 
Once it was known that the correct PCR product was being obtained, pyrosequencing 
was undertaken. PCR product (10µL) was added to 2µL sepherose beads (Sigma 
Aldrich), 40µL pyrosequencing binding buffer (Qiagen) and 28µL water. A 
commercial wash station under vacuum (Qiagen) was used. Initially the probes were 
washed with water and dried under vacuum before placing them in the sampling plate. 
Successive washes were undertaken using 70% ethanol (5 seconds), Pyromark 
denaturation solution (5 seconds; Qiagen) and pyrosequencing wash buffer (10 
seconds; Qiagen). The vacuum was turned off and the probes placed inside a plate 
containing annealing buffer (Qiagen) that interrupts the bonds between the DNA and 
probes. The annealing buffer also contained 1µL of sequencing primer at a 
concentration of 0.3µM (sequencing primer obtained from Eurofins). Appropriate 
volumes of ddNTPs, enzyme and substrate were aliquotted into the pyrosequencer 
cartridge (as determined by the pyrosequencer software) and samples were analysed 
following the designed assay. 
 Assay on OPRM1 -32bp to -7bp assay 
The majority of tests for the -32 to 7bp assay initially failed because of the following 
errors: the sequence detected did not match the reference sequence, there was a low 
signal-to-noise ratio and peak height was too low for quantification. These errors 
occurred as there was not enough DNA present to give a strong signal (Figure 3-14 i). 
This low quantity of DNA caused irregular peak heights, for example Figure 3-14 ii 
peaks 5-9 should all be the same height as the expected sequence dictates that there is 
one G base followed by one T base, one A, one T, one A. The T bases are giving 
greater responses than the other bases suggesting that there are more T bases in the 
sample than there are in the reference sequence (Figure 3-14 b). Also, additional peaks 
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were detected in the sample (Figure 3-14 iii). As a result of these issues a second set 
of samples were amplified using a PCR programme with 40 PCR cycles instead of 35 
cycles to increase the quantity of product. The increased PCR cycles enhanced the 
pyrosequencing response marginally as the peak response increased from 15 to 40 but 
the peaks were still too low to be quantified (Figure 3-14 c). Although the signal 
response was still too low for methylation level quantification the increased quantity 
of DNA did improve the consistency of peak height and alleviated the sample of 
spurious peaks. The temperature of the heating block used during the annealing phase 
was increased which enhanced peak height, alleviated the pyrogram of interfering 
spurious peaks completely and produced consistent peak heights. 
 
 
 
 
 
 
 
 
Figure 3-14. Pyrograms of the OPRM1 promoter region from DNA samples that underwent either 
35 or 40 PCR amplification cycles 
a) Expected DNA sequence, b) sequence obtained from sample that underwent 35 PCR cycles, c) 
sequence obtained from sample that underwent 40 PCR cycles. i) low scale, ii) inconsistent peaks, iii) 
spurious peaks. 
 
 Assay on OPRM1 +12bp to +27bp assay 
Greater peak height  
Consistent peak height  
No spurious peaks  
a) Expected sequence 
b) Sample – 35 cycles 
c) Sample – 40 cycles 
i 
ii iii 
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3 CpG sites were investigated using the +12bp to +27bp primers. Similarly to the 
promoter region pyrosequencing results, a low signal response was reported. 
Following the increase of temperature during the annealing phase all 3 CpG sites of 
interest could be analysed. 
3.5.2 Designing methylation assays for ABCB1/MDR1 and CYP2D6 
Promoter region CpG sites in ABCB1/MDR1 (Figure 3-15; n = 11) were selected based 
on research undertaken by Dejeux et al. (2010). Dejeux et al. (2010) suggested that 
methylation of ABCB1/MDR1 could predict the response to, and efficacy of 
doxorubicin treatment. Differential methylation of ABCB1/MDR1 promoter region 
methylation was also observed in positive and negative tumours (Muggerud et al. 
2010). Therefore ABCB1/MDR1 was considered an appropriate candidate for variable 
response to opioids. 
 
 
 
Figure 3-15. Promoter region and exon 1 of ABCB1/MDR1 with CG regions of interest  
 
The final gene for methylation analysis was CYP2D6. In 2007, Ingelman-Sundberg et 
al. (2007) published an article reviewing epigenetic mechanisms in cytochrome P450 
enzymes. Methylation on CYP1A1 (Okino et al. 2006), CYP1B1 (Tokizane et al. 
2005), and CYP2W1 (Karlgren et al. 2006; Gomez et al. 2007) was shown to affect 
gene expression. Although no research had been undertaken on CYP2D6 methylation, 
Ingelman-Sundberg et al. (2007) illustrated that CYP2D6 contains a high density of 
Assay 2 
-284bp to 
-265bp 
Assay 1 
-356bp to 
-336bp 
  EXON 1 
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CpG dinucleotides and postulated that CYP2D6 expression may be regulated by 
epigenetic mechanisms. To the best of our knowledge, the only research to be 
undertaken on CYP2D6 methylation was published by Kim et al. (2010b). Kim et al. 
(2010b) reported no differences in CYP2D6 promoter region methylation between 
tamoxifen-resistant and control tissues. To date, the influence of CYP2D6 methylation 
on opioid response has not been investigated. As genetic variants within CYP2D6 have 
been shown to influence drug response it was considered an important gene to 
investigate. Therefore, 3 CpG sites were chosen for exploration (boxed in Figure 3-
16). 
GTGACTACATTAGGGTGTATGAGCCTAGCTGGGAGGTGGATGGCCGGGTCCACTGAAACCCTGGTTATCCCAGAAGGCTTTGCAGGCTTC
AGGAGCTTGGAGTGGGGAGAGGGGGTGACTTCTCCGACCAGGCCCCTCCACCGGCCTACCCTGGGTAAGGGCCTGGAGCAGGAAGCAGG
GGCAAGAACCTCTGGAGCAGCCCATACCCGCCCTGGCCTGACTCTGCCACTGGCAGCACAGTCAACACAGCAGGTTCACTCACAGCAGAG
GGCAAAGGCCATCATCAGCTCCCTTTATAAGGGAAGGGTCACGCGCTCGGTGTGCTGAGAGTGTCCTGCCTGGTCCTCTGTGCCTGGTGG
GGTGGGGGTGCCAGGTGTGTCCAGAGGAGCCCATTTGGTAGTGAGGCAGGTATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGT
GGCCATCTTCCTGCTCCTGGTGGACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTGCCCGGGCTG
GGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAGGTGAGGGAGGAGGTCCTGGAGGGCGGCAGAGGTCCTGA
GGATGCCCCACCACCAGCAAACATGGGTGGTGGGTGAAACCACAGGCTGGACCAGAAGCCAGGCTGAGAAGGGGAAGCAGGTTTGGGG
GACTTCCTGGAGAAGGGCATTTATACATGGCATGAAGGACTGGATTTTCCAAAGGCCAAGGAAGAGTAGG 
Figure 3-16. CpG sites located in the promoter region and exon 1 of CYP2D6 
CG represents potential variable methylation sites, CG show the CpG loci to be investigated. 
 
3.5.2.1 Primers for ABCB1/MDR1 and CYP2D6 
Primers were designed following the method described in 3.5.1.1 Primer design with 
the exception of the primers for ABCB1/MDR1. Primers for ABCB1/MDR1 were those 
utilised by Dejeux et al. (2010). Primers were ordered from Eurofins mwg|operon and 
reconstituted in water to make a primer concentration of 100µmol/µL (Table 3-6). 
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Table 3-6. Primers for PCR and pyrosequencing 
Primer Name Sequence 
H2O 
(µL) 
Optimum 
annealing 
temp. (°C) 
B1 and B2 F AAAACAAAATTAAAAATCTAACAAC 682 56.4 
B1 and B2 R BIO TTAGATTTAGGAGTTTTTGGAGTAG 721 49.9 
B1 seq TGGTATTGGATTATGTTGTT 460 na 
B2 seq TGGGTGGGAGGAAGT 279 na 
CYP2D6 F BIO TGGAGTAGGAAGTAGGGGTAAGAAT 412 61.3 
CYP2D6 R AACACAAAAAACCAAACAAAACAC 410 54.2 
CYP2D6 seq AAACACTCTCAACACACC 243 na 
 
3.5.2.2 Bisulfite conversion 
The methodology for bisulfite conversion has been described previously described 
(see section 3.5.1.2 Bisulfite conversion). 
3.5.2.3 PCR amplification 
For the PCR reaction, 1-4μL of bisulfite converted DNA was used (Table 3-7) 
dependent upon the quality and quantity of DNA being analysed (for example, 4μL of 
plasma DNA, 1μL of DNA from whole blood). The volume of the PCR reaction was 
maintained at 25μL by adjusting the volume of water. 
Table 3.7. Master mix for amplification of OPRM1, ABCB1 and CYP2D6 
 
 
 Volume (μL) 
PCR H20 19.1-16.1 
Buffer x10 2.5 
dNTPs 2.0 
Bisulfite converted DNA 1.0-4.0 
Forward primer 0.1 
Reverse primer 0.1 
GoTaq polymerase 0.2 
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The optimal temperature for each set of primers was established following the same 
method as ‘4.2.3 PCR optimisation’. The optimum temperatures and number of PCR 
cycles for each assay is shown in Figure 3-17. 
 
 
 
 
 
Figure 3-27. Temperature program for amplification of samples for sequencing
72°C 72°C 
30 sec 
30 sec 95°C 
30 sec 
ABCB1/MDR1:    50 cycles 
CYP2D6:  35 cycles 
∞ 
7 min 
10 min 
95°C 
ABCB1/MDR1:    57.0°C 
CYP2D6:   58.5°C 
 
4°C 
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3.6 Statistical analysis 
All statistical analyses were undertaken using SPSS v.20 (IBM). Normality was 
verified by Kolmogorov-Smirnov or Shapiro-Wilks tests (P = >0.05, data normally 
distributed). Data that was non-normally distributed was transformed using square 
root or LG10 transformations and Kolmogorov-Smirnov or Shapiro-Wilks tests 
undertaken again. 
Relationships between two or more sets of categorical variables were assessed by Chi-
squared tests utilising the Fisher exact test.  
3.6.1 Normally distributed data 
Student two-tailed t-tests were used when continuous variables with normal 
distribution were to be compared between two categorical/nominal independent 
datasets. If more than two independent datasets were used then one-way ANOVA was 
used to determine their relationship with continuous variables. The relationship 
between two continuous variables was assessed using Pearson’s correlation. 
3.6.2 Non-normally distributed data 
If data was non-normally distributed and could not be corrected by transformations 
the Mann-Whitney U test was employed for testing relationships of continuous 
variables between two categorical/nominal independent datasets. If more than two 
independent datasets were used then Kruskal Wallis H test was used to determine their 
relationship with continuous variables. The relationship between two continuous 
variables was assessed using Spearman’s rho correlation. 
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4.0 IMPACT OF SMOKING ON BUCCAL DNA 
METHYLATION OF OPIOID IMPORTANT GENES 
4.1 Introduction 
As smoke exposure has been shown to effect the methylation of a variety of genes (see 
section 2.2.4.4), the influence of tobacco smoke on opioid related genes was of 
interest. Variable response to opioids as a result of genetic variations have been 
reported within a clinical setting (see section 2.1.4.6), therefore smoke-induced 
genetic alterations may play a role in opioid response. The influence of smoke 
exposure on opioid related genes is of importance when studying subjects with 
addiction to drugs as many drug users are also smokers. Therefore a population of 
non-opioid exposed current smokers, former smokers and non-smokers were recruited 
and the extent of methylation on the promoter region of OPRM1 and CYP2D6 was 
determined.                                                                                                                                                                                                                                                                                                                                                       
4.2 Materials and methods 
4.2.1 Sample collection 
Participants were recruited as described in 3.1.1. Buccal swabs were collected using 
Catch-AllTM brushes following the protocol in 3.2.1.1. The study was approved by the 
Bournemouth University Science, Technology and Health Research Ethics Panel. 
4.2.2 Methylation analysis 
CYP2D6 and OPRM1 gene DNA methylation was determined as described in 3.5.   
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4.3 Results 
Participants (n = 93) were classified into five groups: never-smokers (n = 43); ex-
smokers (n = 16), last smoked 1-24 years prior to study participation; smoke <15 
cigarettes per day (n = 23); smoke >15 cigarettes per day (n = 6); and social smokers 
(n = 5) (Table 4-1). A cut-off of 15 cigarettes per day indicating low / high 
consumption was chosen based on other studies (e.g. Bjartveit and Tvardel 2005).  
The median age of the study population was 29 with a range of 19-52. Of the 93 
participants 25 were undergraduate students, 34 were postgraduate students (Masters 
or PhD) and 34 were teaching staff. The age ranges of each smoking or non-smoking 
group are shown in Table 4-1. Using the Kruskal Wallis H test no difference was found 
in age between the women who have never smoked (median 26) and those who 
smoked previously (median 24). However the ex-smokers tended to be older than the 
social smokers (P = 0.018) and older than those who smoke <15 cigarettes a day (P = 
0.004). 
Table 4-1. Age of smoking and non-smoking study participants 
 
n Age range Median age 
CYP2D6 
methylation % SD 
(n) 
OPRM1 
methylation % SD 
(n) 
Never smoked 43 20 - 50 26 90.8 ±1.7 (43) 11.7 ±5.0 (24) 
Ever smoked 50 19 - 50 24 91.0 ±1.8 (43) 10.5 ±3.1 (43) 
 
Ex-smoker 16 21 - 50 33 91.1 ±2.5 (12) 10.1 ±2.7 (13) 
<15 cig./day 23 19 - 48 22 91.0 ±1.4 (21) 10.7 ±3.0 (19) 
>15 cig./day 6 19 - 40 24 90.8 ±2.6 (5) 10.8 ±5.2 (6) 
Occasional* 5 20 -32 20 90.9 ±1.1 (5) 10.9 ±1.5 (5) 
*“Social smokers”, smoke less than 3 cigarettes per week in a drinking environment. 
Methylation data for CYP2D6 and OPRM1 was obtained in 92% and 72% of cases 
respectively. OPRM1 methylation data from an additional 23 individuals was obtained 
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from the smoker and non-smoker buccal swabs, however during data transfer from the 
pyrosequencer USB to the computer the information was lost as a result of operator 
error. The cases could not be reanalysed within the timeframe of the PhD.  
No relationships were observed following Spearman’s rho correlation between age 
and methylation of either CYP2D6 (correlation coefficient .099, P = 0.363) or OPRM1 
(correlation coefficient .088, P = 0.481). In addition, no methylation differences were 
observed in CYP2D6 or OPRM1 between the different smoking statuses (P = 0.991, 
figure 4-1; P = 0.822, figure 4-2, respectively). 
Figure 4-1. CYP2D6 methylation in non-smokers, ex-smokers, frequent smokers (<15 or >15 
cigarettes/day) and social smokers 
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Figure 4-2. OPRM1 methylation in non-smokers, ex-smokers, frequent smokers (<15 or >15/day 
cigarettes) and social smokers 
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4.4 Discussion 
Regardless of an individual’s smoking exposure the average methylation of 3 CpG 
sites in CYP2D6 and 8 CpG sites in OPRM1 were unchanged. Previous studies have 
shown that smoke exposure can cause methylation alterations, however these 
alterations were observed at repetitive elements within diseased tissues (Smith et al. 
2007; Furniss et al. 2008) and promoter regions, or individual CpG loci of specific 
genes (Zöchbauer‐Müller et al. 2003; Enokida et al. 2006; Marsit et al. 2007; Kupfer 
et al. 2010; Wan et al. 2014). Promoter region CpG sites within OPRM1 were 
investigated in this study as previous research reported higher methylation in 
lymphocyte and sperm DNA of opioid exposed individuals compared to controls 
(Nielsen et al. 2009; Chorbov et al. 2010). The increased methylation was postulated 
to be as a result of opioid exposure; however the effect of smoking was not taken into 
consideration. The data obtained from this study suggests that the CpGs investigated 
in CYP2D6 and OPRM1 of buccal swab DNA are not targets for smoke induced 
methylation changes.  
The lack of variable methylation between smokers and non-smokers in this study may 
in part be explained by tissue choice. Epithelium cells of heavy smokers from four 
different aerodigestive tract tissues were compared and tissue specific methylation was 
identified (Zöchbauer‐Müller et al. 2003). Similarly, Chien (2011) compared 
methylation in blood and buccal swabs and observed variable methylation. The 
methylation differences between paired blood and buccal swabs being greater in 
samples obtained from smokers than non-smokers (Chien 2011). Smoke induced 
methylation differences were observed on CpG sites within the gene body of OPRM1 
in peripheral blood samples of adolescents exposed to maternal smoking (Lee et al. 
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2014). The study by Lee et al. (2014) showed that methylation levels were lower in 
adolescents who were exposed to nicotine prenatally compared to non-nicotine 
prenatally exposed adolescents. The differences in OPRM1 gene body methylation  
are  thought to play a role in regulating the alternative splice sites (Shukla et al. 2011; 
Li-Byarlay et al. 2013; Gelfman and Ast 2013) and may also regulate OPRM1 by 
inhibiting alternative promoters (Maunakea et al. 2010).  
The results from this pilot population suggest that DNA methylation of CYP2D6 and 
OPRM1 is not influenced by smoking therefore methylation differences observed in 
later populations may represent the influence of other factors. 
4.4.1 Study limitations 
Limited information was collected regarding the type of cigarettes smoked, i.e. 
branded or own rolled. This may have an influence on DNA methylation as nicotine 
(the DNA altering chemical) percentage content of different cigarettes may vary. The 
smoking groups were also quite generalised but groupings were necessary to obtain 
substantial groups for comparison. Each individual’s style of smoking may also alter 
the risk of DNA methylation as the volume of smoke inhaled and the length of time 
the smoke was held in the oral cavity will differ. As diet has been shown to change 
gene DNA methylation it would have been of interest to investigate nutritional intake, 
specifically folate and other methyl group donors. Comparison of gene DNA 
methylation with length of time smoked would also have been of interest rather than 
just current smoking status. However this study was undertaken as a pilot population 
to ascertain whether any gene DNA methylation differences were observed between 
smokers and non-smokers and to encourage participation the questionnaires were kept 
minimal. 
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5.0 METHADONE-PRESCRIBED OPIOID-
DEPENDANT MOTHERS AND THEIR NEW-BORN 
BABIES: Babies Born to Methadone-Prescribed Opioid-
Dependant Mothers have Elevated DNA Methylation on 
ABCB1/MDR1, CYP2D6 and OPRM1. 
5.1 Introduction 
Since the early 1900s, methadone has been used for opioid-dependant women during 
pregnancy as it has fewer risks than illicit opioid use (National Institutes of Health 
Consensus Development Panel, 1998; Fisher and Fisher 2000). Despite the popularity 
of methadone there are still significant risks associated with its use for the developing 
foetus. Infants of methadone-prescribed mothers tend to have shorter gestation periods 
and therefore lower birth weights, heights, and smaller head circumferences, and are 
at risk of developing neonatal abstinence syndrome (NAS) (Shaw and McIvor 1994; 
Dashe et al. 2002; Arlettaz et al. 2005; Fajemirokun-Odudeyi et al. 2006; Kakko et al. 
2008; Dryden et al. 2009; Wouldes and Woodward 2010; Cleary et al. 2011).  
The negative effects of intrauterine methadone have been shown to continue into early 
childhood influencing post-natal weight gain, head circumference, height and trends 
towards poorer cognitive, psychomotor and behavioural performance compared to 
non-opioid exposed infants / children (Bauman and Levine 1986; Soepatmi 1994; 
Darke et al. 2000; Pirastu et al. 2006; Whitham et al. 2010; Konijnenberg and 
Melinder 2013; Baldacchino et al. 2014).  
With regards to methadone, Nielsen et al. (2008) reported significantly increased 
DNA methylation of OPRM1 in lymphocytes of former heroin addicts compared to 
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controls. These observations were later replicated by Chorbov et al. (2010) and 
Doehring et al. (2013) who concluded that opioid misuse may alter OPRM1 
methylation. To the best of our knowledge, the influence of intrauterine methadone on 
the developing foetal DNA methylation has not yet been reported. Wachman et al. 
(2014) compared methylation levels in OPRM1 of methadone exposed infants 
requiring NAS treatment, and those that did not require NAS. However they did not 
have a control population to determine the methylation profile of a non-opioid exposed 
population. 
The aim of this study was to examine the different methylation status in selected 
opioid-related genes (ABCB1, CYP2D6 and OPRM1) between, a) babies born to 
MPOD mothers and babies of non-opioid exposed mothers, b) MPOD mothers and 
non-opioid mothers, c) MPOD mothers and their babies, and d) non-opioid exposed 
mothers and their babies. 
5.2 Materials and methods 
5.2.1 Sample collection 
Mother and baby dyads were recruited as described in 3.1.2 and samples collected as 
detailed in 3.2.2. 
5.2.2 Toxicological analysis 
Plasma samples from 18 of the MPOD mothers were analysed for methadone and its 
metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) at the 
Toxicology Unit, Imperial College London as previously described in 3.3.1. 
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5.2.3 DNA methylation analysis 
DNA was extracted from the Catch-AllTM oral swabs as described in 3.4.1.1 and 
methylation profile determined using the pyrosequencing method detailed in 3.5.
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5.3 Results 
MPOD mothers were prescribed a mean methadone dose of 59 ±27.6 mg. Methadone 
plasma concentrations were determined in 18 of the 21 samples. A median methadone 
concentration of 245 ng/mL was observed with a range of 60-720 ng/mL. In addition 
to the prescribed methadone, during pregnancy all the mothers had smoked cigarettes 
and consumed other prescription / illicit drugs e.g. benzodiazepines. The majority of 
opioid-dependant mothers lived in the more deprived areas of Glasgow, as ascertained 
by their DEPCAT score (86%). Of the 21 babies born to opioid-dependant mothers, 
11 required treatment for NAS using either oramorph (73%) or phenobarbititone 
(27%). The MPOD mothers and mothers in the control group were not only matched 
by postcode, but also by age (32 ±4.2 vs. 30 ±5.3 years, P = 0.268, df 51), gestation 
period (272 ±9.4 vs. 277 ±9.2 days, P = 0.122, df 51) and smoking status. Baby birth 
weight was significantly lower in the opioid-dependant group than the non-opioid 
exposed control group (2815 ±352.5 vs. 3386 ±533.7 grams, P = <0.001, df 51). 
5.3.1 Methylation differences between methadone exposed and non-
opioid exposed mothers and babies 
Using independent t-tests, mean methylation of ABCB1/MDR1, CYP2D6 and OPRM1 
was shown to be greater in babies born to MPOD mothers than babies in the control 
population (P = <0.001, df 47, figure 5-1). The most prominent difference was 
observed in ABCB1/MDR1 (17.8% ±0.5 vs. 2.6% ±0.4), followed by OPRM1 (8.5% 
±0.3 vs. 3.5% ±1.6), then CYP2D6 (92.1% ±1.2 vs. 89.3% ±2.4). As observed in the 
baby comparison, the greatest methylation difference between the MPOD mothers and 
control mothers was seen in ABCB1/MDR1 (18.4% vs 3.0% respectively, P = <0.001, 
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df 18, figure 5-2). A statistically significant difference was also observed in CYP2D6 
(92.6% vs. 90.5%, P = 0.001, df 45) but not OPRM1 (8.7% ±0.4 vs. 8.1% ±2.1, P = 
0.147, df 31).  
 
Figure 5-1. Methylation differences between methadone exposed babies and controls in 
ABCB1/MDR1, CYP2D6 and OPRM1 
Control babies (left columns in blue) were significantly less methylated on ABCB1/MDR1, CYP2D6 
and OPRM1 than babies exposed to methadone in utero (right columns in green). 
 
 
Figure 5-2. Methylation differences between methadone exposed mothers and controls in 
ABCB1/MDR1, CYP2D6 and OPRM1 
Control mothers (left columns in red) were significantly less methylated on ABCB1/MDR1 and CYP2D6 
than methadone exposed mothers (right columns in purple), however no difference was observed on 
OPRM1. 
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In the control population the mothers’ methylation levels in OPRM1 and 
ABCB1/MDR1 were greater than that of their babies (P = <0.001, df 53 and P = 0.018, 
df 27 respectively) but no difference in methylation was observed in CYP2D6 (P = 
0.852, df 62). Between the MPOD mothers and their babies no differences were 
observed in any of the genes investigated (Figure 5-3).  
 
Figure 5-3. Methylation differences between methadone exposed mothers – baby dyads and 
control mother – baby dyads in ABCB1/MDR1, CYP2D6 and OPRM1  
Opioid exposed mother and baby dyads (green and purple columns) had similar methylation on the 
three genes investigated. Non-opioid exposed babies (blue column) had less methylation on 
ABCB1/MDR1 and OPRM1 than their mothers (red column), however no difference was observed on 
CYP2D6. 
 
 
5.3.2 Relationship between methylation and smoking / residential status 
Exposure to the chemicals within cigarettes, and residence within deprived or affluent 
regions of Glasgow did not impact the methylation in any of the genes investigated of 
either the mothers or their babies (Table 5-1).  
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Table 5-1. No relationship was observed between smoking exposure or residential status and 
ABCB1/MDR1, CYP2D6 and OPRM1 gene DNA methylation 
 Smoking Exposure Residential Status 
 P (2-tailed) df P (2-tailed) df 
ABCB1/MDR1 
Control Babies 0.083 18 0.083 18 
Control Mothers 0.176 7 0.176 7 
Methadone Exposed Babies nd nd 0.722 17 
Methadone Exposed Mothers nd nd 0.746 17 
CYP2D6 
Control Babies 0.213 30 0.350 30 
Control Mothers 0.317 21 0.274 30 
Methadone Exposed Babies nd nd 0.323 17 
Methadone Exposed Mothers nd nd 0.662 16 
OPRM1 
Control Babies 0.112 28 0.112 28 
Control Mothers 0.059 27 0.135 27 
Methadone Exposed Babies nd nd 0.599 18 
Methadone Exposed Mothers nd nd 0.992 17 
Independent sample t-tests were undertaken on control mother and baby, and methadone exposed mother and baby 
samples. P values of <0.05 were considered significant. nd = no data: all of the methadone exposed mothers were 
smokers so no comparison between smokers and non-smokers could be made for the methadone exposed 
population. 
 
5.3.3 Relationship between methylation and NAS development 
There were no methylation differences between the babies of MPOD mothers that 
required NAS treatment or did not require NAS treatment in any of the genes analysed 
(Table 5-2). 
Table 5-2. No relationship was observed between the development of NAS and ABCB1/MDR1, 
CYP2D6 and OPRM1 gene DNA methylation 
 NAS Development 
P (2-tailed) df 
ABCB1/MDR1 0.343 17 
CYP2D6 0.992 17 
OPRM1 0.992 18 
Independent sample t-tests were undertaken on control mother and baby, and methadone exposed mother and baby 
samples. P values of <0.05 were considered significant. 
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5.3.4 Methylation differences between paired plasma and buccal DNA 
samples 
The methylation percentages observed in the buccal swabs were statistically different 
from the methylation found in paired plasma samples provided by the MPOD mothers. 
This statistical difference was observed in each of the three genes analysed (Figure 5-
4). Methylation was higher in buccal DNA than plasma DNA at the CpG sites 
investigated in ABCB1/MDR1 and OPRM1; however plasma had higher methylation 
in CYP2D6 than buccal DNA. Bivariate Spearman’s rho correlation showed no 
relationship between buccal and plasma ABCB1/MDR1 (.362, P  = 0.140, n = 18) 
CYP2D6 (-.007, P = 0.980, n = 15) or OPRM1 (.178, P = 0.543, n = 14) DNA 
methylation levels.   
 
Figure 5-4. MPOD mother buccal and plasma methylation 
The difference between buccal and plasma gene DNA methylation was assessed using the related-samples 
Wilcoxon signed rank test as the data for plasma DNA methylation was non-normally distributed and could not be 
normalised. 
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5.4 Discussion 
The aim of this study was to determine the effect of in utero methadone exposure on 
baby methylation in ABCB1/MDR1, CYP2D6 and OPRM1. The results suggest that in 
utero exposure to methadone could increase DNA methylation of babies born to 
MPOD mothers; alternatively, or as a co-factor, the methadone associated lifestyle 
could influence DNA methylation patterns.  
The opioid exposed babies had significantly higher methylation of each of the genes 
investigated compared to the non-opioid exposed babies. Unlike previous studies, the 
methylation differences observed between the opioid exposed and non-opioid exposed 
babies are much more prominent, especially the CpG sites investigated in 
ABCB1/MDR1. In studies comparing opioid exposed adults to non-opioid exposed 
adults, significant methylation differences of only a few percent have been reported 
(Nielsen et al. 2009; Chorbov et al. 2010; Doehring et al. 2013) e.g. at CpG -18 of 
OPRM1 average methylation in methadone exposed individuals was 25.4% compared 
to 21.4% in opioid naïve individuals. However, the opioid exposed babies in this study 
had ≥ double the methylation of the control babies. The reported methylation levels 
by Chorbov et al. and Doehring et al. are not comparable as adult populations were 
used, not babies and methylation has been shown to be age dependant (Heyn and 
Estellar 2012). Also, methylation has been shown to be tissue-specific (Zhang et al. 
2013) so DNA from lymphocytes, whole blood, sperm and brain tissue are not be 
comparable to the buccal DNA collected for this study.  
To our knowledge the only study that has investigated CpG sites in saliva samples 
from neonates was published by Wachman et al. (2014) who reported methylation 
levels in OPRM1 that were lower than found in our opioid exposed population (~5.1% 
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v 8.9%) but greater than the methylation levels observed in our control population 
(~5.1% v 3.8%). Wachman et al. (2014) did not have a non-opioid exposed cohort for 
comparison. They did, however find a methylation difference between babies that 
required NAS treatment and those that did not (at CpG -10 in OPRM1); and between 
babies that required more than 2 treatments to alleviate NAS compared to those that 
had 0-1 treatments (CpG -10, -14 and +84). The results of this study do not support 
the report that relationship between CpG methylation and requirement of NAS 
treatment as observed by Wachman et al. (2014).  The proposition that this could be a 
sample size effect should not be excluded. 
The gene methylation disparity between the opioid exposed babies and non-opioid 
exposed babies could be explained by the influence of methadone exposure during 
fertilisation and embryonic development. This period is essential for correct 
development and is a sensitive period of epigenetic reprogramming. Epigenetic marks 
are made during foetal development persist to adulthood (McKay et al. 2012), 
therefore exposure to methadone / methadone-lifestyle during this sensitive period 
could adversely affect the babies DNA methylation with possible consequences in 
later life. Intrauterine exposures have been associated with increased risk of 
developing diseases later in life (Jirtle and Skinner 2007; Reamon-Buettner and Borlak 
2007). 
Potential mechanisms (as discussed by Doehring et al. 2013) by which methadone 
could increase DNA methylation is by G-protein-coupled receptor-mediated increase 
of DNA methyltransferase activity. Stimulation of the CB1R cannabinoid receptor, a 
G-protein-coupled receptor, is thought to increase global methylation status by 
triggering the activation of p38 and, to a lesser extent, the p42/44 mitogen-activated 
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protein kinase-dependant (MAPK) pathways that stimulate transcription factors 
(Paradisi et al. 2008). Methadone binds to the mu-opioid receptor, which is a G-
protein-coupled receptor like CB1R and therefore also triggers the MAPK pathways 
(Morse et al. 2011).  
The increased methylation observed in babies of MPOD mothers however may or may 
not exclusively be a result of methadone exposure. Research into the lifestyle of heroin 
addicts indicates that these individuals experience chaotic, stressful, high risk 
lifestyles (Hulse et al. 1998; Gyarmarthy et al. 2009), with risk of developing 
depression and anxiety (Sordo et al. 2012; Chahua et al. 2013). These factors have 
been associated with variable methylation (McGowan et al. 2009; de Rooij et al. 
2012). Methadone-maintenance treatment improves opioid-dependant individuals’ 
quality of life (Xiao et al. 2010; Wang et al. 2012), however stresses are still 
experienced (Barry et al. 2011). Alongside stressful lifestyles, opioid dependant 
individuals tend to have a poor diet (Himmelgreen et al. 1998; Nazrul Islam et al. 
2002; Saeland et al. 2009; Neale et al. 2012) and be poly-drug users (SAMHSA 2007; 
Brecht et al. 2008; Jansson et al. 2012). The combination of these factors is thought 
to contribute to the negative impact on the developing foetus (Bell and Lau 1995; 
Hulse et al. 1998) and therefore may alter their DNA methylation profiles (Hogg et al. 
2012).  
The results showed that the methadone exposed babies had similar methylation levels 
to that of their MPOD mothers in each of the genes investigated. Less methylation was 
expected in the methadone exposed baby population compared to the MPOD mothers 
as previous studied have shown that methylation of CpG rich regions can be age 
associated (Gopisetty et al. 2006; Heyn and Esteller 2012). However, age related 
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methylation changes can be gene specific and to the best of our knowledge there is 
little age-methylation related data on the CpG sites investigated as part of this study. 
The data obtained from the control (non-opioid exposed) baby and mother population 
however illustrated that methylation of CpG sites within the promoter regions of 
ABCB1/MDR1 and OPRM1 differ, but not in CYP2D6. As the paired mother-baby 
dyads were exposed to the same diet, stresses and chemical exposures, the increased 
methylation differences observed on ABCB1/MDR1 and OPRM1 of the control 
mothers is thought to be due to the acquisition of methylation over time, before 
pregnancy. 
When comparing the methylation in MPOD mothers and controls it is apparent that 
MPOD mothers have increased methylation on ABCB1/MDR1 and CYP2D6 genes. 
The methylation differences observed were not attributable to the mothers’ age, 
whether they smoked or not, or the areas they reside in. As such, the increased 
methylation in MPOD mothers is thought to be as a result of regular opioid exposure, 
or the associated lifestyle. There are no studies to date that have explored the 
relationship between DNA methylation on ABCB1/MDR1 and CYP2D6 and 
methadone exposure. However there have been previous studies investigating the 
methylation of CpG sites within OPRM1. These studies observed CpG point-wise 
differences between the opioid exposed and control populations in OPRM1 (Nielsen 
et al. 2009; Chorbov et al. 2010; Doehring et al. 2013) although, those findings were 
not replicated in our data.  
To maintain DNA methylation patterns essential methyl group donors such as folate, 
choline and methionine are required. These nutrients are obtained from foods such as 
fruits, vegetables, beans and nuts (La Brosse and Albrecht 2012) and diets that 
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deficient of these nutrients have been shown to cause global hypomethylation (Jacob 
et al. 1998; Rampersaud et al. 2000; Pufulete et al. 2005; Niculescu et al. 2006). High 
fat and sugary maternal diets have also shown promoter hypomethylation of rat/mice 
studies in brain (Vucetic et al. 2010), but the changes can be sex-specific (Gallou-
Kabani et al. 2010). A limitation of the present study was that the nutritional intake of 
mothers was not obtained. The MPOD mothers were considered nutrient and vitamin 
deficient. If so, our work suggests that diet is not the factor causing the increased 
methylation observed in OPRM1, ABCB1/MDR1 and CYP2D6 of babies born to 
MPOD mothers.  
Alcohol has been reported to impact DNA methylation (Christensen et al. 2010; 
Lambert et al. 2011) and although there is no literature on benzodiazepines and 
methylation, the behavioural and  neurobehavioral problems of new-borns exposed to 
prescribed and illicit psychoactive substances has been reported (Jansson et al. 2012). 
In addition the majority of MPOD mothers were prescribed or admitted illicit 
benzodiazepine use, and had an unknown amount of alcohol consumption.  
The methadone as well as the stresses and diet that babies born to MPOD mothers are 
exposed to may alter the DNA methylation of important opioid related genes. These 
alterations established during a sensitive period of epigenetic programming are then 
maintained during cell replication which may impact the babies’ behaviour and 
susceptibility to disease and drug use later in life. Our findings suggest that the 
methylation changes on different genes are not diet related. 
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5.4.1 Study limitations 
Numbers for this pilot population were small for the number of variables investigated. 
A bigger population and undertaking a multiple regression would have been 
beneficial. Additional information from the methadone exposed and opioid naïve 
populations would also have been useful. For example, the maternal diet, measurement 
of stress indicators and a record of confounding substrates (e.g. alcohol and prescribed 
and illicit drug use). 
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6.0 METHADONE-PRESCRIBED OPIOID-
DEPENDANT MOTHERS AND THEIR NEW-BORN 
BABIES: The CYP2B6*6 polymorphism protects 
babies exposed to methadone in utero from neonatal 
abstinence syndrome development. 
6.1 Introduction 
Opioid use during pregnancy has increased over the last two decades, as has the 
number of women of child bearing age that are opioid dependant (Unger et al. 2012; 
Brogly et al. 2014; Goettler and Tschudin 2014). This is of concern as unplanned 
pregnancies amongst opioid users are common because of irregular / absent menstrual 
cycles as well as ineffective use of contraceptive drugs (Kreek et al. 1999; Herrmann 
et al. 2014). Infants born to opioid addicted mothers can suffer congenital 
abnormalities, foetal growth restriction, preterm birth, impaired neurodevelopment 
and may experience opioid withdrawal, neonatal abstinence syndrome (NAS) 
(Bandstra et al. 2010).  
Of the infants exposed to intrauterine methadone, ~60-80% exhibit symptoms of NAS 
(Jones et al. 2010; Welle-Strand et al. 2013; Gawronski et al. 2014). NAS manifests 
as tremors, high pitched crying, unrest, yawning, sneezing, vomiting, diarrhoea, fever 
and poor sucking. The onset of these withdrawal symptoms can occur anytime from 
48 hours to 10 days following birth (Dryden et al. 2009; Smirk et al. 2014). A study 
by Dryden et al. (2009) showed that of 450 infants exposed to methadone in utero 
almost 50% required pharmacological treatment for NAS and as such were admitted 
to the neonatal care unit. The length of stay within the neonatal unit ranged from 1 – 
108 days (median 13 days). Although infants born to opioid-dependant women only 
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represented 2.9% of all hospital births, the infants occupied 18.2% of the neonatal cots 
reflecting their increased medical needs. The costs are not only restricted to infant 
monitoring, but also spent on providing breastfeeding and parenting support to the 
mothers as well as social work assessment and support in the community (Dryden et 
al. 2009). The subsequent postnatal care of the opioid exposed infants draws heavily 
upon healthcare resources (Dryden et al. 2009; Patrick et al. 2012; Smirk et al. 2014); 
therefore identification of factors predicting NAS development may enable reduced 
observation or early discharge of less susceptible infants resulting in large financial 
savings. 
A number of factors have been associated with development NAS, including dose of 
methadone prescribed, exposure to tobacco and whether or not the infant is breast fed 
(Kaltenback et al. 2012). Recent research by Wachman et al. (2013, 2014) also 
suggested the use of genetic and epigenetic variations for predicting the development 
of NAS. They found that polymorphisms within the µ-opioid receptor, encoded by 
OPRM1, and the metabolising enzyme for endogenous opioids, COMT, were 
associated with requirement for NAS treatment and extended stay at hospital 
following birth. In addition, Wachman et al. (2014) found that DNA methylation was 
greater within the promoter region of OPRM1 of the infants who required two or more 
treatments for NAS. Identification of genetic variations that may aid NAS prediction 
early among infants at risk is useful so as to allow appropriate monitoring. The NAS 
predictors could also negate prolonged hospital stays for neonates who are less likely 
to develop withdrawal, reducing the healthcare costs associated with NAS monitoring 
e.g. cot occupancy or staff undertaking NAS assessments every 4 hours.   
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6.2 Materials and methods 
6.2.1 Sample collection 
Participant selection and requirements described in 3.1.2. Oral swab and plasma 
samples were collected as detailed in 3.2.2.1 and 3.2.2.2, respectively. 
6.2.2 Toxicological analysis 
Plasma samples from 18 of the MPOD mothers were analysed for methadone and its 
metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) at the 
Toxicology Unit, Imperial College London as previously described in 3.3.1. Plasma 
samples were not collected from two MPOD mothers. 
6.2.3 SNP and gene duplication / deletion analysis  
DNA was extracted from buccal swabs following the protocol detailed in 3.4.1.1 and 
sent to LCG genomics for SNP analysis (following the preparation detailed in 3.4.3). 
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6.3 Results 
The mothers (n=20) had an average age of 32 ±4 and were prescribed methadone doses 
of 59 ±28 mg; alongside the methadone the mothers all smoked. Their babies had a 
mean gestation period of 272 ±9 days and at birth weighed 2815.4 ±353.5 g. After 
birth the babies had a median length of stay at hospital of 11 days (range 5 – 42 days). 
Of the 20 methadone exposed babies recruited, 10 required treatment for NAS. 
Between the babies requiring and not requiring NAS treatment there was no difference 
in length of gestation, birth weight, maternal methadone dose, or maternal plasma 
methadone concentration (Table 6-1) as assessed by independent t-tests. Fisher’s exact 
test showed that there was no relationship between infants that suffered from NAS and 
their mothers’ DEPCAT score, and also no association between NAS development 
and likelihood of baby remaining in the mother’s care. Babies of older mothers had an 
increased likelihood of requiring NAS treatment (P = 0.025, df 18), and babies that 
were treated for NAS required a longer stay at hospital than the babies not requiring 
NAS treatment (P = 0.004, df 18).  
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Table 6-1. Summary of demographic and methylation data of methadone exposed babies (n=20) 
treated or not treated for Neonatal Abstinence Syndrome 
* dose corrected = methadone plasma concentration / prescribed methadone dose. 
 
6.3.1 Associations between ABCB1/MDR1, COMT, CYP2B6, CYP2D6 and 
OPRM1 genes and NAS development 
Buccal DNA was obtained from all 20 babies, however insufficient sample resulted in 
some samples (as detailed in Table 6-2) not being analysed for the SNPs of interest in 
ABCB1/MDR1, COMT, CYP2B6, CYP2D6 and OPRM1. 
 
 
 
 
 
 
 
 
Variables 
Babies requiring 
NAS treatment 
(n=10) 
Babies not 
requiring NAS 
treatment (n=10) 
P value 
Gestation  
Days  (SD) 
274 (±9) 270 (±10) 0.408, df 18 
Birth Weight  
Grams (SD) 
2731 (±315) 2876 (±398) 0.378, df 18 
Maternal methadone dose  
mg (SD) 
66 (±24) 54 (±32) 0.351, df 18 
Length of hospital stay      
Days (range) 
20 (±11) 7 (±2) 0.004, df 18 
Maternal age                           
Years (SD) 
34 (±4) 30 (±4) 0.025, df 18 
Discharged to maternal care 5 6 0.367, df 18 
DEPCAT score >4                    
Total 
8 7 1.000, df 18 
Maternal methadone concentration 
dose corrected (SD)* 
4.6 (±2) 5.3 (±9)  0.591, df 18 
Maternal smoking 
Total 
10 10 1.000, df 18 
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Table 6-2. Baby genotype frequencies (n=20) 
Single nucleotide polymorphism No. Genotype Frequencies Allele Frequencies 
ABCB1/MDR1 
1236C>T  
rs1128503 
19 
CC = 0.21 
C = 0.475 
T = 0.525 
CT = 0.53 
TT = 0.26 
ABCB1/MDR1  
2677G>T  
rs2032582 
20 
GG = 0.15 
G = 0.450 
T = 0.550 
GT = 0.60 
TT = 0.25 
ABCB1/MDR1  
3435C>T  
rs1045642 
19 
CC = 0.21 
C = 0.420 
T = 0.580 
CT = 0.42 
TT = 0.37 
COMT  
186C>T  
Rs4633 
18 
CC = 0.11 
C = 0.390 
T = 0.610 
CT = 0.56 
TT = 0.33 
COMT  
158A>G 
rs4680 
20 
GG = 0.15 
G = 0.450 
A = 0.550 
GA = 0.60 
AA = 0.25 
COMT  
408C>G  
rs4818 
18 
CC = 0.39 
C = 0.610 
G = 0.390 
CG = 0.44 
GG = 0.17 
COMT  
-98A>G  
rs6269 
20 
GG = 0.15 
G = 0.375 
A = 0.625 
GA = 0.45 
AA = 0.40 
CYP2B6  
516G>T 
rs3745274 
18 
GG = 0.50 
G = 0.750 
T = 0.250 
GT = 0.50 
TT = 0.00 
CYP2B6  
785A>G 
rs2279343 
19 
AA = 0.50 
A = 0.750 
G = 0.250 
AG = 0.50 
GG = 0.00 
CYP2D6  20 
1 func. allele = 0.10 
 2 func. alleles = 0.75 
>2 func. alleles = 0.15 
CYP2D6  
1707T>delT 
rs5030655 
20 
TT = 0.95 
T = 0.975 
- = 0.025 
T- = 0.05 
- - = 0.00 
OPRM1  
118A>G  
rs1799971 
19 
AA = 0.89 
A = 0.945 
G = 0.055 
AG = 0.11 
GG = 0.00 
NB CYP2D6 1845 G>A (rs3892097) and CYP2D6 2459 A>delA (rs35742686) are not included in the table as all 
the infants carried the same genotypes at these polymorphisms. 
 
Of the 13 SNPs analysed, all the babies carried the same genotype at two CYP2D6 
SNPs (rs3892097 and rs35742686) so are not represented in Table 6-2. In relation to 
the development of NAS, CYP2B6 516G>T and 785A>G were observed to be 
associated (Table 6-3; P = 0.015, df 18 and 0.023, df 18, respectively). Babies carrying 
the homozygous wild type genotype were more likely develop NAS and require 
treatment that heterozygous babies. No relationship between NAS development and 
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any other SNP was observed. There was also no relationship between the number of 
copies of CYP2D6 and NAS development. 
Table 6-3. Association between baby genotype and NAS development as determined by Fisher’s 
exact test 
 ABCB1/MDR1 
1236 2677 3435 
CC CT/TT GG GT/TT CC CT/TT 
NAS treated 2 7 2 8 2 7 
Untreated 2 8 1 9 2 8 
P value 1.000 1.000 1.000 
 
COMT 
62 158 408 -98 
CC CT/TT GG GA/AA GG GC/CC GG GA/AA 
NAS treated 1 9 1 9 1 7 1 9 
Untreated 1 7 2 8 2 8 2 8 
P value 1.000 1.000 1.000 1.000 
 
CYP2B6 
516 785 
GG GT/TT AA AG/GG 
NAS treated 8 2 7 2 
Untreated 1 7 2 8 
P value 0.015 0.023 
 
CYP2D6 
Number of copies 1707 
1 ≥2 TT T- 
NAS treated 0 10 9 1 
Untreated 2 8 10 0 
P value 0.474 1.000 
 
OPRM1 
118 
AA AG/GG 
NAS treated 8 1 
Untreated 9 1 
P value 1.000 
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The maternal genotype of the SNPs investigated did not predict likelihood of their 
babies requiring NAS treatment (Table 6-4).  
Table 6-4. Association between maternal genotype and baby NAS development as determined by 
Fisher’s exact test 
 ABCB1/MDR1 
1236 2677 3435 
CC CT/TT GG GT/TT CC CT/TT 
NAS treated 2 7 2 8 2 7 
Untreated 2 5 4 6 2 6 
P value 1.000 0.628 1.000 
 
COMT 
62 158 408 -98 
CC CT/TT GG GA/AA GG GC/CC GG GA/AA 
NAS treated 1 8 1 8 1 7 2 8 
Untreated 2 5 2 5 2 6 1 6 
P value 0.550 0.550 1.000 1.000 
 
CYP2B6 
516 785 
GG GT/TT AA AG/GG 
NAS treated 5 2 7 3 
Untreated 1 5 1 5 
P value 0.103 0.119 
 
CYP2D6 
Number of copies 
1 ≥2 
NAS treated 0 8 
Untreated 2 5 
P value 0.200 
 
OPRM1 
118 
AA AG/GG 
NAS treated 8 1 
Untreated 7 0 
P value 1.000 
 
6.3.2 Genetic variations and methadone dose and plasma concentrations 
Independent t-tests were undertaken to ascertain whether there was a relationship 
between maternal methadone dose and plasma methadone concentrations, and 
genotypes. A relationship between maternal dose of methadone and copies of CYP2D6 
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was observed but no other genes (Table 6-5). Mothers with only one functioning allele 
of CYP2D6 required less methadone prescribed than mothers with two or more 
functioning alleles (19 ±23 mg v 64 ±21 mg; P = 0.016, df 13). 
Table 6-5. Association between maternal genotype and baby NAS development as determined by 
Fisher’s exact test 
 Maternal methadone dose 
mg (SD) 
Maternal methadone plasma 
concentration, ng/mL (SD) 
Homozygous 
wild-type 
Heterozygous/ 
homozygous 
mutant 
Homozygous 
wild-type 
Heterozygous/ 
homozygous 
mutant 
ABCB1 
 1236C>T 65 (30) 59 (28) 260 (269) 275 (188) 
 2677G>T 57 (35) 61 (26) 242 (220) 308 (216) 
 3435C>T 46 (37) 61 (26) 255 (273) 307 (226) 
COMT 
 62C>T 70 (25) 61 (30) 447 (276) 281 (207) 
 158G>A 70 (25) 56 (26) 447 (276) 268 (219) 
 408G>C 70 (25) 55 (26) 447 (276) 267 (210) 
 -98G>A 72 (28) 56 (29) 327 (156) 214 (166) 
CYP2B6 
 516G>T 62 (28) 53 (29) 266 (233) 324 (281) 
 785A>G 65 (28) 55 (28) 289 (194) 343 (265) 
OPRM1 
 118A>G 54 (28) 65 (-) 296 (246) 320 (-) 
NB SNPs are not included in the table if all the mothers carried the same genotypes at these polymorphisms. No 
range is given for OPRM1 as only one mother had the heterozygous/homozygous mutant genotype. 
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6.4 Discussion 
The results obtained indicate that babies carrying a mutated allele at CYP2B6 516G>T and 
785A>G are less likely to require NAS treatment than babies homozygous wild type. CYP2B6 
is the predominant CYP isoform responsible for inactivating methadone to the metabolite 2-
ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) modulating methadone plasma 
concentrations and clearance (Kharasch et al. 2008; 2013). The combination of the 516G>T 
SNP and 785A>G SNP forms the CYP2B6*6 haplotype that has been associated with higher 
steady-state plasma methadone concentrations (Crettol et al. 2005; Eap et al. 2007; Wang et 
al. 2011) and requirement of lower methadone doses (Hung et al. 2011; Levran et al. 2013). 
CYP2B6*6 haplotype causes higher plasma methadone concentrations and lower methadone 
doses as it is catalytically deficient compared to the wild type (Gadel et al. 2013) resulting in 
poorer methadone metabolism compared to the wild-type. Therefore, babies with CYP2B6*6 
are less likely to require NAS treatment because the babies’ plasma methadone concentration 
has a slower rate of decline so withdrawal is less abrupt. Following birth, babies carrying the 
CYP2B6 wild-type efficiently and rapidly metabolise the maternally transferred methadone and 
suffer opioid withdrawal symptoms. 
The relationships observed by Wachman et al. (2013) between the OPRM1 SNP 118A>G and 
COMT 158A>G with length of hospital stay and medical treatment of NAS were not supported 
by this study. Babies with the AA genotype at both SNPs required longer hospital stays and 
were more likely to require NAS treatment. However the lack of corroboration between our 
data and that of Wachman et al. (2013) could be a sample size effect in addition to a low 
frequency of mutated alleles in our study population. 
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This is the first study to report a relationship between the CYP2B6*6 genotype, associated with 
poor metaboliser status, and a requirement for NAS treatment.  These findings indicate that 
babies carrying the CYP2B6 wild type are more susceptible to developing NAS. 
6.4.1 Study limitations 
Further studies with a larger population of exposed babies is required before definitive 
conclusions can be drawn. The influence of other in utero exposures must also be considered 
in future studies. All of the babies in this study were not only exposed to methadone but nicotine 
and various other prescription and illicit drugs. A detailed record of the mother’s drug / alcohol 
/ smoking consumption should be obtained. 
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7.0 TISSUE SPECIFIC DNA METHYLATION: DNA 
methylation of ABCB1/MDR1, CYP2D6 and OPRM1 in 
individuals whose deaths were attributed to heroin 
toxicity. 
7.1 Introduction 
Heroin is a highly addictive semi-synthetic opioid that rapidly crosses the blood-brain 
barrier affecting the central nervous (Tamrazi and Almast 2012; Ruha and Levine 
2014), cardiovascular (Dettmeyer et al.  2009; Darke et al. 2010), respiratory 
(Pattinson 2008; van der Schier et al. 2014), gastrointestinal (Holzer 2014) and 
endocrine systems (Elliott et al. 2010); as well as the skin (Fink et al. 2011; Onesti et 
al. 2014). The effects of intravenously injected heroin usually occur within 30 seconds 
and include an initial warm rush of sedation and reduction in blood pressure and heart 
rate creating a sense of well-being and euphoria (Fernandez and Libby 2013). The 
sedative effects last between 2-4 hours and in cases of addiction may be followed by 
the onset of withdrawal symptoms of restlessness, diarrhoea, vomiting and aches and 
pains (Handelsman et al. 1987; Cowan et al. 2005). Heroin users develop dependence 
for the drug, craving the effects of heroin and negating the withdrawal effects through 
continued heroin use. Over time however the addict can develop tolerance to heroin 
and subsequently require increased doses of the drug to obtain the desired euphoria 
(Hoffer et al. 2012; Craft and Lustyk 2013).  
At a molecular level, opioid exposure has been observed to alter DNA methylation. 
When investigating gene methylation however it is important to be aware of tissue 
specific methylation. Genome wide analysis has shown that methylation between 
different tissues is generally well conserved, with tissues of similar function having 
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the highest correlation tissue (Rakyan et al. 2008; Lokk et al. 2014). However tissue 
specific differentially methylated regions occur in promoters of genes associated with 
tissue specific function (Davies et al. 2012; Sleiker et al. 2013; Lokk et al. 2014). For 
example, genes involved with blood vessel development and morphogenesis are 
hypomethylated in arteries, and immune response and leukocyte activation genes are 
hypomethylated in tonsil tissue (Lokk et al. 2014). Therefore, when investigating the 
effect of gene methylation on protein action it is important to obtain DNA from the 
relevant tissue. 
In a bid to increase our understanding of methylation in drug addicted individuals, the 
specific DNA methylation on ABCB1/MDR1, CYP2D6 and OPRM1 in blood, liver, 
psoas muscle and thalamus was examined in deaths attributed to heroin toxicity. The 
extent of methylation in liver, psoas muscle and thalamus was compared against 
samples obtained from non-drug related deaths via the Edinburgh Brain and Tissue 
Bank. Methylation of ABCB1/MDR1, CYP2D6 and OPRM1 in blood was compared 
against a geographically similar post-mortem population of non-drug related deaths. 
Identification of functional changes of opioid exposure may lead to the development 
of a powerful therapeutic tool (Kovatsi et al. 2011; Kouidou et al. 2010; Fragou et al. 
2011) that could ease the financial impact of opioid dependence on society and assist 
with the interpretation of post-mortem toxicology results.  
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7.2 Materials and methods 
7.2.1 Sample collection 
Samples were obtained as described in 3.1.3 and 3.2.3. 
7.2.2 Toxicological analysis 
Concentrations of morphine and its metabolites, morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G) were determined by LC-MS as described in Chapter 
3.3.2. 
7.2.3 SNP and gene duplication / deletion analysis  
SNP and gene duplication were ascertained following the protocols in 3.4. 
7.2.4  DNA methylation analysis 
Gene DNA methylation was determined as described in 3.5. 
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7.3 Results 
The opioid exposed individuals (n = 43) ranged between 21 – 65 years old with a mean 
age of 35; the majority of whom were male (79%). Both of the control cohorts, the 
Dundonian population from which non-opioid exposed blood was obtained and the 
Edinburgh tissue bank liver, psoas muscle and thalamus donors, were older than the 
opioid exposed population (P = <0.001, Table 7-1). There was no gender distribution 
difference between the opioid exposed and control populations (Table 7-1). 
Table 7-1. Age, gender and gene average DNA methylation of opioid exposed and control 
populations 
 
Opioid exposed 
(n = 43) 
Control – blood 
(n = 41) 
Control – liver, 
muscle and 
thalamus            (n = 
10) 
Age (mean, range) 35, 21-65 56, 24-84 55, 44-76 
Gender (% male) 79 85 70 
ABCB1/MDR1 
median 
methylation* 
Blood 1.9 (1.2-3.2) 2.2 (1.5-5.7) na 
Liver 1.7 (1.1-3.4) na na 
Muscle 1.7 (1.1-2.5) na na 
Thalamus 2.3 (1.9-2.8) na na 
CYP2D6 
average 
methylation 
Blood 92.6 (88.1-94.1) 92.8 (80.3-94.9) na 
Liver 20.3 (9.2-77.9) na 84.0 (14.8-87.8) 
Muscle 84.5 (81.4-87.9)  na 84.1 (20.8-89.4) 
Thalamus 88.5 (79.1-91.6) na 86.4 (32.3-89.7)  
OPRM1 
average 
methylation 
Blood 8.2 (4.6-13.1) 9.1 (4.5-19.7) na 
Liver 7.7 (5.3-10.9) na 5.6 (3.4-8.1) 
Muscle 3.5 (3.0-4.1) na 4.4 (3.6-8.0) 
Thalamus 3.7 (2.9-6.2) na 6.1 (3.6-9.2) 
*ABCB1MDR1 methylation data had non-normal distribution, therefore the median methylation and 
range were provided rather than the mean. 
 
The methylation status of ABCB1/MDR1, CYP2D6 and OPRM1 was determined in 
blood, liver psoas muscle and thalamus samples from opioid associated deaths (Table 
7-1). Control methylation data was obtained for CYP2D6 and OPRM1 from blood, 
liver, muscle and thalamus but ABCB1/MDR1 methylation was only determined in 
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non-opioid exposed blood samples (Table 7-1). Not all of the samples were 
successfully analysed for methylation for a number of reasons, detailed below (the 
number of samples successfully analysed using each assay is shown in Figures 7-3 to 
7-7): 
1) poor quality DNA was extracted as a result of tissues being subject to repeated 
freeze-thaw cycles;  
2) bisulfite conversion of DNA was undertaken using plates with only 96 wells and 
as such bisulfite conversions were restricted to converting 90 samples per run 
(with the remaining six spaces used for negatives, methylated and unmethylated 
controls);  
3) complete consumption of the 15µL of bisulfite converted DNA sample as a result 
of preparation or instrumental error;  
4) insufficient time and budget in the PhD timescale to reanalyse samples with 
missing methylation results. 
7.3.1 Age and methylation 
7.3.1.1 ABCB1/MDR1 DNA methylation and age 
No relationships were observed between age and ABCB1/MDR1 gene DNA 
methylation in any of the tissues investigated in opioid exposed and opioid naïve 
individuals (Table 7-2). 
Table 7-2. Correlation between ABCB1/MDR1 gene DNA methylation and age in opioid exposed 
and opioid naïve individuals 
 Opioid exposed Opioid naïve 
Blood Liver Psoas Thalamus Blood Liver Psoas Thalamus 
Pearson r 
Sig. (2-tailed) 
N 
-.081 
.619 
40 
-.082 
.697 
25 
.212 
.279 
28 
.236 
.267 
24 
.038 
.827 
25 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
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7.3.1.2 CYP2D6 DNA methylation and age 
Pearson correlation showed no relationship between age and opioid exposed CYP2D6 
gene methylation in any of the tissues investigated. Non-opioid exposed liver, muscle 
and thalamus sample CYP2D6 gene methylation however were positively correlated 
with age according to Spearman’s Rank correlation (Table 7-3; Figure 7-1).  
Table 7-3. Correlation between CYP2D6 gene DNA methylation and age in opioid exposed and 
opioid naïve individuals 
 Opioid exposed Opioid naïve 
Blood Liver Psoas Thalamus Blood Liver Psoas Thalamus 
Pearson r 
Sig. (2-tailed) 
N 
-.027 
.865 
42 
.025 
.902 
27 
.006 
.975 
27 
-.096 
.641 
26 
-.267 
.100 
39 
.636 
.048 
10 
.867 
.002 
9 
.830 
.003 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-1. Relationship between CYP2D6 methylation and liver, muscle and thalamus from non-
opioid exposed samples  
The average methylation (%) of the 3 CpG sites investigated in CYP2D6 of liver (pink filled circle), 
muscle (grey filled circle) and thalamus (white filled circle) samples were shown to be positively 
correlated with age, P = 0.048, 0.002 and 0.003 respectively. 
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7.3.1.3 OPRM1 DNA methylation and age 
Utilising bivariate correlation age was compared to the methylation status of each gene 
(Table 7-4). Pearson’s correlation showed that the average DNA methylation of 
OPRM1 was positively correlated with age in thalamus of opioid exposed individuals 
(Figure 7-2). No other relationships were observed between age and OPRM1 
methylation in any other opioid exposed tissues. No relationship between age and 
OPRM1 methylation in opioid naïve tissue samples were observed. 
Table 7-4. Pearson correlation between OPRM1 gene DNA methylation and age in opioid exposed 
and opioid naïve individuals 
 Opioid exposed Opioid naïve 
Blood Liver Psoas Thalamus Blood Liver Psoas Thalamus 
Pearson r 
Sig. (2-tailed) 
N 
.013 
.935 
39 
.324 
.141 
22 
.249 
.220 
26 
.588 
.003 
24 
.182 
.364 
27 
-,445 
.230 
9 
-.642 
.062 
9 
.674 
.056 
9 
 
Figure 7-2. Relationship between age and OPRM1 DNA methylation in thalamus samples of 
opioid exposed individuals  
Each data point represents the age and average methylation of the 8 CpG sites investigated in OPRM1 
(%) of thalamus samples from individuals exposed to opioids (n=24). The regression line shows a 
positive correlation between age and OPRM1 methylation (P = <0.003). 
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7.3.2 Gender and methylation 
Independent-samples Mann-Whitney U tests were undertaken on the data represented 
in Table 7-5 and no relationship between gender and extent of methylation in 
ABCB1/MDR1, CYP2D6 or OPRM1 in any tissue investigated was found.  
Table 7-5. Gender differences in ABCB1/MDR1, CYP2D6 and OPRM1 gene methylation in opioid 
exposed and opioid naïve populations 
 
Opioid 
exposed 
(n = 43) 
Control – 
blood 
(n = 41) 
Control – liver, 
muscle and thalamus            
(n = 10) 
ABCB1 
median 
methylation 
Blood 
Male 1.9 (1.2-3.2) 2.1 (1.5-5.7) nd 
Female 2.0 (1.6-2.1) 3.1 (2.9-3.3) nd 
Liver 
Male 1.7 (1.1-3.4) nd nd 
Female 1.6 (1.2-2.7) nd nd 
Muscle 
Male 1.7 (1.1-2.2) nd nd 
Female 1.8 (1.5-2.5) nd nd 
Thalamus 
Male 2.3 (1.9-2.8) nd nd 
Female 2.1 (1.9-2.5) nd nd 
CYP2D6 
average 
methylation 
Blood 
Male 
92.2 (89.6-
94.1) 
92.9 (85.7-
94.9) 
nd 
Female 
93.0 (88.1-
94.0) 
92.0 (80.3-
93.9) 
nd 
Liver 
Male 27.4 (9.2-77.9) nd 85.3 (25.1-87.8) 
Female 
22.6 (13.7-
35.1) 
nd 
38.2 (14.7-85.4) 
Muscle 
Male 
84.8 (81.4-
87.9) 
nd 
84.9 (31.4-89.4) 
Female 
84.5 (83.0-
85.7) 
nd 
32.3 (20.7-84.1) 
Thalamus 
Male 
87.9 (79.1-
90.7) 
nd 
86.8 (34.4-89.7) 
Female 
88.5 (83.7-
91.6) 
nd 
36.8 (32.3-86.2) 
OPRM1 
average 
methylation 
Blood 
Male 8.0 (4.6-13.1) 9.9 (4.5-17.5) nd 
Female 8.0 (6.3-9.3) 
10.1 (8.6-
19.7) 
nd 
Liver 
Male 7.8 (5.3-10.9) nd 4.6 (3.4-8.1) 
Female 7.4 (5.9-9.9) nd 7.2 (6.7-7.6) 
Muscle 
Male 3.5 (3.0-4.0) nd 4.1 (3.6-8.0) 
Female 3.6 (3.0-4.1) nd 6.4 (5.2-6.6) 
Thalamus 
Male 3.8 (2.9-4.5) nd 5.6 (3.6-8.2) 
Female 3.8 (3.4-4.3) nd 8.1 (3.6-5.6) 
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7.3.3 Intra-individual gene methylation tissue differences in opioid 
associated deaths 
Blood, liver, muscle and thalamus obtained from individuals whose deaths were 
associated with opioid toxicity had tissue methylation differences for each gene 
investigated (Figure 7-3 to 7-7, paired t-tests undertaken). CpG sites within the 
promoter region of ABCB1/MDR1 were statistically significantly more methylated in 
thalamus (2.3%) than liver (1.7%, P = 0.004) and muscle (1.7%, P = <0.001) (Figure 
7-3).  
 
Figure 7-3. Median ABCB1/MDR1 methylation (%) in blood, liver, muscle and thalamus obtained 
from opioid associated deaths 
Median methylation scores and range of data points (error bars) were plotted as data had non-normal 
distribution. The brackets illustrate statistically significant methylation differences between paired 
tissue samples, e.g. the greatest ABCB1/MDR1 methylation difference was observed between thalamus 
and blood samples, P = <0.001.   
 
 
  
  
 
  
P 
P n 
 
n = 27       n = 24                n = 27             n = 24 
P = <0.001 
P = 0.004 
P = 0.029 
148 
 
The methylation differences observed at the 3 CpG sites investigated in CYP2D6 were 
significantly more emphasised (Figure 7-4). The median methylation of CYP2D6 was 
20% in the liver samples of opioid associated deaths which was statistically 
significantly lower than blood (93%), muscle (85%) and thalamus (88%), P = <0.001. 
In addition blood samples showed higher CYP2D6 methylation (P = <0.001) whereas 
similar CYP2D6 methylation was observed in muscle and thalamus obtained from the 
same individual.  
 
 
Figure 7-4. Average CYP2D6 methylation (%) in blood, liver, muscle and thalamus obtained from 
opioid associated deaths  
Bars represent the average methylation (%) of 3 CpG sites in CYP2D6 in blood (red), liver (purple), 
muscle (blue) and thalamus (orange) samples. The error bars represent the 95%confidence interval. The 
brackets illustrate statistically significant methylation differences between paired tissue samples, e.g. 
the liver had less methylation than related blood, muscle and thalamus samples, P = <0.001.   
 
 
 
 
 
  
  
P n 
 
n = 27               n = 27                n = 27                 n = 26      
P = <0.001 
P = <0.001 
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Tissue methylation differences were also observed in OPRM1. Blood (8.2%) and liver 
(7.7%) samples taken from the same individual had similar methylation (Figure 7-5). 
The methylation observed in the blood and liver was statistically significantly higher 
than the methylation in muscle (3.5%) and thalamus (3.7%), P = <0.001. 
 
 
Figure 7-5. Average OPRM1 methylation in blood, liver, muscle and thalamus obtained from 
opioid associated deaths  
Bars represent the average methylation (%) of 8 CpG sites in OPRM1 in blood (red), liver (purple), 
muscle (blue) and thalamus (orange) samples. The error bars represent the 95%confidence interval. The 
brackets illustrate statistically significant methylation differences between paired tissue samples, e.g. 
blood and liver samples had higher methylation than related muscle and thalamus samples, P = <0.001.   
 
7.3.4 Intra-individual gene methylation tissue differences in controls 
Unlike the tissues obtained from deaths associated with opioid toxicity, there was not 
a statistically significant difference with respect to CYP2D6 methylation between 
liver, muscle or thalamus samples obtained from non-opioid associated deaths (Figure 
 
 
 
 
 
 
 
 
P 
P n 
 
n = 23                    n = 19                 n = 23                  n = 21 
P = <0.001 
P = <0.001 
P = 0.009 
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7-6). There was also no tissue methylation differences observed in OPRM1 (Figure 7-
7).  
As a consequence of time and cost restrictions, and availability of space on bisulfite 
conversion plates, methylation analysis of ABCB1/MDR1 was not undertaken in the 
control tissues. As the methylation differences in opioid exposed samples were more 
prominent in CYP2D6 and OPRM1, determining the methylation profile in these genes 
was prioritised over ABCB1/MDR1 methylation.  
 
Figure 7-6. Median CYP2D6 methylation (%) in liver, muscle and thalamus obtained from non-
opioid associated deaths  
Median methylation scores and range of data points (error bars) were plotted as data had non-normal 
distribution. 
 
 
  
    
 
 n = 10               n = 9     n = 10 
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Figure 7-7. Average OPRM1 methylation (%) in liver, muscle and thalamus obtained from non-
opioid associated deaths  
Bars represent the average methylation (%) of 8 CpG sites in OPRM1 in liver (purple), muscle (blue) 
and thalamus (orange) samples. The error bars represent the 95%confidence interval.  
 
7.3.5 Opioid exposed tissues v non-opioid exposed tissues 
The degree of CYP2D6 methylation in liver samples of opioid exposed individuals 
was statistically significantly lower than in liver samples of individuals whose deaths 
were non-opioid related (Figure 7-8, P = 0.043). Comparison of opioid and non-opioid 
exposed muscle and thalamus revealed no difference in CYP2D6 methylation. 
 
 
  
 
 
 
 
 
n = 8       n = 9        n = 9 
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Figure 7-8. CYP2D6 methylation (%) in liver, muscle and thalamus from opioid and non-opioid 
associated deaths  
Median methylation scores and range of data points (error bars) were plotted as data had non-normal 
distribution. Opioid exposed liver samples (solid purple) were statistically significantly less methylated 
than opioid naïve liver samples (striped purple), P = 0.043. 
 
Statistically significant OPRM1 methylation differences were observed in each tissue 
between the opioid exposed population and non-opioid exposed population (Figure 7-
9). Methylation was higher in opioid exposed liver samples compared to controls 
(7.6% v 5.6%, P = 0.002). The converse was seen for muscle and thalamus, the 
average methylation of OPRM1 was lower in opioid exposed muscle (3.5% v 5.1%, P 
= 0.012) and thalamus (3.9% v 6.1%, P = 0.015) than the controls. 
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Figure 7-9. OPRM1 methylation in liver, muscle and thalamus from opioid and non-opioid 
associated deaths 
Bars represent the average methylation (%) of 8 CpG sites in OPRM1 in opioid exposed (solid colour) 
and opioid naïve (striped) liver (purple), muscle (blue) and thalamus (orange) samples. The error bars 
represent the 95%confidence interval.  
 
Methylation of ABCB1/MDR1 and OPRM1 in blood obtained from non-opioid 
exposed deaths was greater than ABCB1/MDR1 and OPRM1 methylation in opioid 
exposed blood samples (P = 0.009 and P = 0.009 respectively), Figure 7-10. There 
was no statistical difference in methylation of CYP2D6 between opioid exposed 
individuals or non-opioid exposed blood samples. 
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Figure 7-10. Average methylation (%) of a) ABCB1, OPRM1 and b) CYP2D6 in blood obtained 
from opioid exposed and non-opioid exposed donors  
Bars represent the average methylation (%) of 11 CpG sites in ABCB1, 8 CpG sites in OPRM1 and 3 
CpG sites in CYP2D6 in opioid exposed (solid red) and opioid naïve (striped red) blood samples. The 
error bars represent the 95% confidence interval.  
 
7.3.6 Genetic variations v blood drug concentrations  
 
Morphine was detected in 39 of the 43 heroin attributed deaths at concentrations 
ranging from 10 – 1350 ng/mL (median 160 ng/mL). Analysis for metabolites of 
morphine was also undertaken. Morphine-3-glucuronide (M3G) was detected at 
concentrations of 10 – 1120 ng/mL (median 140 ng/mL) in 42 of the blood samples, 
and morphine-3-glucuronide (M6G) concentrations ranged from 10 – 660 ng/mL 
(median 40 ng/mL) in 32 blood samples. Independent samples t-test showed that the 
only difference between morphine / metabolite concentrations and genotype was 
observed in the ABCB1/MDR1 transport protein (Table 7-6). Individuals carrying the 
 
 
 
 
 
 
  
  
  
  
 
  
 
a)  n = 40   n = 21         n = 39   n = 27                  b)        n = 42   n = 39 
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TT genotype at rs1128503 and rs1128503 had lower morphine:M3G (transformed 
using LG10 to obtain normal distribution) than individuals with either CC/CT (P = 
0.004) and GG/GT (P = 0.001), respectively.  
Table 7-6. Average morphine and metabolite concentrations in different genotypes 
  MOR M3G M6G MOR:M3G MOR:M6G M3G:M6G 
ABCB1 
rs1128503   
 
TT 177.3 250.0 59.0 0.6* 3.4 5.67 
CC/CT 240.0 249.7 80.5 2.5*  6.1 4.8 
rs2032582  
 
TT 138.0 229.1 55.6 0.5* 3.0 5.7 
GG/GT 251.4 257.3 80.9 2.5*  6.1 4.8 
rs1045642  
 
TT 229.2 209.3 56.4 1.0 5.2 5.3 
CC/CT 218.8 270.7 82.9 2.4 5.3 4.9 
COMT 
rs4633 TT 
 
TT 222.5 312.2 141.4 1.3 2.7 5.1 
CC/CT 222.3 232.2 54.8 2.1 6.0 5.0 
rs4680  
 
AA 222.5 312.2 141.4 1.3 2.7 5.1 
GG/GA 222.3 232.2 54.8 2.1 6.0 5.0 
rs4818  
 
CC 213.3 273.1 108.2 2.5 4.3 4.5 
GG/GC 226.3 238.9 55.7 1.7 5.8 5.4 
rs6269  
 
AA 213.3 273.1 108.2 2.5 4.3 4.5 
GG/GA 226.3 238.9 55.7 1.7 5.8 5.4 
CYP2B6 
rs3745274  
 
GG 251.8 246.7 95.6 1.5 4.1 5.1 
TT/TG 177.3 252.7 55.7 2.3 5.8 4.4 
rs2279343  
 
AA 238.1 208.7 54.0 1.9 5.4 5.9 
GG/GA 203.9 302.2 91.2 2.0 5.1 4.3 
CYP2D6 
<2 functioning alleles 396.7 443.3 243.3 1.2 3.2 2.8 
≥2 functioning alleles 207.8 234.5 56.2 2.0 5.5 5.3 
*Statistical differences observed (Independent t-test, P = <0 .05). MOR = morphine; M3G = morphine-
3-glucuronide; M6G = morphine-6-glucuronide; MOR:M3G, MOR:M6G, M3G:M6G = drug 
concentration ratio between MOR and M3G, MOR and M6G, and M3G and M6G, respectively. 
 
The relationships between drug concentrations and extent of ABCB1/MDR1, CYP2D6 
and OPRM1 methylation in each tissue is shown in Table 7-7. The methylation of 
OPRM1 positively correlated with MOR:M3G ratio (following Log10 transformation 
as a result of non-normal distribution), P = 0.030 .437 significant at the 0.01 level (2-
tailed)**.  CYP2D6 methylation positively correlated with M3G concentration (P = 
0.021), and negatively correlated with MOR:M3G (P = 0.030,  -.454*) and M3G:M6G 
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(P = 0.021, -.479*). OPRM1 methylation negatively correlated with M3G 
concentration (P = 0.035), and positively correlated with MOR:M3G (P = 0.015,  
.510) and M3G:M6G (P = 0.015, .510*).  
Table 7-7. Morphine and metabolite concentrations vs tissue specific methylation 
 
MOR+ M3G+ M6G++ 
MOR:M3G
++ 
MOR:M6G
+ 
M3G:M6G 
ABCB1 
methylation 
Blood+ 
.122 
.477 
36 
-.182 
.266 
39 
.021 
.912 
29 
.301 
.079 
35 
.143 
.460 
29 
.294 
.087 
35 
Liver++ 
-.184 
.413 
22 
-.042 
.846 
24 
-.097 
.711 
17 
-.138 
.522 
21 
-.352 
.166 
17 
-.040 
.862 
21 
Muscle 
-.205 
.325 
25 
-.369 
.058 
27 
-.181 
.459 
19 
.109 
.613 
24 
.210 
.388 
19 
-.028 
.898 
24 
Thalamus 
.035 
.877 
22 
.098 
.655 
23 
-.298 
.246 
17 
-.256 
.262 
21 
.093 
.724 
17 
-.293 
.197 
21 
CYP2D6 
methylation 
Blood+- 
.054 
.750 
37 
-.051 
.753 
40 
.288 
.123 
30 
.132 
.441 
36 
-.058 
.763 
30 
.012 
.945 
36 
Liver++ 
.120 
.586 
23 
.179 
.381 
26 
.405 
.095 
18 
-.276 
.213 
22 
-.279 
.262 
18 
-.193 
.390 
22 
Muscle 
.159 
.457 
24 
.451* 
.021 
26 
.318 
.198 
18 
-.454* 
.030 
23 
-.075 
.769 
18 
-.479* 
.021 
23 
Thalamus 
-.140 
.534 
22 
-.045 
.836 
24 
-.318 
.214 
17 
-.116 
.617 
21 
.207 
.425 
17 
-.224 
.329 
21 
OPRM1 
methylation 
Blood 
.234 
.169 
36 
-.262 
.112 
38 
.103 
.587 
30 
.437** 
.009 
35 
.330 
.075 
30 
.267 
.109 
35 
Liver 
-.077 
.755 
19 
-.263 
.249 
21 
.339 
.236 
14 
.016 
.949 
18 
-.229 
.431 
14 
.160 
.525 
18 
Muscle 
.046 
.835 
23 
-.423* 
.035 
25 
.062 
.808 
18 
.510* 
.015 
22 
.254 
.309 
18 
.510* 
.015 
22 
Thalamus 
-.087 
.715 
20 
-.297 
.179 
22 
-.204 
.466 
15 
.120 
.623 
19 
.242 
.385 
15 
-.139 
.571 
19 
+SQRT transformations; +-negative SQRT; ++LG10; *significant at the 0.05 level (2-tailed); 
**significant at the .01 level (2-tailed). MOR = morphine; M3G = morphine-3-glucuronide; M6G = 
morphine-6-glucuronide; MOR:M3G, MOR:M6G, M3G:M6G = drug concentration ratio between 
MOR and M3G, MOR and M6G, and M3G and M6G, respectively. 
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7.4 Discussion 
Intra-individual tissue specific differences were observed in ABCB1/MDR1, CYP2D6 
and OPRM1 of tissue samples obtained from opioid exposed individuals. The most 
prominent tissue methylation difference was observed on the CYP2D6 gene. CYP2D6, 
which is an important metabolising enzyme, was statistically significantly less 
methylated in the liver samples of opioid exposed individuals than related blood, 
muscle or thalamus samples (P = <0.001). The lower CYP2D6 methylation in muscle 
and thalamus was expected as the liver is the primary organ for drug detoxification so 
protein expression is required for drug metabolism. The explanation for this difference 
may be as follows; tissue specific differentially methylated regions have been 
observed in genome wide analyses (Zhang et al. 2013; Lokk et al. 2014).  
Promoter regions of genes associated with tissue specific function are 
hypomethylated, for example genes involved with blood vessel development and 
morphogenesis were hypomethylated in arteries, and immune response and leukocyte 
activation genes were hypomethylated in tonsil tissue (Lokk et al. 2014). Liver 
samples from controls did not have lower CYP2D6 methylation than related muscle 
and thalamus samples, but were significantly more methylated than drug exposed liver 
samples (P = 0.002). The lower CYP2D6 methylation in drug exposed individuals 
may be the body’s response to adapt to drug exposures. CYP2D6 accounts for 2% of 
the hepatic cytochrome P450 content (Shimada et al. 1994), and is fundamental in the 
metabolism of a wide variety of drugs and endogenous compounds (Wang et al. 2013; 
Ravindranath 2014).  
The individuals whose deaths were attributed to opioid toxicity did not only have 
morphine and metabolites in their systems, but also a whole host of xenobiotic 
substances that are metabolised by CYP2D6. The lower methylation of CYP2D6 may 
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result in increased expression of metabolising enzymes to enable the metabolism of a 
range of xenobiotic substances that the opioid dependant individuals consumed. 
Alternatively the lower methylation of CYP2D6 in the opioid exposed population 
could be a result of age. The control population had a median age of 55, whereas the 
population of opioid exposed individuals had a median age of 35 (P = 0.001). A 
positive relationship was observed between control liver, muscle and thalamus 
CYP2D6 methylation and age (P = 0.048, 0.002 and 0.003 respectively). However, 
the control group of consisted of only 10 individuals spanning an age range of ~30 
years so a larger population is required to corroborate the CYP2D6 methylation-age 
relationship. 
Despite the age disparity and differences in drug exposures CYP2D6 methylation in 
blood of controls and opioid users was similar. CYP2D6 was hypermethylated and as 
drug metabolism by CYP2D6 does not occur in the blood higher gene methylation was 
expected compared to liver methylation. Previous research has shown that CYP2D6 
expression is not only apparent in the liver but also in the brain in a region- and cell- 
specific manner, the extent of methylation is induced by a variety of drugs and toxins 
(Miksys et al. 2002; Miksys and Tyndale 2004; Mann et al. 2008; Ferguson and 
Tyndale 2011). The variable expression of CYP2D6 in the brain has been suggested 
to be a cause for inter-individual variation in response to centrally acting drugs (Zhou 
et al. 2013). CYP2D6 expression has been observed in the frontal cortex, cerebellum, 
hippocampus, hypothalamus and thalamus (Miksys et al. 2002; Kircheiner et al. 2011; 
Mann et al. 2012). In this study, the three CpG sites investigated in CYP2D6 in 
thalamus were hypermethylated in opioid exposed samples. The hypermethylation of 
CYP2D6 in opioid exposed thalamus samples suggest that expression is inhibited 
reducing the functional role of CYP2D6 within the brain. 
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7.4.1 Methylation of ABCB1/MDR1 gene 
The methylation difference observed in ABCB1/MDR1 between the different tissues 
was not as prominent as CYP2D6 methylation. Thalamus exhibited statistically 
significantly higher methylation than liver and muscle (P = 0.004 and <0.001 
respectively); however the eleven CpG sites investigated had an average methylation 
of only 2%. The hypomethylation suggests that the ABCB1/MDR1 would be expressed 
in each of the tissues investigated therefore transporting xenobiotics away from tissues 
back into the blood (Choudhuri and Klaassen 2006).  
ABCB1/MDR1 transcription site hypomethylation has been observed in normal (non-
diseased) breast, brain and pancreatic tissue (Dejeux et al. 2010; Muggerud et al. 2010; 
Chen et al. 2012; Oberstadt et al. 2013). In diseased tissue ABCB1/MDR1 methylation 
of up to 85% has been reported and this increased methylation has been postulated to 
be a cause of drug resistance development (Andersson et al. 2003; Lu and Shervington 
2008; Dejeux et al. 2010; Muggerud et al. 2010; Oberstadt et al. 2013). ABCB1/MDR1 
expression can influence drug resistance as the transporter alters the delivery of drugs 
to target tissues therefore affecting the bioavailability, distribution and excretion of 
drugs (Choudhuri and Klaassen 2006). Absence or inhibition of the ABCB1/MDR1 
transporter results in drug accumulation within tissues (Lankas et al. 1997; Borst and 
Elferink 2002). Therefore, the ABCB1/MDR1 hypomethylation in the liver, muscle 
and thalamus of opioid exposed population suggests that the ABCB1/MDR1 
transporter is expressed and drugs are transported back into the bloodstream protecting 
vital organs.  
Control ABCB1/MDR1 methylation data was obtained from blood samples. 
ABCB1/MDR1 methylation in blood samples from controls was significantly higher 
than in the opioid exposed samples (P = 0.009). As the control population were ~20 
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years older than the opioid exposed population (mean age 56 v 35 years old, P = 
<0.001) the increased methylation is postulated to be an artefact of aging.  
7.4.2 Methylation of OPRM1 gene 
The methylation on OPRM1 of opioid exposed samples was significantly greater in 
blood and liver samples than muscle and thalamus (P = <0.001). As opioids exert their 
effects on the central nervous system hypomethylation of OPRM1 that may enable 
expression of the mu-opioid receptor in the thalamus samples was not unexpected. In 
comparison to the control thalamus samples, the opioid exposed thalamus were less 
methylated on OPRM1 (3.9% v 6.1%, P = 0.015) that may result in greater expression 
of the mu-opioid receptor. Our data suggests that the lower methylation of the receptor 
within the opioid exposed thalamus samples compared to the controls may be a result 
of age. OPRM1 methylation was positively correlated with age in the opioid exposed 
thalamus samples (P = <0.0005, Figure 7-2).  
No age relationship was observed in the control thalamus samples but this could be a 
population size affect as only 10 control individuals were analysed. The control 
population had a median age 20 years older than the opioid exposed population 
OPRM1 and age (P = <0.001). Therefore the lower OPRM1 methylation in opioid 
exposed thalamus may be the influence of age rather than an adaptive response to 
opioid exposure. The relationship between age and OPRM1 methylation in thalamus 
has not yet been reported. CpG site specific methylation increases in frontal cortex, 
temporal cortex, pons and cerebellum have been reported with age (Hernandez et al. 
2011) as has the relationship between age and methylation markers within blood 
(Hannum et al. 2013). Increased methylation was observed in genes associated with 
DNA-binding factors and transcription factors (Hernandez et al. 2011) suggesting that 
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age related methylation changes are associated with maintenance of transcriptional 
programs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
162 
 
7.5 Conclusion 
Tissue specific methylation differences of ABCB1/MDR1, CYP2D6 and OPRM1 were 
observed within the blood, liver, muscle and thalamus of opioid exposed individuals. 
The gene methylation differences appear to be related to the function of the tissue 
investigated, e.g. the metabolising enzyme CYP2D6 was less methylated in the liver, 
the primary site of drug detoxification. The same methylation differences were not 
observed for CYP2D6 and OPRM1 in liver, muscle and thalamus from the ten control 
individuals. As a result of the small population and wide age range of the control 
population the tissue specific methylation differences that were observed in the opioid 
exposed population may have been masked. Additionally, although the control 
population were known not to be chronic opioid users a record of drug history was not 
obtained. 
The ABCB1/MDR1, CYP2D6 and OPRM1 methylation differences observed between 
the control and opioid exposed populations are likely to be explained by age rather 
than drug exposure. Previous studies investigating the methylation differences of 
OPRM1 in sperm and lymphocytes of opioid exposed and controls found that 
methylation was higher in the opioid exposed individuals. For this study to be 
comparable an age matched control population of similar size should be recruited. 
To further the work, mRNA expression studies should be undertaken to determine the 
functional consequences of the methylation differences observed between the different 
tissues as well as between the opioid exposed and control populations. 
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8.0 PILOT TRIAL: PERSONALISING OPIOID THERAPY 
FOR CANCER PAIN RELIEF. The influence of DNA 
methylation and SNPs on opioid response 
8.1 Introduction 
At present cancer pain management involves careful titration of an initial opioid 
(usually morphine) according to response (analgesia and side-effects), opioid 
switching if necessary, and further titration of the alternative opioid. There is currently 
no way of prospectively predicting an individual’s response to opioids for cancer pain. 
In many instances patients experience significant pain and / or side-effects during 
analgesic stabilisation which is a process based largely on trial and error.  
In terms of cancer pain, the development of a model incorporating clinical, genetic, 
epigenetic and metabolite data may potentially allow prospective prediction of 
response to different opioid drugs. Personalised prescribing involving choosing the 
correct dose of the correct opioid for each individual patient would result in more rapid 
pain management, reduced side-effects and potentially a better quality of life. The 
studies published to date have not provided any data that can be used in such 
modelling. Therefore we hypothesised that the epigenetic mechanism DNA 
methylation, in addition to genetic polymorphisms in opioid related genes, influence 
response to morphine and oxycodone.  
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8.2 Materials and methods 
8.2.1 Sample collection 
Participants were recruited as described in 3.1.4. Plasma and blood samples were 
collected as detailed in 3.2.4.  
8.2.2 Toxicological analysis 
Blood samples were analysed for morphine, M3G, M6G, oxycodone, noroxycodone 
and oxymorphone following the method described in Chapter 3.3.3.  
8.2.3 SNP and gene duplication / deletion analysis  
SNPs and CYP2D6 deletions and duplications were determined following the protocol 
detailed in 3.4. 
8.2.4  DNA methylation analysis 
Analysis of promoter region methylation of ABCB1/MDR1, CYP2D6 and OPRM1 was 
undertaken as described in 3.5. 
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8.3 Results 
In total, 147 patients were recruited into the study (Figure 8-1). The recruited 
population were largely Caucasian (93%), had an average age of 61 years (±13 years) 
and consisted of 69 males and 78 females. The smoking status of the Royal Marsden 
patients was unknown; of the remaining 18 patients 13 had never smoked, two were 
former smokers and three participants smoked >20 cigarettes per week.  
The participants were diagnosed with cancers including breast, upper and lower 
gastrointestinal, sarcoma, lung, gynaecological, urinary tract, pancreas and 
hepatobiliary, haematological, prostate, malignant melanoma, and head and neck. 
Opioids were prescribed most frequently to alleviate somatic bony pain (41%), defined 
as a dull ache or tender hot spot, followed by somatic pain (37%), sharp pain, burning 
or prickling on the body surface or deep tissue; and finally visceral pain (22%), 
pressure-like or squeezing pain, poorly localised.  
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Figure 8-1. Responders and non-responders to morphine and oxycodone in an opioid naïve cancer 
population 
*Non-responders switched to alternative opioid, be it the alternative study opioid or a non-study opioid. 
 
Morphine was the first-line opioid for 84 participants (Figure 8-1); 51 responded well 
to the morphine reporting pain scores of ≤4 and no / mild side effects (e.g. RB5 Figure 
8-2 and 8-3), however 33 were deemed to be non-responders based upon their 
questionnaire responses. For example RB1 obtained inadequate pain relief (Figure 8-
2), MU1 obtained inadequate pain relief and adverse side effects (Figure 8-2 and 8-3 
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respectively), and RB4 obtained adequate analgesia but suffered from intolerable 
drowsiness (Figure 8-2 and 8-3 respectively). Oxycodone was prescribed to 13 of the 
morphine non-responders and 10 obtained adequate analgesia with no / acceptable side 
effects. The remaining morphine non-responders were switched to alternative non-
study opioids. 
 
 
Figure 8-2. Average pain score / 24 hours over an 11 day period of morphine responders and non-
responders  
RB4 and RB5 were considered non-responders to morphine as their average pain score was below 4 on 
the 11 point likert scale. 
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Figure 8-3. Drowsiness in morphine responders and non-responders over study period 
MU1 and RB4 were considered morphine non-responders as they reported drowsiness values of “quite 
a bit” and “very much”. 
 
Oxycodone was prescribed as the first-line opioid to 63 patients and 54 obtained 
adequate pain relief and tolerable side effects, RB7 for example (Figure 8-4 and 8-5 
respectively). The nine oxycodone non-responders were classified as non-responders 
as a result of inadequate pain relief (e.g. FH2 Figure 8-4), inadequate pain relief and 
intolerable side effects (e.g. RB8 Figure 8-4 and 8-5 respectively) or adequate pain 
relief but intolerable side effects (e.g. MU2 Figure 8-4 and 8-5 respectively). Six of 
the oxycodone non-responders were switched to morphine and obtained suitable 
analgesia and no / minimal side effects. The remaining 3 oxycodone non-responders 
were switched to non-study opioids. 
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Figure 8-4. Average pain score / 24 hours over an 11 day period of oxycodone responders and 
non-responders 
RB7 and MU2 were considered non-responders to oxycodone as their average pain score was below 4 
on the 11 point likert scale. 
 
 
Figure 8-5. Dry mouth and vomiting in oxycodone responders and non-responders over study 
period 
MU2 and RB8 were considered morphine non-responders as they reported dry mouth values of “quite 
a bit” and “very much”. 
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8.3.1 Methylation 
8.3.1.1 Paired tissue gene DNA methylation comparison 
Paired blood and buccal samples were obtained from 17 cancer patients obtained from 
Forest Holme, Poole Hospital, MacMillan Unit and Royal Bournemouth hospital 
(Figure 8-1) (1 patient from this group of hospitals did not provide an oral swab). The 
paired samples t-test showed that blood and buccal swab DNA had statistically 
significantly different methylation in ABCB1/MDR1 and OPRM1 (Table 8-1, P = 
<0.001 and 0.013, respectively) whereas no difference was observed in CYP2D6 (P = 
0.351). There was no correlation between blood and buccal swab methylation obtained 
from the same individual in any of the genes investigated. 
Table 8-1. Relationship between gene DNA methylation in paired blood and buccal samples 
 
N Mean SD 
P             (2-
tailed) 
Correlation 
ABCB1/MDR1 
Blood 
15 
2.4  
±.35 
<0.001 -.206 
Buccal 
12.8  
±5.0 
CYP2D6 
Blood 
17 
92.1 ±1.03 
0.351 .118 
Buccal 91.6 ±1.76 
OPRM1 
Blood 
11 
2.5  
±.33 
0.013 -.400 
Buccal 
3.2  
±.58 
 
8.3.1.2 Gene DNA methylation and effect of age in morphine / 
oxycodone responders and non-responders 
Methylation data was not obtained from all recruited cancer patients because, a) 
plasma samples were completely consumed during toxicology analyses, b) low 
concentrations of DNA in plasma samples, and c) DNA was absent in plasma sample 
as a result of repeat freeze-thaw cycling. As such 46 patient blood or plasma samples 
were analysed for ABCB1/MDR1 methylation, 44 for CYP2D6 and 27 for OPRM1 
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methylation (Table 8-2). OPRM1 methylation in blood was positively correlated with 
age (.515**, P = 0.006) as determined by Spearman’s rho. The strength of this 
relationship was much more evident in the morphine responder group and non-
responder group (Table 8-2, Figure 8-6) than oxycodone exposed patients. No 
relationships between age and ABCB1/MDR1 and CYP2D6 methylation were 
observed. 
Of the 17 buccal swabs obtained, CYP2D6 methylation was obtained from all 17 
participants, 16 for OPRM1 and 11 for ABCB1/MDR1 (Table 8-2). With the exception 
of the negative relationship between CYP2D6 methylation in buccal swabs of 
morphine responders and age (Table 8-2) there were no correlations between age and 
buccal gene DNA methylation.  
Table 8-2. Relationship between age and gene blood and buccal DNA methylation in opioid 
responders and non-responders 
  ABCB1/MDR1 CYP2D6 OPRM1 
Blood 
Pearson r 
P (2-tailed) 
N 
-.015 
.921 
46 
-.064 
.678 
44 
.515** 
.006 
27 
 
Morphine 
responder 
Pearson r 
P (2-tailed) 
N 
-.045 
.855 
19 
.041 
.881 
16 
.745** 
.008 
11 
 
Morphine non-
responder 
Pearson r 
P (2-tailed) 
N 
-.167 
.569 
14 
.160 
.602 
13 
.704** 
.007 
13 
 
Oxycodone 
responder 
Pearson r 
P (2-tailed) 
N 
.030 
.912 
16 
.054 
.848 
15 
-.085 
.893 
5 
 
Oxycodone non-
responder 
Pearson r 
P (2-tailed) 
N 
.130 
.836 
5 
-.265 
.612 
6 
.792 
.060 
6 
Buccal 
Pearson r 
P (2-tailed) 
N 
.113 
.741 
11 
-.248 
.337 
17 
.047 
.862 
16 
 
Morphine 
responder 
Pearson r 
P (2-tailed) 
N 
.510 
.490 
4 
-.788* 
.035 
7 
.120 
.797 
7 
 
Morphine non-
responder 
Pearson r 
P (2-tailed) 
N 
-.091 
.865 
6 
.402 
.323 
8 
.122 
.794 
7 
* Correlation is significant at the 0.05 level (2-tailed); ** Correlation is significant at the 0.01 level (2-
tailed) 
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 Figure 8-6. 
Relationship between age and OPRM1 methylation in morphine responders and non-responders 
 
8.3.2 SNP and gene duplication / deletion analysis  
8.3.2.1 Morphine responders v morphine non-responders 
Age, dose, drug concentrations and methylation of ABCB1/MDR1, CYP2D6 and 
OPRM1 did not differ between morphine responders and non-responders (Table 8-3). 
A statistically significant difference was observed between OPRM1 118AA and 
118AG/GG and morphine responder status (Figure 8-7). Morphine responders were 
more likely to carry a variant allele at OPRM1 118A>G than non-responders (P = 
0.048). 
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Figure 8-6. OPRM1 118AA v AG/GG genotype in morphine responders and non-responders 
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Table 8-2. Gender, age, dose, drug concentration, genotype and methylation differences between 
morphine responders and morphine non-responders 
 Responders Non-responders P 
Gender, male / female 27 / 30 18 / 15 0.512 
Age, years 60 ±11 62 ±12 0.396 
Dose, median in mg (range) 86 (15-240) 88 (20-360) 0.525 
MOR*  0.41 ±0.14 (n=35) 0.46 ±0.17 (n=15) 0.237 
M3G* 3.10 ±0.85 (n=41) 3.07 ±1.69 (n=21) 0.935 
M6G* 1.15 ±0.34 (n=40) 1.16 ±0.64 (n=20) 0.939 
MOR:M3G* 0.13 ±0.04 (n=35) 0.13 ±0.05 (n=15) 0.806 
MOR:M6G** -0.94 ±0.36 (n=35)  -0.93 ±0.34 (n=15) 0.929 
M3G:M6G, median (range) 7.35 (4.58-33.13) (n=40) 
8.64 (4.38-30.59) 
(n=20) 
0.442 
ABCB1/MDR1 1236 CC,  
CT/TT 
16, 32 12, 19 0.626 
ABCB1/MDR1 2677 GG, 
GT/TT 
16, 33 13, 20 0.531 
ABCB1/MDR1 3435 CC, 
CT/TT 
11, 41 7, 26 0.995 
COMT 62 CC, CT/TT 14, 35 9, 21 0.892 
COMT 158 GG, GA/AA 13, 34 8, 21 0.994 
COMT rs4818 GG, GC/CC 9, 42 7, 24 0.585 
COMT rs6269 GG, GA/AA 9, 42 6, 24 0.792 
CYP2B6 516 GG, GT/TT 26, 20 18, 12 0.764 
CYP2B6 785 AA, AG/GG 20, 25 15, 15 0.637 
CYP2D6 1846 GG/GA, AA 18, 0 11, 2 0.085 
OPRM1 118 AA, AG/GG 36, 16 29, 4 0.048 
CYP2D6 *1/*1, *1XN 4, 3 3, 1 0.554 
Blood ABCB1/MDR1* 
methylation %, SD (n) 
1.8 ±0.6 (n=19) 1.7 ±0.5 (n=14) 0.481 
Blood CYP2D6 methylation  
%, SD (n) 
88.1 ±4.4 (n=16) 90.9 ±2.8 (n=13) 0.057 
Blood OPRM1 methylation  
%, SD (n) 
8.9 ±1.2 (n=11) 8.5 ±1.4 (n=13) 0.446 
Buccal ABCB1/MDR1 
methylation  
3.5  ±0.23 (n=4) 3.1 ±0 .72 (n=6) 0.610 
Buccal CYP2D6 methylation 
%, SD (n) 
90.9 ±2.31 (n=7) 92.1 ±1.21 (n=8) 0.281 
Buccal OPRM1 methylation 
%, SD (n) 
11.9 ±5.25 (n=7) 12.6 ±4.93 (n=7) 0.805 
* = SQRT transformation; ** = LG10 transformation; t-tests were undertaken for normally distributed 
data; Mann-Whitney U for non-normal distribution; Pearson chi square for comparing ordinal data. 
MOR = morphine; M3G = morphine-3-glucuronide; M6G = morphine-6-glucuronide; MOR:M3G, 
MOR:M6G, M3G:M6G = drug concentration ratio between MOR and M3G, MOR and M6G, and M3G 
and M6G, respectively.  
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The frequency of ABCB1/MDR1, COMT, CYP2B6 and CYP2D6 haplotypes in 
morphine responders and non-responders did not statistically significantly differ 
(Table 8-4). 
Table 8-3. Frequency of haplotypes in morphine responders and non-responders 
  Responders 
Non-
responders 
P 
CYP2D6 
Decreased 
*4/*4; *4/*4XN;  *4/*6 
0 2 
.172 
Normal 
*1/*1; *1/*3; *1/*4; *1/*5; *1/*6 
48 29 
Increased 
*1/*1XN; *1XN/*4 
3 1 
ABCB1/MDR1 
Homozygous wild type  
1236CC, 2677GG, 3435CC 
10 5 
.482 Variant 
1236CT/TT, 2677GT/TT, 
3435CT/TT 
34 26 
CYP2B6 
Wild type 
516GG, 785AA  
20 14 
.882 
Variant 
516GT/TT, 785AG/GG 
20 13 
COMT 
Wild type 
472AA, 408CC, -98AA 
14 9 
.895 Variant 
472AG/GG, 408CG/GG, -
98AG/GG 
30 18 
 
8.3.2.2 Oxycodone responders vs oxycodone non-responders 
Age, dose, drug concentrations and methylation of ABCB1/MDR1, CYP2D6 and 
OPRM1 did not differ between oxycodone responders and non-responders (Table 8-
5). Statistically significant differences were observed between three SNPs and 
oxycodone responder status, ABCB1/MDR1 1236C>T and 3435C>T, and CYP2B6 
516G>T (Figure 8-8). Oxycodone responders were more likely to carry a variant allele 
at ABCB1/MDR1 1236C>T and 3435C>T than non-responders, whereas the variant 
allele at CYP2B6 516G>T was more prominent in the non-responder group (P = 0.037, 
0.013 and 0.003 respectively).  
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Figure 8-7. a) ABCB1/MDR1 1236 CC v CT/TT, b) ABCB1/MDR1 3435 CC v CT/TT and c) 
CYP2B6 GG v GT/TT genotype in oxycodone responders and non-responders 
N
u
m
b
er
 o
f 
p
at
ie
n
ts
 w
it
h
 g
en
o
ty
p
e 
N
u
m
b
er
 o
f 
p
at
ie
n
ts
 w
it
h
 g
en
o
ty
p
e 
N
u
m
b
er
 o
f 
p
at
ie
n
ts
 w
it
h
 g
en
o
ty
p
e 
177 
 
Table 8-4. Gender, age, dose, drug concentration, genotype and methylation differences between 
oxycodone responders and oxycodone non-responders 
 Responders Non-responders P 
Gender, male / female 29, 35 7, 5 0.407 
Age, years 62 ±13 61 ±12 0.856 
Dose* 1.7 ±0.28  1.9 ±.043 0.128 
Oxy  0.73 ±0.38 (n=45) 0.65 ±.60 (n=6) 0.640 
nOxy 0.60 ±0.37 (n=45) 0.47 ±0.41 (n=6) 0.429 
OxyMor* -1.66 ±0.21 (n=7) -1.91 (n=1) 0.312 
Oxy:nOxy* 0.11 ±0.25 (n=45) 0.09 ±.21 0.744 
Oxy:OxyMor 36.55 ±20.44 (n=7) 50.76 0.540 
nOxy:OxyMor  27.71 ±20.80 (n=7) 21.05 0.775 
ABCB1/MDR1 1236 CC,  
CT/TT 
22, 35 8, 3 0.037 
ABCB1/MDR1 2677 GG, 
GT/TT 
23, 39 7, 4 0.099 
ABCB1/MDR1 3435 CC, 
CT/TT 
12, 50 6, 5 0.013 
COMT 62 CC, CT/TT 16, 40 3, 8 0.930 
COMT 158 GG, GA/AA 12, 39 2, 8 0.808 
COMT rs4818 GG, GC/CC 10, 46 2, 10 0.922 
COMT rs6269 GG, GA/AA 9, 50 1, 10 0.592 
CYP2B6 516 GG, GT/TT 44, 13 3, 7 0.003 
CYP2B6 785 AA, AG/GG 30, 19 3, 7 0.070 
OPRM1 118 AA, AG/GG 42, 20 7, 4 0.789 
CYP2D6 *1/*1, *1XN 44, 10 7, 3 0.407 
Blood ABCB1/MDR1* 
methylation %, SD (n) 
3.2 ±1.3 (n=16) 4.5 ±4.1 (n=4) 0.578 
Blood CYP2D6 methylation  
%, SD (n) 
87.6 ±4.8 (n=15) 84.7 ±11.1 (n=5) 0.592 
Blood OPRM1 methylation  
%, SD (n) 
10.4 ±2.6 (n=5) 8.4 ±1.7 (n=5) 0.259 
Buccal ABCB1/MDR1 
methylation  
2.4 ±0.38 (n=2) 2.8 ±0.47 (n=2) 0.700 
Buccal CYP2D6 
methylation %, SD (n) 
92.3 ±0.52 (n=3) 92.4 ±0.56 (n=3) 1.000 
Buccal OPRM1 
methylation %, SD (n) 
16.2 ±0.94 (n=3) 9.2 ±0.05 (n=2) 0.200 
 * lg10 transformation; t-tests were undertaken for normally distributed data; Mann Whitney U for non-
normal distribution; pearson chi square for comparing ordinal data; Oxy = oxycodone; nOxy = 
noroxycodone; OxyMor = oxymorphone. 
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The statistically significant difference between oxycodone responders and non-
responders observed in ABCB1/MDR1 at a single SNP level remained significant 
during haplotype analysis (P = 0.010, Table 8-6). However, there was no significant 
difference between homozygous wild type CYP2B6 516GG and 785AA haplotype 
versus 516GT/TT and 785AG/GG haplotype in oxycodone responders and non-
responders (Table 8-6). 
Table 8-5. Frequency of haplotypes in oxycodone responders and non-responders 
  Responders Non-responders P 
CYP2D6 
Decreased 
*4/*4; *4/*4XN;  *4/*6 
0 0 
0.530 
Normal 
*1/*1; *1/*3; *1/*4; *1/*5; *1/*6 
53 10 
Increased 
*1/*1XN; *1XN/*4 
10 3 
ABCB1/M
DR1 
Homozygous wild type  
1236CC, 2677GG, 3435CC 
10 6 
0.010 
 Variant 
1236CT/TT, 2677GT/TT, 3435CT/TT 
45 5 
CYP2B6 
Wild type 
516GG, 785AA  
29 4 
0.207 
Variant 
516GT/TT, 785AG/GG 
18 6 
COMT 
Wild type 
472AA, 408CC, -98AA 
15 3 
0.700 
Variant 
472AG/GG, 408CG/GG, -98AG/GG 
30 8 
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8.4 Discussion 
No differences were found in promoter region methylation of ABCB1/MDR1, 
CYP2D6 and OPRM1 in blood of morphine / oxycodone responders or non-
responders. This is the first study to investigate methylation of opioid related genes in 
relation to response to either morphine or oxycodone in a cancer population. Although 
there were no methylation differences between opioid responders and non-responders, 
the 118A>G polymorphism in OPRM1 was found to be associated with morphine 
responder status; and polymorphisms in ABCB1/MDR1 (1236C>T and 3435C>T) and 
CYP2B6 (516G>T) were associated with oxycodone responder status. The statistical 
differences observed in ABCB1/MDR1 of oxycodone responders and non-responders 
remained significant when comparing homozygous wild type at 1236C>T and 
2677G>T and 3435C>T to carriers of the variant allele haplotype (p = .010). 
The data indicates that the variant allele OPRM1 118G was more prevalent in 
morphine responders than non-responders (P = 0.048) which is contrary to the existing 
research. Previous studies have shown that carriers of a mutated allele at 118A>G 
obtain less pain relief and require higher doses of morphine to achieve analgesia than 
homozygous wild type counterparts (Klepstad et al. 2004; Reyes-Gibby et al. 2007; 
Campa et al. 2008; Tan et al. 2009; Sia et al. 2008, 2013). Carriers of the mutated 
allele are postulated to have reduced sensitivity to opioids as a result of, 1) the loss of 
a putative glycosylation site, and 2) the creation of an additional CpG site susceptible 
to DNA methylation. The loss of a glycosylation site and possible methylation within 
exon 1 are thought to reduce receptor signalling efficacy and receptor expression 
(Mestek et al. 1995; Kroslak 2007; Oertel 2009, 2012; Mura 2013). However, the 
reduced response to opioids was not replicated by other chronic pain studies (Janicki 
et al. 2006; Lotsch et al. 2009; Klepstad et al. 2011) and was not apparent in our study 
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population. The lack of reproducibility between studies may be a result of sample size 
as well as confounding factors such as gene-gene and gene-environment interactions, 
differences in pain perception, environmental influences, multiple comorbidities and 
polydrug use (Chou et al. 2006a; Likar et al. 2008).   
Heterozygous or homozygous carriers of the polymorphism at ABCB1/MDR1 
1236C>T, 2677G>T and 3435C>T were more likely to respond to oxycodone than 
homozygous wild type. Variable doses and responses to opioids in conjunction with 
these polymorphisms have been previously reported. Doses of methadone and 
morphine were higher in carriers of 1236CC, 2677GG and / or 3435CC (Coller et al. 
2006; Lotsch et al. 2009; Barratt et al. 2012; Bastami et al. 2014). The ABCB1/MDR1 
wild type genotypes have been also associated with adverse side effects following 
morphine consumption compared to carriers of heterozygous or homozygous 
mutations (Coulbault et al. 2006; Fujita et al. 2010).  
In relation to analgesic response, individuals with 3435TT genotype obtained an 
increased analgesic effect to morphine (Campa et al. 2008). This effect was not evident 
in our morphine responder / non-responder population and was also not replicated by 
Sia et al. (2010) who found no association between ABCB1/MDR1 polymorphisms 
and morphine consumption, pain scores or side effects. In addition Zwisler et al. 
(2009; 2012) reported no association between ABCB1/MDR1 2677G>T and 3435C>T 
polymorphism and response to oxycodone in a population of postoperative patients. 
However in a population of 33 healthy patients exposed to experimental pain, better 
antinociception and less adverse side effects were experienced in individuals carrying 
a variant allele at 2677G>T and 3435C>T (Zwisler et al. 2010). 
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The studies to date concerning the influence of ABCB1/MDR1 polymorphisms on 
expression and function remain inconclusive as a result of conflicting findings (Fung 
and Gottesman 2009). For example, Hoffmeyer et al. (2000) and Kim et al. (2001) 
observed decreased expression of ABCB1/MDR1 in individuals carrying the T allele 
at 3435C>T and 2677G>T, respectively. However the expression of ABCB1/MDR1 
was found to be increased in carriers of the T allele in a Japanese and Caucasian 
population (Sakaeda et al. 2002; Siegmund et al. 2002). Research undertaken by Wang 
et al. (2005b) concluded that 3435T was associated with mRNA stability as transcripts 
carrying the T allele degraded faster than wild type transcripts. But this finding was 
not supported by other researchers (Kimchi-Sarfaty et al. 2007; Gow et al. 2008; Hung 
et al. 2008).  
The 1236C>T and 3435C>T SNPs are synonymous so do not cause an amino acid 
substitution, however synonymous SNPs in other genes have functional consequences 
(Chamary et al. 2006; Sauna et al. 2007) and therefore 1236C>T and 34335C>T could 
modify ABCB1/MDR1 function. A combination of mutations, i.e. haplotypes, are 
postulated to alter the shape of ABCB1/MDR1 by causing different folding that 
changes substrate specificity compared to the wild type (Kimchi-Sarfaty et al. 2007; 
Hung et al. 2008; Fung and Gottesman 2009). Therefore the greater frequency of the 
heterozygous or homozygous mutations of 1236C>T, 2677G>T and 3435C>T in the 
oxycodone responder group may be an ABCB1/MDR1 modification that is 
advantageous in this cancer population.  
Oxycodone is primarily metabolised by CYP3A4 to noroxycodone, and to a lesser 
extent CYP2D6 to the active metabolite oxymorphone. Genetic variability in CYP2D6 
has been estimated to cause reduced enzyme activity in 5-10% of Caucasians and rapid 
metabolism in 1-7% (Evans et al. 1980; Bertilsson et al. 1992; Lovlie et al. 1996; 
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Bathum et al. 1998; Heiskanen et al. 1998). The influence of CYP2D6 was not 
observed in this study which may be a result of small sample size. However the 
516G>T variant in CYP2B6 was observed to be more prevalent in the oxycodone non-
responder group compared to oxycodone responders.  
CYP2B6 polymorphisms (750T>C, 516G>T, 785A>G) have been associated with 
decreased CYP2B6 expression resulting in increased substrate blood concentrations, 
e.g. methadone, postulated to increase toxicity susceptibility (Lang et al. 2001; Crettol 
et al. 2007; Eap et al. 2007; Bunten et al. 2010). Although CYP2B6 does not 
metabolise oxycodone, adverse drug reactions as a result of drug-drug and genetic-
drug interactions in addition to nutrition, disease and environmental influences have 
been documented (Stamer and Stuber 2007; Gudin 2012). For example, inhibition of 
CYP3A or CYP2D6 by ketoconazole or quinine respectively, can alter the efficacy of 
oxycodone as an analgesic (Hagelberg et al. 2009; Samer et al. 2010). The inhibition 
of one enzyme has been observed to increase the metabolic rate of the alternative 
enzyme. In the case of CYP3A inhibition, CYP2D6 activity increases the metabolism 
of oxycodone into the active metabolite oxymorphone. The increased concentration of 
oxymorphone results in increased analgesia, but also increased toxicity (Samer et al. 
2010). The effect is further enhanced if the individual has an ultrarapid CYP2D6 
metaboliser status in addition to an inhibited CYP3A enzyme (Samer et al. 2010). As 
the CYP2B6 516G>T polymorphism is associated with reduced expression, 
concomitant medication metabolised by CYP2B6 may be in competition with the 
oxycodone for alternative metabolising enzymes (CYP2D6, CYP3A4) resulting in 
slower detoxification of oxycodone, causing toxicity or enhanced effect. 
The results of this research show that the average methylation of 11 CpG sites 
investigated in ABCB1/MDR1, 3 CpG sites in CYP2D6 and 8 CpG sites in ORPM1 
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are not indicators of response to morphine or oxycodone. The lack of relationship does 
not mean that these genes or methylation is not associated with responder status.  
The promoter region of ABCB1/MDR1, CYP2D6 and OPRM1 were explored in this 
study as that is where CpG density was greatest and potential transcription factor 
binding sites are located. However, variable methylation in regions less densely 
populated by CpG sites and within the gene body have been associated with altered 
gene function and disease development (Shann et al. 2008; Ball et al. 2009; Irizarry et 
al. 2009; Illingworth et al. 2010; Maunakea et al. 2010; Deaton et al. 2011; Kinoshita 
et al. 2013). Therefore, other CpG sites further upstream from the transcription start 
site or surrounding alternative promoters in the gene body of ABCB1/MDR1, CYP2D6 
or OPRM1 may influence opioid responder status. Alternatively, no relationship was 
observed between the genes’ methylation profiles and morphine or oxycodone 
response as a result of the tissue investigated.  
Blood was analysed as previous research detected variable methylation in blood 
samples of OPRM1 between different populations (Nielsen et al. 2009, 2010). Buccal 
swabs were investigated to determine its usefulness as a pain free, easy and relatively 
non-invasive alternative to blood for genetic analysis. However the ABCB1/MDR1 
transport protein is located at blood-tissue membranes, CYP2D6 is primarily 
expressed in the liver and the µ-opioid receptor in the central nervous system. 
Therefore, the methylation profile of these genes within their associated tissue may 
reflect response to opioids. The variable methylation of ABCB1/MDR1, CYP2D6 and 
OPRM1 of opioid dependant and opioid naïve populations has been discussed in 
Chapters 5 and 7.  
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The variable response to morphine and oxycodone is likely to be a complex 
phenomenon contributed to by a number of interacting clinical and genetic factors 
(Diatchenko et al. 2005). Studies to date have focused on single genetic variants, or at 
most the interaction of two variants. More complex modelling is required to explore 
the concept of epistasis i.e. gene-gene and gene-environment interactions (Moore 
2003).  
The choice of gene investigated also needs to be widened as focus is mainly on 
OPRM1, COMT and ABCB1/MDR1. There has been only one genome-wide 
association study in cancer patients taking opioids, and this data has not been 
replicated (Galvan et al. 2011). To take into account the wide range of variables that 
have been postulated to influence opioid response, a large population is required to 
provide statistically significant findings. 
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9.0 THESIS DISCUSSION  
The aim of this thesis was to explore the influence of opioid-related gene DNA 
methylation on analgesic response to morphine and oxycodone. Humans obtain 
different responses to morphine and oxycodone as a result of a numerous factors, 
including the formulation of the opioid and the route of administration, body 
composition and organ dysfunction, the use of concomitant medication or illicit drugs, 
and genetic variations within genes involved in opioid pharmacokinetics and 
pharmacodynamics. Although relationships between each of these factors and opioid 
response have been obtained, they are not fully understood. Other factors must be 
contributing to produce the variable response to opioids. Therefore it was decided to 
investigate the epigenetic gene regulatory mechanism, DNA methylation, on the 
relevant genes governing metabolism, membrane transport and efficacy in relation to 
pain response.   
Patients that require either morphine or oxycodone to alleviate pain are already in 
considerable discomfort, therefore relatively non-intrusive and pain free method for 
the epigenetic analysis is a favourable approach. Obtaining genomic DNA using 
buccal swabs is a clearly a better method than from blood. Therefore analysis of DNA 
methylation status of those aforementioned genes was largely undertaken using 
buccal DNA, but paired blood samples were obtained for comparison in the final 
studied pilot population.   
Previous research has shown that DNA methylation, unlike genetic polymorphisms, 
is a dynamic mechanism influenced by environmental factors. Two such factors that 
have been shown to alter ‘normal’ DNA methylation patterns are smoking and chronic 
opioid use. As such a population of smokers and non-smokers were recruited and the 
DNA methylation profiles of opioid related genes (ABCB1/MDR1, CYP2D6 and 
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OPRM1) were investigated between the two sample groups. It was hoped that DNA 
polymorphisms and methylation of these opioid related genes could be a set of useful 
biomarkers for revealing opioid response in a readily accessible and non-intrusive 
way.   
Does smoking influence buccal DNA methylation?  
Despite the fact that 50 female smokers and 43 female non-smokers between the ages 
of 18-50 were recruited for the study, no difference of methylation on any of the above 
mentioned genes were observed. Previous studies investigating the response of smoke 
exposure on buccal DNA methylation found that widespread changes occur. 
However, the smoke exposure induced methylation changes were observed at 
repetitive elements (Smith et al. 2007; Breton et al. 2009) or mapped to genes 
involved in the detoxification of the carcinogenic agents in tobacco smoke, i.e. 
polycyclic hydrocarbons (PAH), such as the aryl hydrocarbon receptor repressor 
(AHRR), CYP1A1 and CYP1B1 (Zeilinger et al. 2013; Teschendorff et al. 2015). 
CYP2D6 is not one of the genes significantly associated with PAH metabolism 
(Shimada et al. 2001) which could explain why no CYP2D6 methylation differences 
were observed between smokers and non-smokers in this study.   
OPRM1 methylation however was reported to be associated with smoke exposure 
(Lee et al. 2014). Nonetheless, this study is not comparable since Lee et al. (2014) 
explored DNA methylation of blood samples (rather than buccal swabs) from 
adolescents who were prenatally exposed to maternal cigarette smoking. In addition, 
although Lee et al. (2014) analysed CpG sites within the introns and exons of the 
OPRM1 gene, they did not report DNA methylation in the promoter region CpGs. It 
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is intriguing if DNA methylation in the promoter region or in the intron/exon region 
could affect gene expression in the same way.  
It is also questionable if the DNA methylation states revealed from blood samples 
could truly reflect the same DNA methylation states in the brain tissue where the 
OPRM1 receptor is expressed. The importance of tissue specific methylation has 
already been highlighted in numerous studies when investigating the influence of 
smoke exposure on DNA methylation of genes (Zöchbauer Müller et al. 2003; Chien 
2011; Teschendorff et al. 2015). However, for this study, ascertaining the effect of 
smoke exposure on the methylation of opioid related genes within buccal cells was 
the aim so that any differences found could be taken into account when investigating 
and comparing other populations. Analysis of buccal samples of smokers and non-
smokers demonstrated that there is no DNA methylation differences on the promoters 
of CYP2D6 and OPRM1 genes. Therefore, those methylation differences observed in 
later populations were considered as results of other variables, not the influence of 
smoking.  
Methadone-prescribed opioid-dependant mothers and their new-born babies: 
Babies Born to Methadone-Prescribed Opioid-Dependant Mothers have 
Elevated DNA Methylation on ABCB1/MDR1, CYP2D6 and OPRM1.  
To assess the effect of chronic opioid exposure on DNA methylation, woman 
undergoing methadone maintenance treatment programmes and their new-born 
babies, and opioid naïve women-baby dyads were recruited and the same genes were 
analysed as the smoking population. Previous studies showed that chronic opioid 
exposure altered DNA methylation (Nielsen et al. 2009; Chorbov et al. 2010). 
However, the focus of the studies by Nielsen et al. (2009) and Chorbov et al. (2010) 
was on the µ-opioid receptor in lymphocytes and sperm, respectively. As such it was 
188  
  
necessary to investigate the methylation of ABCB1/MDR1, CYP2D6 and OPRM1 in 
other tissues, namely buccal cells, blood, liver, muscle and thalamus, of opioid 
exposed individuals compared to non-opioid exposed individuals.  
The opioid-dependant mothers had been prescribed methadone during pregnancy. 
Non-opioid exposed mother-baby dyads were recruited as controls and matched by 
age and postcode to negate the effects of aging and potentially deprived living 
standards on gene DNA methylation. In spite of the relatively small populations of 
mother-baby dyads (opioid exposed n = 21; non-opioid exposed n = 31), this research 
showed that methylation was statistically different between the opioid exposed adults 
and opioid naïve adults (ABCB1/MDR1 and CYP2D6, but not OPRM1); and between 
the opioid exposed and opioid naïve babies (in all genes investigated, P = <0.001). 
The increased methylation of the opioid exposed populations compared to the control 
populations could not be explained by age, smoking status or area of residence and as 
such was attributed to the effect of regular opioid exposure or lifestyle associated with 
opioid dependency.   
To date, the influence of chronic opioid exposure on DNA methylation of 
ABCB1/MDR1, CYP2D6 and OPRM1 genes from adult buccal tissue has not been 
published. However increased methylation within the opioid exposed populations was 
expected as opioid exposure, and the stressful lifestyle and poor diet associated with 
opioid dependency has been previously reported to cause variable DNA methylation 
in tissues other than buccal DNA (McGowan et al. 2009; Nielsen et al. 2009; Chorbov 
et al. 2010; de Rooij et al. 2012; Doehring et al. 2013). Conversely to the existing 
literature (Nielsen et al. 2009; Chorbov et al. 2010; Doehring et al. 2013), no OPRM1  
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DNA methylation differences were observed between the opioid exposed and opioid 
naïve mothers. The disparity between previous studies and this study may be a result 
of tissue specific methylation.   
With regards to baby DNA methylation, one recent study by Wachman et al. (2014) 
investigated methylation of OPRM1 in saliva samples of opioid exposed babies. 
Unfortunately, they did not recruit an opioid naïve population of babies for 
comparison. The methylation percentages that Wachman et al. (2014) reported for the 
opioid exposed babies were lower than those found in our opioid exposed babies, but 
greater methylation levels were observed than that of our opioid naïve population. 
This suggests that opioid exposure, and / or the lifestyle associated with opioid 
dependency increases the methylation of OPRM1. The extent of DNA methylation 
may be influenced by maternal dose of methadone as the mothers recruited by 
Wachman et al. (2014) were receiving lower doses of methadone compared to the 
mothers recruited as part of this study.   
The purpose of the work undertaken by Wachman et al. (2014) was not to explore the 
effects of opioid exposure on DNA methylation, but to ascertain whether DNA 
methylation of OPRM1 influences the development of NAS. They found that the -10 
CpG site was hypermethylated in babies requiring NAS treatment compared to those 
that did not, but this difference did not retain significance after multiple testing 
correction. The lack of relationship between OPRM1 DNA methylation and 
likelihood of developing NAS observed by Wachman et al. (2014) was corroborated 
by this study suggesting that DNA methylation is not a suitable biomarker for the 
likelihood of developing NAS.  
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Methadone-prescribed opioid-dependant mothers and their new-born babies: 
The CYP2B6*6 polymorphism protects babies exposed to methadone in utero 
from neonatal abstinence syndrome development.   
Although no relationship between DNA methylation and NAS development was 
observed, a relationship that has not been previously reported was found between  
CYP2B6 polymorphisms and NAS development. Babies carrying a variant allele at 
CYP2B6 516G>T and 785A>G (CYP2B6*6 genotype) were statistically less likely to 
require NAS treatment than babies with the CYP2B6*1 genotype. CYP2B6 is the 
predominant metabolising enzyme of methadone and the CYP2B6*6 genotype has 
been reported to catalytically deficient compared to the wild-type (Gadel et al. 2013).  
 The reduced metabolic activity of CYP2B6*6, associated with the poor metaboliser 
phenotype, is postulated to have protected babies carrying this genotype from NAS 
development by prolonging the presence of maternally transferred methadone; 
whereas babies with the wild-type would efficiently and rapidly metabolise 
methadone resulting in the opioid withdrawal symptoms signifying NAS. Increased 
methadone plasma concentrations following methadone administration and lower 
requirement of methadone dose of individuals with CYP2B6*6 compared to wild-type 
has been reported in adult populations (Crettol et al. 2005; Eap et al. 2007; Bunten et 
al. 2011; Hung et al. 2011; Wang et al. 2011; Levran et al. 2013) but there is no 
literature with regards to baby NAS development and CYP2B6 polymorphisms.   
Other genes associated with opioid pharmacokinetics and pharmacodynamics have 
been associated with the development of NAS. A study undertaken by Wachman et 
al. (2013) found that babies heterozygous or homozygous for the variant allele at 
OPRM1 118A>G were less likely to require treatment for NAS that those babies with 
homozygous wild-type. This finding was not observed in our population of 
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methadone exposed babies, as reported in Chapter 6. The lack of relationship between 
the OPRM1 118A>G SNP and NAS development may be a result of limited sample 
size as well as low occurrence of the mutated allele in our studied human subjects.   
  
Tissue specific DNA methylation: DNA methylation of ABCB1/MDR1, CYP2D6 
and OPRM1 in individuals whose deaths were attributed to heroin toxicity.   
The second opioid exposed population investigated were heroin associated fatalities 
undergoing autopsy at Sir James Black Mortuary, Dundee. Tissue specific DNA 
methylation was investigated using these post-mortem blood, liver, psoas muscle and 
thalamus samples. Comparison of methylation within opioid exposed intra-individual 
tissue samples showed that ABCB1/MDR1 had higher methylation in thalamus 
compared to liver and muscle; CYP2D6 was less methylated in liver tissue compared 
to blood, muscle and thalamus tissue; and OPRM1 was less methylated in thalamus 
and muscle compared to DNA obtained from blood and liver (detailed in Chapter 7).   
The variable gene methylation between the tissues appeared to be related to tissue 
function. The most prominent example being the hypomethylation of CYP2D6 in liver 
compared to its hypermethylation in other tissues investigated. CYP2D6 is an 
important hepatic metabolising enzyme, fundamental in the metabolism of a wide 
variety of drugs and endogenous compounds (Wang et al. 2013; Ravindranath 2014). 
The hypomethylated CYP2D6 gene in the liver samples is speculated to enable the 
protein to be expressed more readily in the liver so as to enable detoxification of not 
only the opioids consumed but also the wide variety of drugs detected in the 
postmortem blood samples (drugs listed in 3.3.2).   
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Clearly further research is required to determine the effect of variable gene 
methylation on expression of proteins within various tissues. Tissue-specific 
differentially methylated regions have been observed in genome wide analyses 
(Zhang et al. 2013; Lokk et al. 2014). For example, the receptor involved with the 
development of epithelial tissue and bone, MST1R, is less in demand in the brain 
tissue and is therefore heavily methylated in comparison to other tissues (Byun et al. 
2009). Analysis of the post-mortem population has shown that methylation of the 
opioid related genes is tissue specific. In addition the post-mortem population 
illustrated that there was no correlation between methylation of related samples. This 
study highlights that gene methylation in peripheral tissues does not necessarily 
suggest that methylation is not influencing gene expression in the tissue of gene 
function, thereby altering opioid response.   
Pilot trial: Personalising opioid therapy for cancer pain relief. The influence of 
DNA methylation and SNPs on opioid response.   
Unlike smoking, opioid exposure influenced DNA methylation on opioid related 
genes. Therefore, an opioid naïve population of patients requiring either morphine or 
oxycodone to alleviate cancer related pain were recruited to determine the influence 
of DNA methylation on opioid responder status. In addition to DNA methylation 
analysis, genetic variations in ABCB1/MDR1, COMT, CYP2B6, CYP2D6 and 
OPRM1 that have been associated with opioid response by previous studies 
(summarised in  
2.2.5) were investigated. This study is the first to show that buccal and plasma 
ABCB1/MDR1, CYP2D6 and OPRM1 DNA methylation is not indicative of how an 
opioid naïve population would respond to morphine or oxycodone analgesics.  
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Although DNA methylation was not associated with opioid response the OPRM1 
118A>G, ABCB1/MDR1 1236C>T, ABCB1/MDR1 3435C>T, and CYP2B6 516G>T  
polymorphisms were statistically significantly different between opioid responders 
and non-responders. Individuals carrying the variant allele at OPRM1 118A>G were 
more likely to be respond well to morphine analgesia which is inconsistent with 
previous studies. Previous research has indicated that carriers of 118G allele obtain 
less pain relief and require higher doses of morphine to achieve analgesia (Klepstad 
et al. 2004; Campa et al. 2008; Tan et al. 2009; Sia et al. 2008, 2013).   
However the lack of a relationship between the 118A>G polymorphism and opioid 
response has also been reported (Janicki et al. 2006; Klepstad et al. 2011). Three of 
the studies that observed a relationship between 118A>G and morphine response were 
undertaken using Asian populations administered morphine during childbirth or 
hysterectomy surgery (Sia et al. 2008; Tan et al. 2009; Sia et al. 2013). As reported 
by Tan et al. (2009), ethnicity, independent of the OPRM1 118A>G polymorphism, 
is a significant contributor to opioid response. Therefore the Caucasian population 
recruited for this study is not comparable to studies of Asian populations.   
Also the studies by Sia et al. (2008, 2013) and Tan et al. (2009) detail the use of 
intravenous morphine, and as discussed in 2.1.3 the route of opioid administration 
alters drug efficacy and duration as a result of differing bioavailability and rate at 
which the opioid reaches the target site. Intravenous administration of morphine 
results in a more rapid analgesic response as it by-passes first-pass metabolism and 
therefore reduces the influence of genes such as ABCB1/MDR1 which plays a role in 
blood-tissue opioid transportation. As such, the study undertaken by Klepstad et al. 
(2004) is the most similar to this study as a Caucasian population was recruited and 
were prescribed oral morphine for cancer related pain. In addition, similar population 
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sizes were recruited by Klepstad et al. (2004) and this study. Possible explanations, 
then, for the contradictory OPRM1 118A>G polymorphism and opioid response 
outcomes include (as postulated by Chou et al. 2006; Likar et al. 2008) confounding 
factors such as gene-gene and gene-environment interactions, environmental 
influences, multiple comorbidities and drug-drug interactions. To explore the effect 
of all these factors a large population of patients would need to be recruited.   
Carriers of the variant alleles at ABCB1/MDR1 1236C>T and 3435C>T, and CYP2B6 
516G>T were more likely to respond to oxycodone than those cancer patients with 
the wild-type genotype. The statistical difference observed in the ABCB1/MDR1 
polymorphisms of oxycodone responders and non-responders was retained when the 
wild-type haplotype was compared to the variant haplotype (P = 0.010). The 
occurrence of better opioid response (with regards to pain as well as side effects) in 
patients with a variant allele at ABCB1/MDR1 1236C>T and 3435C>T has been 
previously reported (Coulbault et al. 2006; Campa et al. 2008; Fujita et al. 2010; 
Zwisler et al.2010). The polymorphisms are associated with a transport protein with 
reduced expression and / or efficacy (Hassan et al. 2009) and as a result the 
pharmacological effects of opioids are prolonged through increased absorption and 
CNS accumulation. Further, larger studies should be undertaken to corroborate these 
findings.  
The largest population of patients to be recruited to date is by the European 
Pharmacogenetic Opioid Study (EPOS) group (n = 2294). The EPOS found no 
relationship between any polymorphism and opioid response (Klepstad et al. 2011); 
however their cancer patient population lacked homogeneity. Patients experiencing 
neuropathic pain were merged with those suffering somatic and visceral pain which 
operate through different pain signalling pathways (Woolf 2011). Not only that, but a 
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wide range of opioids with different cell signalling transduction pathways were 
prescribed (morphine, oxycodone, fentanyl in addition to other opioids) via different 
routes of administration.   
As part of this study, the choice of opioid was limited to oral administrated morphine 
or oxycodone and patients suffering from neuropathic pain were considered not 
eligible for the study. It should be noted that the target population of cancer patients 
to be recruited was 200. However, a number of delays were encountered whilst 
designing and writing the protocol as well as obtaining ethical approval that resulted 
in a shortened period for patient recruitment (full details of delays encountered 
attached as Appendix D1.0). Although >18 months were consumed by the 
administration aspects, a considerable amount knowledge was learnt from having to 
choose appropriate wording for writing the protocol and supporting appendices, 
liaising with clinicians and corresponding with the ethics committee.   
Conclusion  
In conclusion, DNA methylation on the ABCB1/MDR1, CYP2D6 and OPRM1 gene 
promoter regions of blood and buccal samples cannot be used to predict individual 
response to morphine and oxycodone. However this research showed that DNA  
methylation of the genes is tissue-specific. Therefore it is plausible that differences in 
DNA methylation on the above genes between opioid responders and non-responders 
may reflect the functional state (on or off expression) of the genes in specific tissues 
of relevance. As such future research should investigate the DNA methylation states 
of ABCB1/MDR1, CYP2D6 and OPRM1 genes in cells obtained from blood-tissue 
barriers, liver and central nervous system, respectively, in relation to opioid response 
outcome. Chapter 5 and 7 illustrated that chronic opioid use, or the lifestyle associated 
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with opioid dependency are important factors to be considered when exploring DNA 
methylation of opioid related genes, whereas smoking did not influence their DNA 
methylation (Chapter 4).   
Although DNA methylation was not associated with responder status, relationships 
were observed with polymorphisms in ABCB1/MDR1 and OPRM1 genes. These  
findings clearly need to be confirmed in future studies with larger population sample 
sizes. The identification of SNPs associated with opioid response is potentially very 
valuable for clinicians prescribing opioids to patients in need of Step III opioids to 
alleviate pain.  
 Additionally this study has identified genetic polymorphisms that could act as a 
diagnostic tool for predicting the susceptibility of babies exposed to methadone in 
utero to develop NAS. The CYP2B6*6 genotype is more frequent in babies who do 
not require treatment for opioid withdrawal symptoms. Indicators of NAS 
development enables appropriate monitoring of babies who are more susceptible to 
developing NAS, which could negate unnecessary long hospital stays for babies 
protected from developing NAS. The reduced hospital stay of babies less susceptible 
to NAS development would reduce the healthcare costs associated with NAS 
monitoring.  
In conclusion this study has;   
1. suggested that smoke exposure does not influence buccal DNA methylation 
of CYP2D6 or OPRM1 therefore smoking was not considered as a methylation 
altering factor for these genes.  
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2. illustrated that opioid exposure, or the opioid associated lifestyle increases 
gene DNA methylation so an opioid naïve population was necessary to 
investigate opioid response in relation to gene methylation.  
3. identified genetic polymorphisms that could act as a diagnostic tool for 
predicting the susceptibility of babies exposed to methadone in utero to 
develop NAS. The CYP2B6*6 genotype is more frequent in babies who do not 
require treatment for opioid withdrawal symptoms.  
4. confirmed previous studies that DNA methylation is tissue specific therefore 
methylation of relevant genes may be of more interest than DNA analysis of 
genes in peripheral tissues.  
5. determined that methylation of ABCB1/MDR1, CYP2D6 and OPRM1 did not 
influence the response to morphine or oxycodone in an opioid naïve 
population, however polymorphisms in ABCB1/MDR1 and OPRM1 may.  
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Poppy McLaughlin(1), Tamas Hickish(2) and David Osselton(1)  
(1) Centre for Forensic and Biological Sciences, School of Applied Sciences,  
Bournemouth University and (2)Royal Bournemouth Hospital.  
  
1. Background  
Chemicals within in tobacco smoke can damage DNA. This damage can be in the 
form of mutations which alters the DNA sequence or epigenetic mechanisms that 
add or remove compounds to the DNA sequence. One such epigenetic mechanism is 
called DNA methylation and involves the addition of methyl groups onto particular 
sequences of DNA; specifically when cytosine and guanine bases fall in succession 
(CpG). DNA methylation is an essential mechanism for gene regulation. If a gene is 
heavily methylated then that gene is effectively switched off as transcription factors 
cannot bind and translate the DNA sequence into a protein.  
Recently we undertook a study involving mothers on maintenance treatment 
programmes whilst pregnant. From both the mother and newborn baby buccal swabs 
were obtained. The methylation of CpG sites in the mu-opioid receptor (OPRM1), 
transport protein (ABCB1) and 3 CpG sites in CYP2D6, a phase one metabolising 
enzyme were determined in the buccal DNA. The aim of this study was to establish 
the effect of prolonged opioid exposure on the mother’s buccal DNA methylation of 
opioid important genes, and to determine the effect of methadone exposure in utero 
on their neonate. Unfortunately all of the mothers who were taking methadone were 
also smokers. Smoking has been shown to alter buccal DNA methylation, causing 
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variable methylation of certain genes compared to non-smokers (Breitling et al. 
2011; Chien et al 2011). Similar smoking-related DNA methylation gene specific 
and genome wide alterations have been observed in neonates exposed to smoking in 
utero (Breton et al 2009; Flom et al. 2011). However to date, the effect of smoking 
on methylation of the mu-opioid receptor (OPRM1), transport protein (ABCB1) and 
phase I metabolising enzyme, CYP2D6, has not been reported. Therefore it is not 
known whether the methylation profile observed in the methadone exposed mother 
and baby population is as a result of the methadone exposure, tobacco smoke or is a  
“normal” methylation profile.  
Hypothesis: Smoking causes increased DNA methylation in buccal DNA compared 
to non-smoker buccal DNA methylation.  
  
2. Study Design  
We plan to undertake a prospective non-interventional fully anonymised genetic 
study. Study subjects will only be asked to complete a short questionnaire and 
provide a buccal swab.  
2.1 Study Population  
The aim is to enrol 100 females between the ages of 18 and 50; 50 smokers and 50 
non-smokers.   
2.2 Population Recruitment and Requirements  
2.2.1 Bournemouth University staff, PhD researchers and 
students will be approached and asked to read a patient 
information sheet that details the background and purpose 
of the study.  
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2.2.2 The eligible volunteers must sign an informed consent form 
after having read the patient information sheet to 
participate in the study.  
2.2.3 On introduction to the study the volunteer will be assigned 
a unique study number. This unique study number will be 
matched to the buccal swab provided. There will be no 
record linking a volunteer to their study number.  
2.2.4 The volunteer’s age, smoking history and opioid use will 
be recorded.  
2.2.5 Following obtaining consent and completing the 
questionnaire volunteers will be asked to provide a buccal 
swab. Buccal swabs will be collected using Catch-AllTM 
brushes for DNA analysis.   
  
2.3 Sample Collection, Storage and Analysis  
2.3.1 To collect buccal DNA volunteers will be asked to swill 
their mouth with water a couple of times to remove any 
external contaminants.  
2.3.2 The cotton bud-like buccal swab will be rubbed gently on 
the inner side of both cheeks 10-20 times each.  
2.3.3 The buccal swab will be air dried in a hard plastic case 
until sample is dry (about 20 minutes).  
2.3.4 Samples will be stored at -20 until extraction at Royal 
Bournemouth Hospital.   
2.3.5 Methylation analysis will be undertaken at Royal 
Bournemouth Hospital  
  
Molecular Pathology Department using previously developed pyrosequencing 
assays.  
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3. Statistical Analysis  
Methylation profile of each gene will be compared between smokers and non-
smokers using t-tests if the data is normally distributed and there are no outliers. 
Alternatively independent nonparametric tests will be undertaken.   
The methylation profile of the smokers and non-smokers will also be compared to 
the methylation profile of methadone exposed mothers to ascertain whether the 
mothers’ methylation is impacted by opioid exposure.  
  
4. Costs of the project  
Analysis will be undertaken by Poppy McLaughlin at the Centre for Forensic and  
Biological Sciences, Bournemouth University, and Molecular Pathology department,  
Royal Bournemouth hospital under the direct supervision of Prof. David Osselton 
and Dr Tamas Hickish. The cost of all analyses will be borne by the Centre for 
Forensic and Biological Sciences, Bournemouth University (buccal swabs - already 
purchased) and Royal Bournemouth hospital charitable funds (for pyrosequencing 
analysis – already purchased).  
  
5. Timeline  
It is anticipated that 50 smokers and 50 non-smokers can be recruited within a four 
week period.   
  
6. Summary and likely outcomes from this project  
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The results from this study will illustrate the impact of smoking on buccal DNA 
methylation. If there is no difference in methylation between smokers and non- 
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methylation profile found in the methadone mothers is more likely to be due to their 
methadone use than smoking. This will show that methadone has an adverse effect 
of buccal DNA and may alter drug response.  
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Does smoking affect buccal DNA?  
  
Participant Information Sheet  
  
  
You are being invited to participate in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please read the following information carefully and discuss it with others if 
you wish. Ask us if anything is unclear or if you would like more information.   
  
What is the purpose of the study?  
Buccal DNA (genetic material collected from the mouth cavity) has been obtained 
from mothers taking methadone to alleviate their craving for other drugs, 
specifically heroin. These buccal samples have been analysed for a genetic 
mechanism that plays a role in gene expression. This genetic mechanism is called 
DNA methylation. DNA methylation is known to be affected by age, lifestyle, 
environmental exposures, smoking and diet. We decided to research what affect 
continued methadone exposure has on buccal DNA methylation however all the 
mothers analysed were also smokers. Therefore we do not know whether the DNA 
methylation identified is as a result of methadone use, a result of smoking, or could 
be a combination of the two factors.  
  
In order to determine the effect of smoking on buccal DNA methylation we would 
like to collect and analyse buccal samples from female smokers and non-smokers.  
  
Why have I been chosen?  
We are asking a sample of female staff and students at Bournemouth University if 
they will take part in this study.  
  
Do we need to take part?  
No. It is entirely up to you.  If you do decide that you will take part you will be 
given this information sheet to keep and be asked to sign a consent form.  You will 
be free to withdraw from the study at any time and you won’t have to give a reason.    
  
What will happen to me if I take part?  
After signing the consent form we will collect a mouth swab from you to check 
your genes (DNA). The mouth swab is painless and will only take a few seconds. 
The DNA samples will be stored and analysed at the University of Bournemouth. 
We will keep a note of your smoking status and whether or not you take drugs, but 
otherwise the samples provided will be completely anonymised.   
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What are the possible risks of taking part?  
There are no risks from taking part in this study.  
  
What are the possible benefits of taking part in this study?  
There is not expected to be any direct benefit to yourself from taking part in this study.    
  
Suggestions and complaints.  
If taking part in this research project harms you there are no special compensation 
arrangements.  If you wish to complain about any aspect of the way you have been 
treated during the course of this study a complaint in writing can be made to Prof 
David Osselton, C237, Talbot Campus, Bournemouth University, BH12 5BB.   
  
Will our taking part in this study be kept confidential?  
All information collected about you during the course of this research will be kept strictly 
confidential.    
  
What will happen to the results of the research study?  
Information gathered from this study will be analysed and the results submitted for 
publication in a medical journal.  Information may also be presented at scientific 
meetings.  You will not be identified in any presentation or written document.  
  
Who is funding this research?  
The mouth swab tests will be carried out at the University of Bournemouth as part of 
a PhD.  
  
Who has reviewed this study?  
This study has been approved by Bournemouth University Ethics Committee.  
  
Contact for further information  
Poppy McLaughlin, PhD researcher, can be contacted at any time on 01202 961831.    
  
Thank you for taking time to consider this research study.  
  
Yours sincerely,  
  
Poppy McLaughlin     
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CONSENT FORM  
  
Study: Does smoking affect buccal DNA?  
  
Name of Researcher: Poppy McLaughlin  
  
  
Study Number:              
           Please initial each box  
  
1. I confirm that I have read and understand the information sheet dated March  
2014 (version 1) for the above study and have had the opportunity to ask questions.          
  
2. I understand that my participation is voluntary, and that I am free to withdraw 
 consent at any time without giving any reason.                                                    
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Study: Does smoking affect buccal DNA?  
  
Questionnaire  
  
Study No:  
  
1. How old are you?       ________________ years old  
  
2. Please choose one of the following statements and complete as necessary:  
a. I have never smoked  
b. I used to smoke but stopped in ________________ (year)  
c. I smoke less than 15 cigarettes a day  
d. I smoke more than 15 cigarettes a day  
  
3. Do you take regular opioids, e.g. morphine, methadone, heroin, oxycodone?  
a. No  
b. Yes, I take _______________________________  
  
  
  
Thank you for your participation!   
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1 Study Summary  
Morphine is the initial analgesic opioid of choice for relieving chronic cancer pain 
that cannot be controlled by non-opioid analgesics, however patient responses are 
variable. Whilst many patients achieve satisfactory pain relief from morphine, 
1030% of patients obtain inadequate or no pain relief and may suffer intolerable 
adverse side effects such as nausea and constipation (Cherny et al. 2001; Ross et al. 
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief   APPENDIX B1.0  
Protocol  
Version 1.4  
24/01/2013    3  
2005; Oertel et al. 2006). The dose of analgesic is titrated gradually until affective 
analgesia is obtained with minimal side effects but this process can be slow, as well 
as painful for the patients. In the event that patients do not obtain the desired pain 
relief from morphine or have unacceptable side effects, alternative opioids such as 
oxycodone are prescribed but these analgesics also produce variable inter-individual 
responses. This “trial-by-error” method for drug administration has a detrimental 
effect on patients’ quality of life as well as being expensive for health care 
organisations.  
The literature has shown that genetic variations can lead to varying analgesic affects 
of opioids. As of yet no study has created an algorithm that takes into account the 
various polymorphisms as well as lifestyle choices to calculate the most appropriate 
opioid and the correct dose on first administration rather on a trial-by-error basis. 
Initially a pilot study will be carried out to gauge participant recruitment rate, 
compliance with the study, participant drop-out rate and to explore genetic and 
toxicological information. Patients with cancer who require a Step III analgesic such 
as morphine or oxycodone to relieve cancer related pain will be asked to participate 
in this observational, non-invasive study. Treatment of patient’s cancer pain will not 
be affected by participating in this study, however patients will be asked to complete 
questionnaires and provide blood and oral fluid samples. Each patient will be asked 
to rate the efficacy of their pain relief by completing pain and side effect 
questionnaires at regular intervals until they are on a stable dose of either morphine 
or oxycodone (usually within 7-10 days). If the initial opioid is ineffective and the 
patients are switched to the alternative study opioid (either morphine or oxycodone), 
the patient may continue to participate in the pilot trial. The participants’ blood and 
oral fluid samples would be analysed to quantify opioid concentrations and to 
identify potential genetic variants which may affect drug response. The opioid 
concentrations detected in the blood and oral fluid samples would be compared to 
ascertain the suitability of using oral fluid in place of blood samples for monitoring 
opioid levels. Oral fluid collection is a less invasive and has a gentler collection 
procedure so would be more comfortable for the cancer patients who undergo 
innumerable tests and blood collections. Previous research (Hansen et al. 2007) has 
shown that patients prefer to provide oral fluid samples over blood samples. 
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2 Background  
2.1 Opioids for cancer pain  
The World Health Organisation (WHO) defined a pain relief step ladder in 1986 
(Burton and Cleeland 2001) that directs the pharmacological management of cancer 
pain. This is a step-wise approach, starting with the use of non opioids (e.g. 
paracetamol and aspirin) for mild pain (Step I), adding weak opioids (e.g. codeine) 
for moderate pain (Step II), and using regular strong opioids such as morphine for 
moderate to severe pain (Step III).   
  
There are a number of different strong (Step III) opioids available, including 
morphine, oxycodone, fentanyl, alfentanil and methadone. Some opioids differ in 
their mode of metabolism and therefore some are recommended as being safer in 
certain circumstances than others e.g. alfentanil in renal failure. There is little 
evidence however to suggest superiority of one opioid over another in terms of 
efficacy (Hanks et al. 2001). There have been very few randomized controlled trials 
comparing different opioids and those that have been carried out have tended to be 
small.   
  
It is standard clinical practice in the UK to commence patients with moderate to 
severe cancer pain on a regular (usually 4 hourly) low dose of a short-acting 
immediate release preparation of an opioid (usually morphine). The opioid dose is 
then adjusted over a number of days depending on the level of pain relief achieved 
and whether or not the patient is experiencing opioid related side-effects.  When / if 
the patient reaches a state where the pain is well controlled without intolerable 
opioid side-effects, he / she is generally converted to a modified release longer 
acting opioid which just needs to be administered once or twice a day.   
2.2 Inter-individual variation in response to opioids for cancer pain  
Clinical experience and a growing number of studies have demonstrated marked 
variability in individual patient’s response in terms of the level of pain relief 
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achieved, the side-effects experienced and the daily dose of opioid required (Argoff 
2010). Up to 30% of cancer patients on oral morphine for pain are known as 
“morphine non-responders” (Cherny et al. 2001; Ross et al. 2005; Oertel et al.  
2006). These “morphine non-responders” present in a number of different ways 
(Mercadante et al. 2006):   
• Patients who achieve good analgesia but with intolerable side-effects.  
• Patients who do not achieve good analgesia because of dose-limiting 
sideeffects.  
o It is not uncommon for opioid side-effects such as nausea, vomiting, 
sedation, confusion, hallucinations and myoclonus to become apparent as 
the dose is increased. These toxicities may often be managed with other 
medications e.g. antiemetics / antipsychotics but sometimes they persist or 
become intolerable and thus dose-limiting.  In this case, patients 
(morphine non-responders) are switched from morphine to an alternative 
opioid.  
• Patients who do not achieve good analgesia but do not experience sideeffects 
either, despite escalating morphine doses.  
The analgesic variability of morphine has been reported as early as the 1980’s when 
Austin et al. (1980) reported dramatic pain responses with minimal changes in 
morphine serum concentrations. Recommendations for individualised doses have 
been suggested (Tamsen et al. 1979) with administrations of morphine varying 
1000-fold between patients (EAPC 1996). Although most work in this area had been 
carried out in patients on morphine, inter-individual variation in response to other 
strong opioids for cancer pain also exists. Emerging evidence suggests that there 
may be two broad groups of opioid non-responders:  
• Patients who do not achieve an adequate clinical response to the initial 
opioid shortly after initiation, when the opioid dose is relatively low, 
reflecting that not all drugs are efficacious in all patients. “Heterogeneity of 
treatment effects” is seen with most pharmaceutical medications and may be 
explained in part by individual pharmacokinetic or pharmacodynamic 
factors.  
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• Patients who appear to become non-responsive to the initial opioid at either 
higher doses or after chronic opioid therapy. This may be due to 
development of physical tolerance to the initial opioid (Slatkin 2009).  
Recognition of this substantial inter-individual variation in response to morphine for 
cancer pain has resulted in the emergence of "opioid switching" as a clinical 
manoeuvre to redress the balance between analgesia and side-effects. If patients are 
considered to be “non-responders” to the initial opioid, it is common clinical 
practice to switch them to an alternative strong opioid (Quigley 2003; Dale et al. 
2011). For example, if a patient is a non-responder to morphine, he / she may be 
switched to oxycodone.   
The theoretical basis supporting this practice is that although all strong opioids act 
on opioid receptors, there are pharmacokinetic and pharmacodynamic differences 
which may explain why some opioids are more or less effective in different patients. 
Morphine exerts its action by binding to the μ-opioid receptor which is expressed by 
the OPRM1 gene. Morphine is metabolised by UDP-Glucuronosyltransferase-2B7 
(UGT2B7) in the liver, principally to morphine-3-glucuronide (M3G) and to a lesser 
extent, morphine-6-glucuronide (M6G). M3G does not have any analgesic affect, on 
the contrary M6G has been found to be pharmacologically active; the extent of 
potency depends on the route of administration. M6G also carries out its 
pharmacological effects on the μ-opioid receptor (Smith and South 2001). 
Oxycodone on the other hand, is a semi-synthetic opioid that has agonist activity on 
the μ, δ and κ-opioid receptors. Oxycodone metabolism is carried out by cytochrome 
P450s. CYP2D6 O-demethylates oxycodone to a potent narcotic analgesic, 
oxymorphone and CYP3A4 and CYP3A5 N-demethylate oxycodone to 
noroxycodone, an inactive metabolite (Baselt 2002). Oxymorphone is a more potent 
analgesic than oxycodone and has a higher binding affinity to the μ-opioid receptor 
than oxycodone. Oxymorphone is further metabolised in the liver by CYP2D6 and 
CYP3A4 (Childers et al. 1979).   
The evidence supporting the efficacy of opioid switching is based on observational 
studies and clinical anecdote, mainly because large randomised controlled trials in 
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this area have not been carried out. However most studies demonstrate a reduction 
in pain and side-effect scores with the alternative opioid (Dale et al. 2011).   
2.3 Pharmacogenetics of opioid response   
Inter-individual variation in response to opioids for cancer pain may be a result of 
factors such as age, gender, disease and lifestyle that affect the pharmacodynamic 
and pharmacokinetic properties of a drug. A recent study of over 2000 patients 
suggested that psychological issues and sleep deprivation may also play a role 
(Knudsen et al. 2011). To date no clinical factors (with the exception of renal 
impairment) have been identified which can be used prospectively to predict opioid 
response in this cohort. Therefore there is a growing interest in the possibility that an 
individual’s genetic makeup may influence opioid response. Pharmacogenetics is 
the study of genetic variations that lead to differing drug responses. The word itself 
is derived from “pharmacology”, the study of drugs activity on the body and 
“genetics”, the study of inherited traits (Bukaveckas 2004). In many areas of 
medicine, pharmacogenetics has yielded some very exciting results. An individual’s 
response to drugs such as irinotecan, abacavir and warfarin can now be accurately 
predicted through integration of genetic and clinical data. This facilitates prospective 
decision making regarding choice of the correct dose of the correct drug for a given 
patient and reduces subsequent side-effects. Thus in a number of different areas of 
medicine including oncology and haematology, pharmacogenetics has 
revolutionised drug prescribing.   
One of the best characterised pharmacogenetic phenomena involves codeine. 
Codeine, a weak opioid, is metabolised to morphine via the genetically 
heterogeneous enzyme CYP2D6 (Dayer et al. 1988; Sindrup et al. 1990). Up to 10% 
of Caucasians (and varying proportions of other populations) lack CYP2D6 activity.  
These are known as “poor metabolisers” and thus experience little analgesia from 
codeine, as compared to “extensive metabolisers”. CYP2D6 gene duplication on the 
other hand is associated with ultra-rapid metabolism of codeine to morphine, found 
in 3% of Caucasians. There is a case report of fatal neonatal opioid toxicity in a 
child who was being breastfed by a CYP2D6 ultra-rapid metabolising mother 
(Koren et al. 2006). Variation in at least 16 alleles has been shown to influence 
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CYP2D6 activity (Sachse et al. 1997). Surprisingly, the impact of genetic variation 
in CYP2D6 on codeine response has not been extensively studied in cancer patients.  
2.4 Previously published data in this area  
There have been a number of clinical studies examining the role of 
pharmacogenetics on response to opioids for cancer pain. Overall the results of these 
genetic association studies have provided limited and often conflicting results.  The 
reasons for this include:  
1. Small study size. Until the recent European Pharmacogenetics on Opioids 
study (EPOS) (Klepstad et al. 2011), the largest genetic association studies in this 
field included less than 300 subjects (Rakvag et al. 2005; Ross et al. 2005). The 
recent EPOS was a multi-centre study in which 2294 cancer patients from 17 centres 
in 11 European countries were included. Although the clinical applicability of the 
genetic association results from this study is somewhat inconclusive, this study 
supports a multi-centre study design to achieve adequate study numbers in a field 
where, due to the poorly nature of many of the patients, recruitment is often 
challenging.  
2. Lack of consensus on study outcomes. There is no consensus in research in 
this field as to the best clinical phenotype of opioid response. Some studies have 
examined daily opioid dose requirements (regardless of the level of pain control 
achieved), some have explored a single side-effect. Similarly different studies use 
different pain measures.   
3. Only a limited numbers of genes and genetic variants have been 
assessed. The opioid pharmacogenetic studies in cancer patients which have shown 
some positive results have primarily focused attention on three genes; OPRM, 
COMT and MDR1. The main findings from these studies are summarised in Table 
1. There has been only one genome-wide association study in cancer patients taking 
opioids, and this data has not been replicated (Galvan et al. 2011).   
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4. Response to opioids for cancer pain is likely to be a complex 
phenomenon, contributed to by a number of interacting clinical and genetic factors 
(Diatchenko et al. 2005). Studies to date have focused on single genetic variants, or 
at most the interaction of two variants. More complex modelling is required to 
explore the concept of epistasis i.e. gene-gene and gene-environment interactions 
(Moore 2003).   
A patient’s response to either morphine or oxycodone may depend on a number of 
factors including their body’s ability to carry out drug absorption, distribution, 
metabolism and elimination. Resultant drug concentration at the target site and the 
number and morphology of target receptors, together with variation in multiple 
downstream events after receptor / ligand binding will also influence individual 
response. Thus, genetic variation of multiple genes may influence an individual’s 
response to opioids (Ross et al. 2005).   
Single nucleotide polymorphisms (SNPs) are the most common type of genetic 
variant at a DNA level. A SNP represents a change in a single nucleotide at a 
particular position along the DNA strand. All published genetic association studies 
of response to opioids for cancer pain have examined SNPs. DNA deacetylation, 
phosphorylation and methylation can also affect drug response as these variations 
can alter the expression of a gene (Doehring et al. 2011). Former heroin addicts 
have a higher level of methylation in the promoter region of the OPRM1 gene 
compared to control populations (Nielsen et al. 2010).  Associations between degree 
of methylation and alcohol dependence and nicotine addiction have also been found 
(Bleich et al. 2006; Philibert et al. 2008). Due to these epigenetic changes, the 
expression of the μ-opioid receptor may be altered therefore altering efficacy 
(Nielson et al. 2010). Similarly, links between methylation of the COMT gene and 
nicotine dependence have been found (Xu et al. 2010).  
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Table 1: Summary of the published pharmacogenetic studies of response to opioids for cancer pain*    
 
Genes  
 
 
Author  N  
exa mined  
Opioid  Clinical outcome  Type of study  
Klepstad  
  
  
Rakvag  
Reyes - Gibby  
99  
  
  
207 197 ,   
207  
OPRM1   
  
  
COMT  
OPRM1 /  
COMT  
Morphine  
  
  
Daily morphine dose  
  
  
  
Prospective observational study. Single  
time point  
  
Campa  145  OPRM1  Morphine  
Change in pain scores b etween baseline and  
week 1  
Prospective observational study. Scores  
measured 1 week apart  
Holthe  ,  77 175  UGT2B7  Morphine  Morphine, M - 3 - G and M - 6 - G concentrations  
Prospective observational study. Single  
time point  
Ross  
186  
  
  
  
  
228  
OPRM1  
Β arrestin2   
Stat6  
UGT2B7  
  
COMT  
MDR1  
Morphine  
“Morphine responders” versus “non - 
responders”.  Morphine responders were  
taking morphine for at least 1 month with  
good pain control and minimal side - effects.  
Morphine non - responders had inadequate  
pain control and/or intolerable  side - effects  
Central side - effects of morphine (drowsiness,  
confusion, hallucinations)  
Prospective observational study. Single  
time point  
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Reyes-Gibby  140  IL-6  
TNF-α  
Any strong 
opioid 
including 
morphine, 
oxycodone,  
fentanyl, 
methadone  
Morphine equivalent daily dose  
Pain severity  
Change in pain severity   
Prospective observational study. Scores 
measured at baseline and 30 days post 
first assessment at the Supportive Care  
Centre for pain management  
Klepstad 2011   2294  
OPRM1,  
OPRD1,  
OPRK1,  
ARRB2,  
GNAZ, HINT1,  
Stat6, ABCB1,  
COMT, HRH1,  
ADRA2A,  
MC1R, TACR1,  
GCH1, DRD2,  
DRD3, HTR3A,  
HTR3B,  
HTR2A,  
HTR3C,  
HTR3D,  
HTR3E, HTR1,  
CNR1  
Any strong 
opioid 
including 
morphine, 
oxycodone,  
fentanyl, 
methadone  
Daily morphine (or morphine equivalent) dose  
Nausea and vomiting  
Extremes of pain relief**  
  
Prospective observational study. Single 
time point  
  
*modified from Droney et al. 2011  
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** A genome wide association study was carried out on a subset of patients (n=1008) using a pooled DNA approach  
  
2.5 Opioid blood concentrations  
Opioid concentrations in the blood vary depending on the route of drug administration, dose 
and frequency of dose, disease, liver and kidney function as well as a person’s ethnicity, age 
and lifestyle. As a result these variables can have a considerable impact on the interpretation 
of drug concentrations found in various samples.  
  
No study to date has been able to find a definitive correlation between opioid blood 
concentrations and clinical response. Therapeutic concentrations of morphine and oxycodone 
range from 0.01 – 0.07 mg/L and 0.015 – 0.062 mg/L in plasma samples, respectively 
(Moffat et al. 2011). Peak plasma concentrations after intramuscular administration of 
oxycodone were 0.034 mg/L whereas slightly higher peak plasma concentrations of 0.038 
mg/L were found in the same patients when given an oral dose of oxycodone (Pöyhiä et al. 
1993). However, cancer patients receiving daily oxycodone doses may have steady-state 
plasma concentrations at much higher concentrations than normal therapeutic doses. Hardy 
et al. (2011) reported plasma concentrations of 0.001 to 0.256 mg/L from cancer patients 
receiving 10 – 600 mg of sustained released oxycodone a day. Similarly concentrations equal 
to or above the therapeutic range were found in cancer patients receiving morphine sulphate 
tablets and morphine sulphate solution for an extended period of time (Neumann et al.  
1982).  
3 Rationale for Study  
At present cancer pain management involves careful titration of an initial opioid (usually 
morphine) according to response (analgesia and side-effects), opioid switching if necessary, 
and further titration of the alternative opioid. There is currently no way of prospectively 
predicting an individual’s response to opioids for cancer pain. In many instances patients 
experience significant pain and / or sideeffects during analgesic stabilisation which is a 
process based largely on trial and error. In terms of cancer pain, the development of a model 
incorporating clinical, genetic and metabolite data may potentially allow prospective 
prediction of response Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief    
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to different opioid drugs. Personalised prescribing involving choosing the correct 
dose of the correct opioid for each individual patient would result in more rapid pain 
management, reduced side-effects and potentially a better quality of life. The studies 
published to date have not provided any data that can be used in such modelling.   
This pilot study has been designed to ascertain the feasibility and logistics of 
recruiting cancer patients, and explore genetic variations which may affect an 
individual’s response to opioid analgesics. The investigators have considerable 
experience in carrying out similar studies in palliative care patient populations (Ross 
et al. 2005; Riley et al. 2006; Ross et al. 2006; Ross et al. 2008) so we are confident 
that the patient requirements for participation in this study are not too burdensome 
or lengthy. The information gathered from this pilot study will be taken forward to a 
large, multi-centre study which will have the aim of obtaining and integrating 
robust, meaningful clinical and laboratory data into a model to explore inter-
individual variability in patient response to opioids.   
4 Aims and Objectives  
4.1 Primary Objectives   
 Feasibility:  
o Evaluate the success rate of patient recruitment   
o Analgesic outcome (focussed observation over 7-10 days on commencement 
of step III opioid morphine/oxycodone).  
o Evaluate any variation between sites in palliative care procedures that might 
impact a larger multicentre trial.  
• Explore the logistics of patient sample collection and analysis. 4.2 
Secondary Objectives  Exploration of polymorphisms within DNA 
sequences that may enhance or decrease opioid response in patient studied 
(analgesia and / or side-effect profile);  
  
 15 o Identify SNPs and the degree of methylation occurring on receptor, metabolising and 
transportation genes and determine its influence on opioid  response.  
• Establish whether oral and parenteral sample collection provides comparable 
information (DNA extraction; Opioid concentrations).  
5 Study Design  
This is a prospective non-interventional observational study. This is not a clinical trial of an 
investigative medicinal product. Study subjects will receive their normal clinical care. 
Involvement in this study will only require volunteers to complete a number of observational 
questionnaires and to provide blood and oral fluid samples (illustrated in Figure 1). 
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5.1 Centres  
Three NHS Foundation Trusts will participate in this pilot study; Royal 
Bournemouth and Christchurch Hospitals, Poole Hospital, and the Royal Marsden 
Hospital (Fulham site, London, and Sutton site, Surrey).  
5.2 Study Population  
The aim is to enrol 200 patients with advanced cancer who are commencing use of 
Step III opioid analgesics.   
5.3 Patient Eligibility Criteria  
A patient will be eligible for inclusion in this study if all of the following criteria 
apply:   
 5.3.1  A cancer diagnosis   
5.3.2 Requiring regular morphine or oxycodone, via any route, to relieve cancer 
related pain.  
 5.3.3  Age 18 years or above.   
 5.3.4  Able to give written informed consent.   
 5.3.5  Able to understand and complete questionnaires in English.  
5.4 Patient Exclusion Criteria  
A patient will not be eligible for the trial if any of the following criteria apply:  
 5.4.1  Does not consent to participate with the study.  
 5.4.2  Patients lack capacity to fully understand their requirements.  
 5.4.3  Patients who are pregnant.  
 5.4.4  Patients with predominately neuropathic pain.  
 5.4.5  Creatinine levels 1.5 x upper limit of normal   
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5.5 Patient Enrolment  
5.5.1 All patients who are being started on a Step III opioid or being converted 
from another Step III analgesic (e.g. fentanyl) to morphine or 
oxycodone, will be considered for entry to the study and will be 
screened for inclusion according to the eligibility criteria above.  
 5.5.2  Inpatients and outpatients will be eligible for inclusion in this 
study.  
5.5.3 Patients currently on Step II analgesia will be given a Patient Information 
Sheet. This would serve to educate the patient regarding the trial and 
empower them to contact the research team directly or indirectly to 
participate if they were to require Step III analgesia in the future.  
5.5.4 Patients can discuss the objectives, risks, benefits, inconveniences, and 
their right to withdraw from the study with a member of the clinical 
team before deciding whether or not to participate in the study.  
5.5.5 Patients will have at least 24 hours to read the Patient Information Sheet 
and discuss with family / friends / members of the clinical team before 
deciding whether or not to participate in the study.  
5.5.6 Patients who do not enter the trial either because of personal preference or 
were missed by the recruitment team will be noted along with reasons 
for lack of inclusion (if patients volunteer a reason).  
5.6 Consent and Confidentiality  
5.6.1  Eligible patients will be approached by a member of the clinical research 
team.  
5.6.2 Consent may be obtained from the patient during routine hospital visits; 
alternatively the patient will be visited by a member of the research team 
at their home address subject to the patient’s consent. Visits to patients’ 
homes will only occur if the patient has given permission for home visits  
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to take place. The patient’s agreement to allow home visits will be 
recorded in the patient’s notes.  
5.6.3 Patients must sign and date an Informed Consent form after having read the 
Patient Information Sheet. Special considerations will be given to 
explain the implications of genetic testing and permission will be gained 
for collecting and storing samples for future analyses. No less than 24 
hours will given from having being invited to taking consent for the 
study.  
5.6.4 Three copies of the consent form will be made, one copy retained by the 
patient, one copy to be stored in the patient’s medical record and the 
remaining copy to be stored in the study file.  
5.6.5 On introduction to the study, patients would be assigned a unique study 
number and data collated will be anonymised. Only designated members 
of the team would have access to patient identifiers.  
5.6.6 All data will be stored in line with principle of GCP, the Data Protection 
Act and trust policies regarding information governance.    
5.7 Initial Patient Assessment  
5.7.1 Information regarding patient’s cancer type, prescribed medication for 
treating the cancer, concomitant medication (including other analgesic 
agents, laxatives and saliva substitutes), biochemistry and haematology 
results and liver and kidney function tests will be collated by a member 
of the research team.  
5.7.2 Patient demographic data will also be collected, including age, gender, 
smoking history and ethnicity.  
5.7.3 Before initial morphine or oxycodone dose or within 24-48 hours of initial 
dose, patients will be asked about pain severity using a validated 
modified Brief Pain Inventory questionnaire. This tool tests five 
dimensions of pain severity using an 11-point numerical rating scale.   
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5.7.4 Opioid-specific side effects will be assessed using a 4 point adjectival 
Likert scale (None, a little, quite a bit, and very much) which has been 
used in a number of studies and is adapted from the European 
Organisation for Research and Treatment of Cancer (EORTC) 
questionnaire.  
5.7.5 On entry to the study, patients will be asked to fill in a constipation 
questionnaire that has been used in a number of previous studies.  
5.7.6 On entry to the study oral health will be scored according to NCI CTC 
(common toxicity criteria) version 3.   
5.8 Additional Patient Assessments  
5.8.1 Patients will be asked to fill in a modified Brief Pain Inventory and opioid 
side-effect assessment within 24 hours of initial opioid dose and every 
other day until they are stabilised on an opioid or switched to an 
alternative opioid.   
5.8.2 A constipation questionnaire will be completed when a stable opioid dose is 
reached or when the patient’s opioid is switched to an alternative opioid.   
a. The definition of whether a patient is a responder or non-responder to their 
opioid will be determined by both objective assessment of the clinical 
team and also whether or not they achieve adequate pain control. A 
patient will be considered a responder to the opioid and having reached a 
stable opioid dose when:  
• the patient requires ≤ 2 breakthrough pain doses / per day,   
• average pain score  ≤4,   
• minimal / acceptable side-effects (≤ “a little” on the likert 
scale).  
There may be circumstances where the patient may be considered to 
have reached a stable opioid dose and therefore would be considered a 
“responder” but who do not fulfil these criteria (e.g. if the patient is 
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unable to carry out pain and side-effect assessments or if the patient is 
experiencing incident pain). The clinical reasons for deviation from 
these factors will be documented.    
5.8.3 In the event a stable dose is not obtained because the patient does not 
achieve adequate pain control despite escalating opioid dose and / or 
experiences dose-limiting opioid side-effects, then he / she will be 
considered a non-responder to that opioid.   
• the patient requires > 2 breakthrough pain doses / per day,   
• average pain score  > 4 for a period up to 10 days,   
• unacceptable side-effects (“very much” on the likert scale).  
5.8.4 Patients who do not respond to the initial study opioid will be switched to 
an alternative opioid. If the patient’s alternative opioid is either 
morphine or oxycodone the patient will remain in the study and asked to 
complete the following questionnaires at the time intervals stated below:  
• Modified brief pain inventory and side effect assessment within 24 hours 
of first opioid dose and every other day until they are stabilised on an 
opioid / switched to an alternative opioid  
• Constipation questionnaire once patient is stable on the opioid / switched 
to an alternative opioid.  
5.8.5 NCI CTC version 3 assessment of oral health will be scored whenever oral 
fluid is collected (see 5.9.1.2)  
5.9 Sample Collection  
5.9.1 Sample Collection   
5.9.1.1  Once consent has been obtained, blood and oral fluid samples will be 
collected.   
a. 2 mL whole blood will be collected in tubes containing EDTA for DNA 
analysis.   
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b. Buccal swabs will be collected using Catch-AllTM Brushes for DNA 
analysis.  
5.9.1.2 Following patient stabilisation on an opioid, a blood and oral fluid sample 
for opioid concentration analysis will be collected or when switched to 
an alternative analgesic.  
a. 10 mL blood samples will be collected in sodium fluoride and potassium 
oxalate tubes for parent drug and metabolite analysis.   
b. 2 mL oral fluid will collected using Concateno Certus oral fluid 
collection devices for parent drug and metabolite analysis.  
5.9.1.3 In the event a stable dose is not obtained and the patients are switched to 
either oxycodone or morphine as the alternative opioid, the following 
blood and oral fluid samples will be collected:  
a. 10 mL blood samples will be collected in sodium fluoride and potassium 
oxalate tubes for parent drug and metabolite analysis.   
b. 2 mL oral fluid will collected using Concateno Certus oral fluid 
collection devices for parent drug and metabolite analysis.  
5.10 Sample Analysis Location and Storage  
 5.10.1  Samples will initially be stored at their respective sites in freezers.  
a. Whole blood preserved with EDTA for DNA analysis stored at -80°C.  
b. Whole blood preserved with sodium fluoride and potassium oxalate for 
toxicological analysis stored at -80°C.  
c. Catch-AllTM buccal swabs for DNA analysis stored at -80°C.  
d. Oral fluid samples in a pH 6 buffer will be stored at -80°C.  
 5.10.2  Tissue trackers will be in place at all sites in line with GCP.  
5.10.3 Parent drug and drug metabolite analyses will be carried out at 
Bournemouth University.   
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a. Material transfer agreements (MTA) will be in place so that blood and 
oral fluid samples can be transported in batches to Bournemouth 
University, Applied Sciences department for toxicological analysis 
by P. McLaughlin.  
5.10.4  Genetic analyses will be undertaken at Bournemouth University, Royal  
Bournemouth hospital Molecular Pathology department and Imperial 
College London. Relevant MTA will be in place to support this. 
External agencies may be recruited to design and run the genetic assays 
for this study.  
5.10.5  Long term storage of;  
a. DNA samples at Imperial College, London and Royal Bournemouth 
Hospital.  
b. Blood and oral fluid samples used for drug analysis at Royal 
Bournemouth Hospital.  
5.10.6 In the event of a participant withdrawing from the study, the subject has the 
option to request that their blood and oral fluid samples and their data 
are destroyed (explained in patient information sheet and consent 
process). If the subject does not request this then their samples and data 
will be used in this study.  
a. Samples that have been requested to be destroyed will be incinerated 
at their respective hospital  
5.11 Study Endpoints  
5.11.1  Patients will have completed the study when they have:  
a. Completed the modified Brief Pain Inventory and side effect and 
constipation assessments when stabilised on a study opioid / switched 
to a non study opioid.  
b. Provided blood and oral fluid samples for parent drug and metabolite 
analysis when stabilised on a study opioid / switched to a non study 
opioid.  
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 5.11.2  Patients will terminate the study prematurely if;  
a. Non-response to opioid morphine / oxycodone and switched to an 
alternative opioid treatment.  
b. Patient dies.  
c. Patient stops taking Step III opioids on clinical grounds.  
d. Patient clinically deteriorates or loses capacity and is unable to 
complete study requirements.  
6 Sample Analyses  
6.1 Genetic Analysis  
6.1.1 Blood and oral fluid samples would be used to sequence the individuals 
DNA to help identify regions which affect their response to opioid 
analgesia. Sequences for genes involved in opioid metabolism, 
transportation and receptor genes will be obtained from online databases 
such as NCBI to help identify SNPs, methylated regions and design 
primers.  
6.1.2 Candidate genetic variants which effect the metabolism, transportation and 
receptor sites for morphine and oxycodone, such as, but not limited to, 
µ-opioid receptor, β-arrestin2, stat6, UGT2B7, HNF1-α, OCT-1, MDR-
1, COMT, CYP3A4, CYP3A5, -opioid receptor will be examined and 
explored. Potential candidate genes and SNPs for which assays have 
already been validated in our laboratory are included in appendix 17. 
Samples will be genotyped using SSP-PCR.  
6.1.3 Oral swabs will be collected using CatchAllTM Brushes and DNA 
quantified using Human Quantifiler® kit and the 48 well StepOneTM 
real-time PCR instrument (Applied Biosystems). DNA would be 
extracted from blood using the Qiagen DNeasy Blood and Tissue Kit 
and quantified in the same manner as the oral swab.  
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6.1.4 To identify new SNPs and areas of methylation, the Applied Biosystems 
Genetic Analyzer 310 will be used which has the ability to sequence 
regions up to 500 bp.   
6.2 Opioid Quantification  
6.2.1  Whole blood: Monitor opioid concentrations by quantifying morphine, 
oxycodone and their metabolites using Gas Chromatography – tandem 
Mass Spectrometry (GC-MS/MS) and/or High Pressure Liquid 
Chromatography – tandem Mass Spectrometry (HPLC-MS/MS)  
6.2.2 Oral fluid: The oral fluid collected will be diluted with a buffer and 
analysed using GC-MS/MS or HPLC-MS/MS as per blood analysis.  
7 Statistical Considerations  
A study population of 200 has been chosen to ensure that meaningful data can be 
collected to explore the secondary objectives of this pilot trial. The primary 
objective, ascertaining the feasibility and logistics of carrying out a study of this 
nature, could be carried out with a smaller population however there are many 
variables within this study which will affect the statistical significance of the results 
we obtain. Patients will be taking either morphine or oxycodone, they will be of 
various ages, gender and ethnicity so a larger population is needed to determine 
genetic variants which affect patient response to morphine / oxycodone analgesics.  
Initially the data will be explored using morphine responder versus non-responder as 
the primary clinical outcome. This study will focus on the early stage of morphine 
response versus non-response, which is likely to be due to pharmacokinetic and 
pharmacodynamic differences rather than later changes in response which are likely 
to be related to the development of tolerance. The clinical data will also be explored 
to define the clinical phenotype of opioid response using more detailed pain and 
side-effect scores.  This study is powered to 200 based on the primary clinical 
phenotype of morphine responder versus non-responder. Up to 30% of cancer 
patients are “morphine non-responders”. Therefore it is expected that approximately 
140 morphine responders and 60 morphine non-responders will be recruited to this 
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study. These numbers are comparable to studies previously carried out in this field 
(Rakvag et al. 2005; Ross et al. 2005). These numbers are sufficient to allow 
preliminary exploration of approaches for clinical phenotype definition 
incorporating pain and side-effect scores and to build preliminary multi-variate 
models of genegene and gene-environment interactions.   
The patient samples will undergo genetic screening in addition to opioid 
quantification. Exploratory relationships found between DNA polymorphisms and 
analgesic effect will be noted and carried forward to a multi-centre study where 
statistical power will be obtained by using a large study population and sample size 
can be more reliably defined using the initial estimates. The indicative information 
provided by this study can aid the choice of genetic variations analysed in the larger 
collaborative study. This study requires multivariate analysis due to the volume of 
data and variable data to be collected. SPSS software will be used to find 
statistically significant associations and trends. Preliminary modelling will be 
carried out to explore gene-gene and gene environment interactions.   
7.1 Hypotheses  
Null hypothesis 1: There is no relationship between pain control and opioid:   
a) Receptor phenotypes;     
b) Transporter phenotypes;     
c) Metabolising phenotypes.  
  
Null hypothesis 2: There is no relationship between side effects and opioid:   
a) Receptor phenotypes;     
b) Transporter phenotypes;     
c) Metabolising phenotypes.  
  
Null hypothesis 3: There is no methylation in the:  
a) Receptor;     
b) Transporter;     
c) Metabolising   
genes that will affect the patients response to opioid analgesia.  
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Null hypothesis 4: There is no association between opioid concentrations, parent 
drug or metabolites, and opioid:  
a) Receptor phenotypes;     
b) Transporter phenotypes;     
c) Metabolising phenotypes.  
  
Null hypothesis 5: Oral swabs and blood samples will be equal in enabling quality 
DNA extraction.  
  
Null hypothesis 6: Oral fluid and blood samples will be equally sensitive for opioid 
concentration evaluation.  
7.2 Statistician  
Professor Peter Thomas, Professor of Health Care Statistics and Epidemiology, 
Bournemouth University, Dorset.  
8 Safety Reporting  
This is an observational non-interventional study. This trial is designed to identify 
patients who are not responders to either morphine or oxycodone i.e. they may 
experience inadequate analgesia or they may experience side-effects from morphine 
or oxycodone. The clinical and research team may be alerted to the fact that the 
patient is not responding to their current opioid by the patient presenting with  
“opioid toxicity”.  In some instances these side-effects or lack of adequate analgesia 
may necessitate hospitalisation. The presence of opioid-specific side-effects or 
hospitalisation in this instance is not considered an adverse event and will be 
recorded on the relevant CRF in the relevant section.   
Many, if not most, of the patients who are entered onto this trial will have 
advanced metastatic cancer. These patients have a limited prognosis and 
withdrawal of some patients due to death or disease progression is expected and 
will be recorded. These are expected outcomes in this study population and do not 
constitute adverse events. The clinical team will be informed of response to the 
opioid as documented in the study files.   
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The following trial-specific situations will be recorded in the CRF and documented 
as adverse events (AE):  
• Death due to opioid toxicity (i.e. respiratory depression that is deemed by 
medical judgement to be due to opioid medication).  
• Opioid toxicity that is life-threatening (i.e. respiratory depression that is   
deemed by medical judgement to be due to opioid medication).  
All members of the research team who observe an AE are responsible for reporting 
it to the Consultant in Charge immediately.   
  
8.1 Protocol Violations  
8.1.1 Protocol violations are any unplanned or unintended changes or 
deviations from the approved study protocol, consent document or 
recruitment process. Protocol violations may be major or minor in 
severity.  
8.1.2 Record of both major and minor protocol violations will be kept 
prospectively by the research team using the trial protocol violation 
log. The log pertaining to each study subject will be kept in their CRF.  
8.1.3 A major protocol violation is a deviation that has an impact on subject 
safety, may substantially alter risks to subjects, may have an effect on 
the integrity of the study data, or may affect the subject’s willingness to 
participate in the study.  Major protocol violations must be reported to 
the Study Sponsor within 24 hours, and CCR and REC must be notified 
in a timely fashion. The PI has ultimate responsibility for reporting 
protocol violations to the Study Sponsor. The Study Sponsor must 
report the major violation to MHRA within 5 working days. Examples 
of major violations include;   
• Failure to obtain informed consent from the subject.  
• Enrolling a subject who does not meet the inclusion and exclusion 
criteria.  
8.1.4 A minor protocol violation is one that does not impact subject safety, 
compromise the integrity of the study data or affect the subject’s 
willingness to participate in the study.  Minor protocol violations do not 
need to be reported immediately. They are documented and submitted to 
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R&D department at annual intervals. Examples of minor violations 
include;  
• Use of unapproved recruitment procedures or materials (slightly 
altered).  
• Inappropriate consent process documentation (dated by someone 
other than the subject, missing signature of person obtaining consent, 
incorrect date on consent).  
• Use of expired or outdated consent or CRF documentation.   
• Due to the poorly nature of many of the study subjects, it is likely 
that study visits or completion of questionnaires may occur outside 
the protocol-prescribed window (for example if the subject was on 
holiday, unable to be contacted, or was ill and was late for 
assessment). Similarly some patients may decline or postpone blood 
or oral fluid sampling.  These will not be considered protocol 
violations as part of this study but the dates of the assessments etc 
will be recorded in the CRF. These data will be important in the 
feasibility analysis.  
9 Quality Control and Assurance  
9.1 Trial monitoring committee  
The Royal Bournemouth Hospital Trial Management Group will monitor the 
conduct and progress of the trial.   
9.2 Committee for clinical research  
Approval has been granted by the R & D department at the Royal Bournemouth  
Hospital.    
9.3 Ethical approval  
Ethical approval has been sought from the South Central Berkshire B Ethics 
Committee.  
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10 Financial and Insurance Matters  
10.1 Study funding  
The trial will be funded by Royal Bournemouth Hospital and Bournemouth 
University.  
10.2 Trial sponsor  
Royal Bournemouth Hospital has accepted the role of sponsor for this study.  
11 Publication Policy  
11.1 Informing subjects of results   
Subjects are asked if they would like to be informed of the results of this study 
during the process of consent and their answer is recorded on the consent form.  If 
they agree to being informed, results will be disseminated by post when the results 
are available.  Results will be presented to the academic staff at Bournemouth 
University as well as the staff at The Royal Bournemouth Hospital, Poole Hospital 
and The Royal Marsden at hospital meetings.  
11.2 Dissemination of results  
Information from this study will be disseminated nationally and internationally.  
11.3 Peer review  
Results of the trial will be collated, analysed and presented for publication in peer 
review scientific journals.  
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12 National/Local Implications for Future Practice, 
Education and Research   
12.1 Change to clinical practice   
The information obtained from this pilot trial regarding patient recruitment rate, 
drop-out rate, compliance with study requirements and potential genetic variations 
involved with opioid response, will enable a large multi-centre study to be carried 
out. A substantial palliative care population will then be recruited so as to ascertain 
links between genetic variations and opioid response.  
  
If genetic variants can be linked with opioid response it will allow physicians to 
administer an appropriate opioid and an effective dose rather than prescribing 
opioids on a trial-by-error basis. This will not only reduce discomfort of the cancer 
patient but also reduce costs to the health care systems as analgesics would be used 
effectively and the need to administer drugs for side effects would also be reduced.  
12.2 Predictive model  
A predictive model of an individual’s likely tolerance to a particular opioid will 
enable appropriate, evidenced-based prescribing of Step III analgesics.  A model 
would minimise the development or avoidance of intolerable side effects and, 
overall, improve in quality of life for each patient.   
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APPENDIX B1.1  
INCLUSION AND EXCLUSION CRITERIA  
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Centre: ………………………………………  Date: ………………… (dd/mm/yyyy)  
  
Patient Identification Number: ………………………………………………  
INCLUSION  
The answer must be YES to all the questions below to be eligible for entry into the study:  
   
Have a cancer diagnosis.  Yes  
Requiring regular morphine or oxycodone, via any route, for cancer related  
pain.  
Age 18 years or above.  Yes  
Able to give written informed consent.   Yes  
Able to understand and complete questionnaires in English.  Yes  
  
EXCLUSION  
The answer must be NO to all the questions below to be eligible for entry in to the study:  
   
Does not consent to participate with the study. No  
Patient lacks capacity to fully understand their requirements. No  
Patient is pregnant. No  
Patient has predominately neuropathic pain. No  
Creatinine clearance 1.5 x upper limit of normal No  
  
  
ELIGIBILITY   
The patient is suitable to be included in the study?  Yes  
If Yes;  
Date Patient Information Sheet and Consent Form received: ……………………..  
(dd/mm/yyyy)  
No  
No  
No  
No  
No  
Yes  
Yes  
Yes  
Yes  
Yes  
No  
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PATIENT 
INFORMATION SHEET  
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‘We would like to tell you about a research study that you might like to 
consider participating in. It is important for you to understand why the 
research is being undertaken and what it will involve. Please take the time 
to read the following information carefully and discuss it with friends, 
relatives and your doctor if you wish. Ask your doctor or nurse if there is 
anything that is not clear or if you would like more information. Thank you 
for reading this.’ What is the purpose of the study?  
A number of studies have been carried out that found links between a 
person’s genetic make-up and how they respond to pain killers. However, 
these studies have either only a small number of participants which means 
that their findings may not represent the wider population or they have not 
collected adequate information about the effectiveness and side effects of 
the pain killers. We would like to carry out a study to evaluate the 
difficulties associated with enrolling patients into studies and monitor how 
well participant requirements are fulfilled. This study will also help establish 
the costs and time restraints involved in exploring patient samples for 
genetic make-up variations and pain killer concentrations. The information 
gained from this pilot study will be carried forward to a large national study 
in which we hope to identify links between genetic make-up variations and 
pain relief response. The ultimate goal is to be able to give patients the 
right pain killer at the right dose first time so effective and fast pain relief 
can be obtained.  
What are we researching and why?  
A number of pain killers can be prescribed for the treatment of cancer pain, 
the two most widely used being morphine and oxycodone. The majority of 
people who receive morphine obtain successful pain relief, however a 
small number of people find that morphine is not effective in relieving pain 
and that it causes side effects. In the event that patients do not receive 
adequate pain relief from morphine, oxycodone has been recommended as 
an alternative pain killer. Nonetheless, ineffective pain relief and side 
effects have been reported with the use of this drug also.  
At the moment, the most effective pain relief drug for cancer patients 
cannot be predicted, nor can the drug which will give the least side effects. 
It is possible that because of individual differences in our genetic make-up, 
some people will achieve better pain control and fewer side effects by 
taking morphine whilst others will find greater benefit with oxycodone. We 
are interested to know if by identifying differences in individual genes we 
  
will be able to predict, in the future, which pain killers will work better for 
individual patients with fewer or no side effects.   
Why would I be invited to take part?  
Your clinician may decide to start you on a new medication for your pain. If 
your clinician chooses either morphine or oxycodone to relieve your cancer 
related pain we would like to record the effectiveness and possible side 
effect profile of these medications.    
Do I have to take part in the study?  
It is up to you to decide whether or not to take part.  If you decide to take 
part you are still free to change your mind or withdraw at any time and 
without giving a reason. This will not affect the standard of treatment or 
care you receive.    
What will happen to me if I take part?  
You will be asked to complete questionnaires about your pain and any side 
effects that you experience at the start of the study and every other day 
until you are stable on a drug.  You will also be asked detailed questions 
about your bowel function at the start of the study and again once you are 
stable on either morphine or oxycodone. Constipation is a common side-
effect of morphine and one which may be improved with laxatives. The 
clinical team will adjust the dose of your laxatives on each occasion in 
order to minimise constipation in conjunction with the NHS Hospital 
Palliative Care symptom control guidelines.   
You will be asked to provide blood and oral fluid samples before you start 
your new medication and once you are stable on a pain killer. In the event 
that you do not respond to the initial pain killer, a blood and oral fluid 
sample will be taken and you will be switched to an alternative drug. If this 
drug is either morphine or oxycodone we will ask you to provide additional 
blood and oral fluid samples until you are stable on the second pain killer. 
The use of any drugs other than morphine and oxycodone to manage your 
cancer pain means you can no longer participate in the study.   
Participation in this study will not affect or delay your pain relief treatment.  
What will happen to my samples?  
The samples collected will be used to analyse the genes involved in 
response to and breakdown of morphine and oxycodone. If you choose to 
withdraw from the study we will retain your samples unless you request 
that your samples be destroyed.  
We would like to store your blood and oral fluid samples for possible future 
tests and if you consent to take part, this includes permission for us to do 
so. We will only do research related to pain and side effect profiles on your 
samples. We will not seek further permission from you for doing any 
  
additional research, but approval will be obtained from the local Ethics 
Committee for any further research using your donation.  
What are the possible side effects?  
Common side effects of morphine and oxycodone include drowsiness, 
sickness, constipation, confusion, hallucinations and itchiness. Most of 
these side effects tend to occur at the beginning of treatment and usually 
wear off after several days.  If symptoms persist it may be necessary to 
either reduce the dose of drug or change to an alternative medication.  
What are the possible benefits of taking part?     
This study will not directly benefit you however the results from this 
research may enable us to find out more about why some people react 
differently to painkillers and this will benefit future patients by allowing us to 
improve our pain management protocols.    
What happens when the research study stops?  
If your pain has improved, you will continue the treatment that you have 
been allocated for as long as you need it.  
Will my taking part in this study be kept confidential?   
If you consent to take part in the research any of your medical records may 
be looked at by a member of the research team. Your name, however, will 
not be disclosed outside the hospital. You will not be identified in any report 
or publication that arises as a result of the study. With your permission, 
your GP and community team will be informed about the study and that 
you are participating in it.  
What will happen to the results of the research study?  
Results of this study are likely to be available in 2014/2015. They will be 
presented in a range of publications.  
Who is organising and funding the research?  
The research will be funded by Royal Bournemouth Hospital, 
Bournemouth.  
Who has reviewed the study?  
South Central Berkshire B Ethics Committee has approved this study.  
What now?  
If you decide to voluntarily take part in this study, then you’ll be asked to 
sign a consent form. You will be given not less than 24 hours to make your 
decision as to whether you wish to take part. With your permission you 
may be visited at your home by a member of the research team who will go 
through the study process thoroughly with you and obtain consent. Ideally 
we would like to see you before you start the new pain killers as we would 
  
like to gather some baseline information. However, if you agree to 
participate and the initial questionnaires have been taken within 48 hours 
of your first dose of morphine or oxycodone you will still be able to 
participate in the study.  
  
What if I have any concerns?   
If you have any concerns or other questions about this study or the way it has 
been carried out, you should contact your study doctor (see below) on telephone 
number (see below), or you may contact the hospital complaints department.   
Any complaints will be assessed on a case by case basis and will be dealt 
with or forwarded on to the relevant regulatory bodies as required. We 
recommend that you obtain a copy of your hospitals complaints procedure 
or policy if you intend to make a complaint.  
Contact for Further Information  
Thank you for reading this information sheet. If you require any further 
information then please contact the following:  Dr. Tamas Hickish on 
01202 704789 (Consultant)  
He can discuss any aspect of the study with you and change your 
treatment if necessary. There will always be someone to talk to you at any 
time of the day or night.  
  
APPENDIX B1.3  
  
  
CONSENT FORM  
  
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief  
  
Centre: ……………………………………… Date: ………………… 
(dd/mm/yyyy)  
  
Patient Identification Number: …………………………………………………………  
  
Name of Chief Investigator: Dr. Tamas Hickish  
  
    
1. I  confirm  that  I  have  read  and  understand  the 
 information  sheet                        dated…......................... 
(Version………) for the above study and that I have had an opportunity to 
ask questions which have been answered to my satisfaction.  
  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving a reason, and my medical care and 
legal rights will not be affected.  
  
3. I agree to give samples of blood and oral fluid for research in this project. I 
understand how the sample will be collected and that giving a sample for 
this research is voluntary.    
  
4. I understand that should I withdraw from this study I can request that my 
data and blood and oral fluid samples will be destroyed.  
  
5. I understand that I will be asked to complete questionnaires regarding the 
pain I experience as well as side effects felt at intervals throughout my 
treatment.  
  
6. I am willing to allow access to my medical records to check that the study 
is being carried out correctly. I have been assured that strict confidentiality 
will be maintained.  
  
7. I understand that my doctor and / or I, (as appropriate) will be informed if 
any of the results of the medical tests done as a part of the research are 
important for my health.  
  
8. I understand that I will not benefit financially if this research leads to the 
development of a new treatment or medical test.  
Please  
INITIAL 
boxes  
  
  
9. I agree that my GP may be notified about my participation in this study.  
  
    
10. I agree to give a sample of blood and oral fluid for research in this project. I 
understand that my blood and oral fluid samples will be stored and I agree 
that  samples may be sent to Bournemouth University and Imperial College 
for analysis.   
  
  
I agree that my samples may be used for possible use in future projects related to pain, 
response to opioids and side effect profiles.  I understand that these projects will be 
carried out by researchers from the Department of Palliative Medicine at  the Royal 
Marsden Hospital and Bournemouth University. The investigators will  not seek further 
permission from me for doing any additional research, but  approval will be obtained 
from the local Ethics Committee for any further research using my donation.  
  
11. I understand that this study will include genetic research aimed at 
understanding more about genetic differences and individual response to 
morphine and  oxycodone.    
  
12. I understand that the results of these investigations are unlikely to have 
any implications for me personally.  
  
  
  
  
I would like to be informed of the results of this study.                                         Yes / No  
  
  
  
..............................................   ........................  ........................................  
Name of Patient        Date    
(BLOCK CAPITALS)  
  
  Signature  
..............................................   ........................  ........................................  
Name of Person obtaining consent Date      
(If different from Principal Investigator)  
  
Signature  
..............................................   ........................  ........................................  
Principal Investigator     Date      Signature  
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Poole Hospital  
Longfleet Road  
Poole  
Dorset   
B
H15 2JB Date: Dear Dr.  
  
RE:   
  
I am writing to inform you that this patient has kindly consented to take part in the 
following study which has been approved by South Central Berkshire B ethics 
committee:  
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief   
Patients whom require the transition from a Step II opioid to a Step III opioid, either 
morphine or oxycodone, are being approached to participate in the study. A blood 
and oral fluid sample will be taken to determine their genetic phenotype and opioid 
metabolite levels. The patients will also be asked to complete pain and side effect 
questionnaires.  
The patients will be asked to provide samples and complete the questionnaires:  
A: At time of entry to the study.  
B: Alternate days from initial dose (pain and side effect questionnaires only).  
C / D: Stabilised on first line opioid / Before opioid switch if non-response to first 
line opioid.  E: Alternate days from initial dose of second Step III opioid (pain and 
side effect questionnaires only).  
F / G: Stabilised on second line opioid / Before opioid switch if non-response to 
second line opioid.  
  
It is anticipated that stability on an opioid takes between 7-10 days. However, if the 
patient does not respond to the initial analgesic the maximum duration for a patient 
to be involved in the study is up to 28 days.  
The pain questionnaire will involve the patients rating their pain on a scale of “0” 
(no pain) to “10” (worst imaginable pain). The side effect questionnaire will ask 
which side effects they experience and at what severity. The constipation 
assessment will ask for descriptions of their stool movement over the period of a 
week.  
I enclose the patient information sheet.  If you require any further information about 
the study, please do not hesitate to contact me.  
Yours sincerely,  
  
  
  
  
  
Dr. Tamas Hickish  
01202 704789  
GP Letter   
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DEMOGRAPHIC INFORMATION  
  
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief   
  
Centre: ………………………………………  Date: …………………  
(dd/mm/yyyy)  
  
Patient Identification Number: ………………………………………………  
Gender  Male / Female  Date of Birth ........................ 
(dd/mm/yyyy)  
Cancer Diagnosis 
...............................................................................................  
Height  .................................(cms)  Weight  ...............(Kgs)  
Is your Natural Hair Colour Red?  Yes / No  
Ethnicity  White;     Black;    
British Caribbean  
Irish African  
Other, please specify Other, please  
.................................... specify  
......................  
Asian;   Mixed;  Indian White and  
Pakistani Black  
Bangladeshi Caribbean  
Other, please specify White and  
.................................... 
 Bla
ck African 
White and  
Asian  
 Jewish;     Chinese  
Sephardic  
Ashkenazi  
Other Ethnic Background, please specify 
……………………………  
Quantity Smoked, on average, per week;  
  
  None  
1-10  
11-20  
21-30  
>20  
Number of hours spent excercising, per week;  
  None  
1-10  
11-20  
21-30  
>20  
   
Demographic Information  
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MODIFIED BRIEF PAIN INVENTORY  
  
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief  
  
 Centre: ………………………………………  Date: …………………  
(dd/mm/yyyy)  
  
Patient Identification Number:  
…………………………………………………………  
  
Time points: (please circle)  
  
A:   At time of entry to the study.  
B:  Alternate day from initial dose (initial opioid).  
C:  Stabilised on first line opioid (approx one week).   
D:   Before second alternative opioid, in the event of non-response to first opioid.   
E:   Alternate day from initial dose (alternative opioid).  
F:  Stabilised on second line opioid (approx one week post-switch).  
G:   Before third alternative opioid, in the event of non-response to first opioid.   
  
1. Throughout our lives, most of us have had pain from time to time (such as 
minor headaches, sprains and toothaches).  Have you had pain other than 
these everyday kinds of pain today?  
        
 1.  Yes      2.  No  
2. On the diagram, shade in the areas where you feel pain.   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
Version 1.0  
 01/11/2011    Page  of 3  
  
Modified Brief Pain Inventory       1  APPENDIX B1.7  
3. What type of pain is the participant describing? (please circle)  
  
Somatic  
  
Body surface (usually sharper and may have a burning or 
pricking quality)or deep tissues (i.e. musculoskeletal)  
Somatic (bony)  
  
dull ache within bones or tender hot spot   
Visceral  
  
Pain due to infiltration, compression, extension or stretching of 
the thoracic, abdominal or pelvic viscera (internal organs within a 
cavity).  Visceral pain is usually not well localized and described 
pressure-like/squeezing.  
Neuropathic  Due to injury to the nervous system, usually burning or tingling. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
B1.7 
  
PAIN SCORES  
  
1. Please rate your pain by circling the one number that best describes 
your pain at its worst in the last 24 hours.  
  
0 1  2  3  4  5  6  7  8  9 10  
No pain              Pain as bad as you can imagine 
    
  
2. Please rate your pain by circling the one number that best describes 
your pain at its least in the last 24 hours.  
  
0 1  2  3  4  5  6  7  8  9 10  
No pain                      Pain as bad as you can imagine  
  
  
3. Please rate your pain by circling the one number that best describes 
your pain on average.  
  
0 1  2  3  4  5  6  7  8  9 10  
No pain                                                        Pain as bad as you can 
imagine  
  
4. Please rate your pain by circling the one number that describes how much 
pain you have right now.  
  
              0   1  2  3  4  5  6  7  8  9  10  
No pain                                                   Pain as bad as you can imagine
                   
  
5. In the last 24 hours, how much relief have pain treatments or medications 
provided for your pain? Please circle the one percentage that most shows 
how much relief you have received?      
              0% 10%  20%  30%  40%  50%  60%  70%  80%  90%  100%  
             No relief              Complete relief  
 
  
 Investigators Signature:             Date:  
  
 
       3 
   
Version 1.0  
 01/11/2011    Page  of 3  
APPENDIX 
B1.8 SIDE EFFECT SCORES  
  
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief  
  
 Centre: ………………………………………  Date: …………………  
(dd/mm/yyyy)  
  
Patient Identification Number: ……………………………………………………  
  
  
Time points: (please circle)  
  
A:   At time of entry to the study.  
B:  Alternate day from initial dose (initial opioid).  
C:  Stabilised on first line opioid (approx one week).   
D:   Before second alternative opioid, in the event of non-response to first opioid.   
E:   Alternate day from initial dose (alternative opioid).  
F:  Stabilised on second line opioid (approx one week post-switch).  
G:   Before third alternative opioid, in the event of non-response to first opioid.   
  
During the Past Week, have you:  
  
    Not at All     A Little     Quite a Bit   Very Much  
Felt Nauseous?  0  1  2  3  
Vomited?  0  1  2  3  
Had a Dry Mouth  0  1  2  3  
Had Constipation?  0  1  2  3  
Had Diarrhoea?  0  1  2  3  
Been Drowsy?  
Felt Confused, Disorientated 
0  1  2  3  
or had Hallucinations?  0  1  2  3  
Had Bad Dreams?  0  1  2  3  
  
Please record any other adverse effects you have experienced with either 
morphine or oxycodone, and score appropriately as above:  
Symptom  Not at All  A Little  Quite a Bit  Very Much  
  
……………………………  
……………………………  
  
Modified Brief Pain Inventory  
Version 1.0  
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0  
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2  
3  
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B1.9 
CONSTIPATION ASSESSMENT  
  
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief  
  
 Centre: ………………………………………  Date: …………………  
(dd/mm/yyyy)  
  
Patient Identification Number:  
…………………………………………………………  
  
  
Time points: (please circle)  
  
A:   At time of entry to the study.  
C:  Stabilised on first line opioid (approx one week).   
D:   Before second alternative opioid, in the event of non-response to first opioid.   
F:  Stabilised on second line opioid (approx one week post-switch).  
G:   Before third alternative opioid, in the event of non-response to first opioid.   
  
Thank you for taking part in this study. Many of these questions appear 
similar. Please answer them individually.  
Are you satisfied with how your bowel has functioned during the PAST  
WEEK? Please Circle  
 YES  NO  
  
In the PAST WEEK have you been constipated? Please Circle  
 Not at All  A Little  Quite a Bit  Very Much  
  
In the PAST WEEK please rate how constipated you have been?  
Please Circle  
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 0  1  2  3  4  5  6  7  8  9  10  
 Not at                    
Worst Imaginable  
All  
  
What does being constipated mean to you?  
……………………………………………………………………………………………….  
…………………………………………………………………………………………………  
  
  
  
Constipation Assessment 
1 
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During the PAST WEEK has your bowel activity been;  
More constipated  Usual for you  Less constipated  
a) A little more constipated a) A little less constipated  
b) Quite a bit more b) Quite a bit less constipated constipated  
c) A lot more constipated c) A lot less constipated  
  
During the PAST WEEK did you open your bowels;  
More frequently  Usual amount  Less frequently  
a) A little more frequently a) A little less frequently  
b) Quite a bit more frequently b) Quite a bit less frequently  
c) A lot more frequently c) A lot less frequently  
  
During the PAST WEEK how many times did you open your bowels?  
More than once a day  _____________ times a week  None at all  
  
Everyone’s USUAL bowel activity is different. How many times a week do you 
USUALLY open your bowels?  
______________________________  
  
During the PAST WEEK what has your stool consistency been like in general? 
(Please tick)  
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Constipation Assessment 
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B1.9 
  
During the PAST WEEK has your stool been HARD? (Please circle)  
 Never  Rarely  Occasionally  Nearly always  
  
During the PAST WEEK did you have to STRAIN to open your bowels? (Please 
circle)  
  
 Not at all  A little  Quite a bit  Very much  
  
Laxatives taken during the PAST WEEK:   
Laxative Name  
Dose and how 
often taken a day?  
How many days was 
the medication 
taken?  
Any side effects with 
this medication?  
        
  
        
  
  
During the PAST WEEK how active have you been?  
 Fully active, able to carry out all activities without restriction  
 Fully mobile, able to carry out light work. Unable to carry out physically 
strenuous activity  
 Mobile, capable of self-care, unable to carry out any work. Up and about more 
than 50% of waking hours  
 Unable to carry out self-care. Totally confined to bed or chair  
  
During the PAST WEEK what has your food intake been like? (Please circle)  
 As usual  Less than usual  More than usual  
  
During the PAST WEEK what has your fibre intake been like? (Please circle)  
 As usual  Less than usual  More than usual  
  
During the PAST WEEK what has your fluid intake been like? (Please circle)  
 As usual  Less than usual  More than usual  
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 Investigators Signature:            Date:  
Constipation Assessment 
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OPIOID HISTORY AND TITRATION  
  
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief  
  
Centre: ………………………………………  Date: ……………(dd/mm/yyyy)  
  
Patient Identification Number: ……………………………………………………  
  
Time points:   
A:   At time of entry to the study.  
B:  Alternate day from initial dose (initial opioid).  
C:  Stabilised on first line opioid (approx one week).   
D:   Before second alternative opioid, in the event of non-response to first opioid.   
E:   Alternate day from initial dose (alternative opioid).  
F:  Stabilised on second line opioid (approx one week post-switch).  
G:   Before third alternative opioid, in the event of non-response to morphine / 
oxycodone.   
PREVIOUS STEP 2 ANALGESIC  
APPROX. START 
DATE  
APPROX. FINISH 
DATE  
Name:      
Dose:  
Time Point A: STEP 3 ANALGESIC (PLEASE CIRCLE)  
 Morphine  Oxycodone  
Dose:  Frequency of Dose:  
TITRATION  TIME/DATE  
Time Point B    
Dose:  
Frequency of Dose:  
 APPENDIX 
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Breakthrough Opioid:  
Dose:  
Frequency of dose:  
Time Point B    
Dose:  
Frequency of Dose:  
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
Opioid history and titration 
1 4 
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TITRATION (Cont.)  
 
TIME/DATE  
Time Point B     
Dose:   
Frequency of Dose:   
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
 
Time Point C     
Dose:   
Frequency of Dose:   
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
 
Time Point D     
Dose:   
Frequency of Dose:   
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
 
Time Point E*     
Morphine  Oxycodone  
Dose:   
Frequency of Dose:   
Time Point E     
Dose:   
Frequency of Dose:   
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
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Time Point E     
Dose:     
Frequency of Dose:     
Opioid history and titration 
APPENDIX B1.10 
  
TITRATION (cont.)  DATE  
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
  
Time Point F    
Dose:  
Frequency of Dose:  
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
Time Point G    
Opioid:  
Dose:  
Frequency of Dose:  
  
*In the event that the patient is not stabilised on either morphine or oxycodone 
and is switched to a non-study opioid complete Time Point G.  
  
  
  
  
  
  
  
  
  
  
  
Opioid history and titration 
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ADDITIONAL TIME POINTS  DATE  
Time Point ___    
Dose:  
Frequency of dose:  
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
Time Point ___    
Dose:    
Frequency of dose:  
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
Time Point ___    
Dose:  
Frequency of dose:  
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
Time Point ___    
Dose:  
Frequency of dose:  
Breakthrough Opioid:  
Dose:  
Frequency of dose:  
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Criteria for changing to an alternative opioid  
  
  
Pilot Trial: Personalising Opioid Therapy for Cancer Pain Relief  
  
Centre: ……………………………………… Date: ………………… 
(dd/mm/yyyy)  
  
Patient Identification Number: …………………………………………………………  
  
  
Please give reason for changing to an alternative opioid  
  
1) Uncontrolled Pain     
  
2) Opioid Toxicity   
  
Side effects which are intractable despite appropriate intervention and at a level 
unacceptable to the patient)  
  
- Nausea    
  
- Vomiting    
  
- Constipation    
  
- Drowsiness    
  
- Hallucinations   
  
- Nightmares    
  
- Pruritis    
  
- Myoclonus    
  
- Any other symptom    
  
Describe………………………………………….  
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Was patient already on medications to control this symptom?     Yes / 
No If so, what (Medication and dose)?  
  
 
.......................................................................................................................................
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Table 1 Concentrations and volumes of DNA samples sent to LGC Genomics for SNP analysis  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
M01  Plasma  4  50  B10  Buccal  17  40  424_12  Liver  28  40  DC06  Blood  6  30  
M02  Buccal  23  40  B11  Buccal  23  40  433_11  Psoas  20  40  DC07  Blood  5  25  
M03  Buccal  14  35  B12  Buccal  15  40  448_12  Psoas  21  40  DC08  Blood  5  20  
M04  Buccal  21  40  B13  Buccal  19  40  480_11  Blood  22  40  DC09  Blood  15  20  
M05  Buccal  16  35  B14  Buccal  13  40  482_11  Blood  12  30  DC10  Blood  8  30  
M06  Buccal  27  40  B15  Buccal  26  40  494_12  Blood  6  40  DC11  Blood  7  35  
M07  Buccal  18  35  B16  Buccal  16  40  500_11  Blood  18  40  DC12  Blood  26  40  
M08  Buccal  21  35  B17  Buccal  22  40  535_11  Blood  18  40  DC13  Blood  23  20  
M09  Buccal  19  35  B18  Buccal  16  40  585_11  Blood  22  40  DC14  Blood  9  40  
M10  Plasma  3  50  B19  Buccal  17  40  576_11  Psoas  19  40  DC15  Blood  21  40  
M11  Buccal  17  40  B20  Buccal  19  40  582_11  Blood  13  30  DC16  Blood  7  20  
M12  Buccal  19  40  055_12  Blood  15  35  604_10  Liver  21  40  DC17  Blood  13  40  
M13  Buccal  24  40  089_12  Liver  26  40  618_10  Liver  30  40  DC18  Blood  19  15  
M14  Buccal  14  40  147_11  Blood  22  40  619_10  Blood  5  40  DC19  Blood  12  35  
M15  Buccal  24  40  163_11  Blood  16  40  636_12  Blood  9  40  DC20  Blood  8  30  
M16  Buccal  26  40  182_12  Liver  17  40  649_12  Psoas  16  40  DC21  Blood  18  30  
M17  Buccal  26  40  207_12  Blood  19  40  652_10  Blood  17  40  DC23  Blood  11  40  
M18  Buccal  20  40  217_12  Blood  14  40  704_10  Liver  25  40  DC24  Blood  15  25  
M19  Buccal  20  40  245_12  Blood  22  40  737_10  Liver  18  40  DC25  Blood  15  20  
M20  Buccal  19  40  288_11  Psoas  8  40  779_11  Blood  21  40  DC26  Blood  16  40  
B01  Buccal  15  40  336_12  Blood  18  40  781_10  Liver  16  40  DC27  Blood  18  40  
B02  Buccal  20  40  345_12  Blood  10  40  801_10  Blood  15  35  DC29  Blood  11  30  
B03  Buccal  11  30  346_12  Blood  16  35  818_10  Blood  22  40  DC31  Blood  17  40  
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Table 4 continued: Concentrations and volumes of DNA samples sent to LGC Genomics for SNP analysis 
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
B04  Buccal  20  40  380_12  Blood  14  40  863_11  Blood  16  40  DC32  Blood  17  40  
B05  Buccal  19  35  383_11  Liver  23  40  873_11  Blood  16  40  DC33  Blood  13  40  
B06  Buccal  21  40  383_12  Blood  23  40  DC01  Blood  7  35  DC34  Blood  14  40  
B07  Buccal  16  40  388_12  Liver  24  40  DC02  Blood  10  30  DC35  Blood  6  40  
B08  Buccal  17  40  396_11  Liver  23  40  DC04  Blood  6  30  DC36  Blood  12  30  
B09  Buccal  21  40  398_11  Blood  7  40  DC05  Blood  5  20  DC37  Blood  16  30  
DC38  Blood  24  40  DC70  Blood  16  25  FH4  Buccal  21  40  RMH36  Plasma  3  50  
DC39  Blood  17  40  DC71  Blood  8  35  FH5  Buccal  16  40  RMH37  Plasma  3  50  
DC40  Blood  14  30  DC72  Blood  14  40  MU1  Buccal  12  40  RMH38  Plasma  3  50  
DC41  Blood  15  30  DC73  Blood  15  40  MU2  Buccal  16  40  RMH39  Plasma  4  50  
DC44  Blood  14  40  DC74  Blood  17  40  RMH02  Plasma  3  50  RMH40  Plasma  1  50  
DC45  Blood  8  30  DC75  Blood  22  40  RMH03  Plasma  3  50  RMH43  Plasma  4  50  
DC46  Blood  17  40  DC76  Blood  25  40  RMH04  Plasma  5  50  RMH44  Plasma  2  50  
DC47  Blood  5  30  DC77  Blood  17  40  RMH05  Plasma  2  50  RMH45  Plasma  2  50  
DC48  Blood  8  30  DC78  Blood  17  40  RMH07  Plasma  3  50  RMH47  Plasma  3  50  
DC49  Blood  18  40  DC79  Blood  10  40  RMH08  Plasma  3  50  RMH48  Plasma  4  50  
DC50  Blood  8  40  DC80  Blood  23  40  RMH10  Plasma  6  50  RMH49  Plasma  3  50  
DC51  Blood  9  25  DC81  Blood  21  20  RMH11  Plasma  3  50  RMH52  Plasma  4  50  
DC52  Blood  9  40  DC82  Blood  9  40  RMH12  Plasma  4  50  RMH55  Plasma  4  50  
DC53  Blood  25  40  DC83  Blood  14  40  RMH13  Plasma  3  50  RMH56  Plasma  4  50  
DC54  Blood  23  15  DC84  Blood  10  25  RMH15  Plasma  2  50  RMH57  Plasma  3  50  
DC55  Blood  15  35  RB1  Blood  19  40  RMH16  Plasma  2  50  RMH58  Plasma  5  50  
DC56  Blood  14  25  RB2  Buccal  16  38  RMH17  Plasma  3  50  RMH59  Plasma  7  50  
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Table 4 continued: Concentrations and volumes of DNA samples sent to LGC Genomics for SNP analysis 
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA 
conc. 
(ng/µL)  
Vol 
(µL)  
DC57  Blood  23  40  RB3  Buccal  19  40  RMH19  Plasma  3  50  RMH60  Plasma  3  50  
DC58  Blood  15  25  RB4  Buccal  22  40  RMH20  Plasma  2  50  RMH61  Plasma  6  50  
DC59  Blood  11  30  RB5  Buccal  14  40  RMH21  Plasma  6  50  RMH62  Plasma  5  50  
DC60  Blood  15  25  RB6  Buccal  12  40  RMH22  Plasma  2  50  RMH63  Plasma  3  50  
DC61  Blood  15  35  RB7  Buccal  18  40  RMH25  Plasma  2  50  RMH64  Plasma  2  50  
DC62  Blood  22  40  RB8  Buccal  18  40  RMH26  Plasma  4  50  RMH66  Plasma  2  50  
DC63  Blood  12  35  PH1  Buccal  24  40  RMH28  Plasma  3  50  RMH68  Plasma  4  50  
DC65  Blood  19  10  PH2  Buccal  23  38  RMH30  Plasma  3  50  RMH70  Plasma  2  50  
DC66  Blood  10  40  PH3  Buccal  21  40  RMH31  Plasma  3  50  RMH74  Plasma  5  50  
DC67  Blood  10  30  PH4  Buccal  27  40  RMH32  Plasma  2  50  RMH77  Plasma  4  50  
DC68  Blood  14  35  FH2  Buccal  14  40  RMH33  Plasma  2  50  RMH79  Plasma  6  50  
DC69  Blood  14  30  FH3  Buccal  14  40  RMH35  Plasma  3  50  RMH81  Plasma  3  50  
RMH82  Plasma  4  50  RMH125  Plasma  3  50  RMH170  Plasma  4  50  BC14  Buccal  22  45  
RMH83  Plasma  12  50  RMH126  Plasma  5  50  RMH171  Plasma  4  50  BC15  Buccal  18  45  
RMH84  Plasma  2  50  RMH127  Plasma  23  50  RMH172  Plasma  2  50  BC16  Buccal  10  45  
RMH85  Plasma  2  50  RMH129  Plasma  2  50  RMH174  Plasma  2  50  BC17  Buccal  9  45  
RMH86  Plasma  6  50  RMH130  Plasma  4  50  RMH175  Plasma  3  50  BC18  Buccal  17  45  
RMH87  Plasma  2  50  RMH132  Plasma  4  50  RMH176  Plasma  3  50  BC19  Buccal  11  45  
RMH89  Plasma  2  50  RMH133  Plasma  2  50  RMH179  Plasma  2  50  BC20  Buccal  10  45  
RMH90  Plasma  3  50  RMH136  Plasma  5  50  RMH182  Plasma  2  50  BC21  Buccal  16  45  
RMH91  Plasma  3  50  RMH137  Plasma  4  50  RMH185  Plasma  4  50  BC22  Buccal  17  45  
RMH92  Plasma  2  50  RMH138  Plasma  5  50  RMH187  Plasma  4  50  BC23  Buccal  13  45  
RMH93  Plasma  2  50  RMH141  Plasma  5  50  RMH191  Plasma  4  50  BC24  Buccal  14  45  
Table 4 continued:  Concentrations and volumes of DNA samples sent to LGC Genomics for SNP analysis   
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Name  Type  DNA conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA conc. 
(ng/µL)  
Vol 
(µL)  
Name  Type  DNA conc. 
(ng/µL)  
Vol 
(µL)  
RMH94  Plasma  5  50  RMH142  Plasma  2  50  RMH192  Plasma  6  50  BC25  Buccal  13  45  
RMH95  Plasma  4  50  RMH144  Plasma  4  50  RMH193  Plasma  5  50  BC26  Buccal  13  45  
RMH97  Plasma  1  50  RMH143  Plasma  4  50  RMH194  Plasma  3  50  BC27  Buccal  16  45  
RMH98  Plasma  2  50  RMH145  Plasma  2  50  RMH198  Plasma  6  50  BC28  Buccal  8  45  
RMH99  Plasma  3  50  RMH146  Plasma  3  50  RMH199  Plasma  3  50  BC29  Buccal  15  45  
RMH100  Plasma  3  50  RMH147  Plasma  3  50  BC01  Buccal  12  45  BC30  Buccal  6  45  
RMH101  Plasma  2  50  RMH148  Plasma  3  50  BC02  Buccal  20  45  BC31  Buccal  12  45  
RMH103  Plasma  7  50  RMH149  Plasma  2  50  BC03  Buccal  17  45  BC32  Buccal  20  45  
RMH104  Plasma  3  50  RMH152  Plasma  6  50  BC04  Buccal  16  45  MC01  Buccal  12  45  
RMH106  Plasma  3  50  RMH153  Plasma  3  50  BC05  Buccal  21  45  MC02  Buccal  14  45  
RMH107  Plasma  3  50  RMH155  Plasma  3  50  BC06  Buccal  17  45  MC03  Buccal  16  45  
RMH113  Plasma  2  50  RMH157  Plasma  2  50  BC07  Buccal  14  45  MC04  Buccal  18  45  
RMH116  Plasma  2  50  RMH158  Plasma  1  50  BC08  Buccal  12  45  MC05  Buccal  20  45  
RMH119  Plasma  6  50  RMH161  Plasma  3  50  BC09  Buccal  11  45  MC06  Buccal  19  45  
RMH121  Plasma  3  50  RMH163  Plasma  4  50  BC10  Buccal  16  45  MC07  Buccal  15  45  
RMH122  Plasma  2  50  RMH165  Plasma  3  50  BC11  Buccal  12  45  MC08  Buccal  15  45  
RMH123  Plasma  2  50  RMH166  Plasma  2  50  BC12  Buccal  12  45  MC09  Buccal  13  45  
RMH124  Plasma  2  50  RMH168  Plasma  7  50  BC13  Buccal  16  45  MC10  Buccal  13  45  
MC11  Buccal  14  45  MC17  Buccal  14  45  MC23  Buccal  15  45  MC28  Buccal  16  45  
MC12  Buccal  19  45  MC18  Buccal  12  45  MC24  Buccal  17  45  MC29  Buccal  18  45  
MC13  Buccal  15  45  MC19  Buccal  11  45  MC25  Buccal  21  45  MC30  Buccal  17  45  
MC14  Buccal  17  45  MC20  Buccal  17  45  MC26  Buccal  13  45  MC31  Buccal  12  45  
MC15  Buccal  19  45  MC21  Buccal  13  45  MC27  Buccal  17  45  MC32  Buccal  18  45  
MC16  Buccal  17  45  MC22  Buccal  13  45                  
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DIFFICULTIES FACED OBTAINING STUDY SAMPLES  
FROM CANCER PATIENTS  
1.0 Delays encountered whilst writing the protocol  
Getting to the stage to be able to recruit patients into the pharmacogenetic study was 
much slower than anticipated. The initial hurdle was writing the protocol. The 
protocol was written in collaboration with clinicians at Bournemouth and London 
who had experience with numerous clinical trials, but due to their workload and the 
distance between Bournemouth and London finding time to discuss the study proved 
to be difficult. Despite the difficulties the collaboration with the Royal Marsden 
Hospital was a necessity as the study would not have been possible without their 
support and guidance. A few of the difficulties encountered when writing the 
protocol are detailed below:  
1.1 Incorporation of patients prescribed morphine and 
oxycodone.  
At the Royal Bournemouth Hospital the practice is to treat cancer pain using 
morphine. The Royal Marsden Hospital and MacMillan unit however use 
oxycodone as an alternative to morphine. If the study was to solely include patients 
prescribed morphine only a small study population would be obtained that would 
have poor statistical power. The study was altered to include patients prescribed 
oxycodone, but only oxycodone as the number of variables introduced had to be 
kept to a minimum.  
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1.2 Patient inclusion / exclusion criteria.   
A number of amendments were made to the inclusion / exclusion criteria as each 
hospital had different definitions and time points as to when patients’ pain relief 
dose should be escalated to Step III analgesics. Also, the use of morphine to relieve 
cancer related pain is in part determined by the patients liver function but both 
hospitals measure liver function using different scales therefore a common unit had 
to be discussed and agreed upon.  
1.3 Transportation of samples.  
All samples from the cancer patients needed to be transported to the Royal 
Bournemouth Hospital or Bournemouth University for drug / genetic analysis. For 
this to happen Material Transfer Agreements (MTAs) were set up.  
1.4 Sample storage.  
It was thought the samples would be analysed and stored at Bournemouth University 
however, the university does not have a human tissue license so the samples had to 
be stored at Royal Bournemouth Hospital and logged into their Tissue Auditor 
system.  
1.5 Determining the study endpoint / when a patient was stable on 
an opioid.  
Different authors have different opinions on what classifies as a stable response to 
an opioid. For example, if a patient has a 4-point improvement change on the 11-
point pain scale from before taking the opioid compared to a week later the patient 
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may be considered an opioid responder. However, the patient could still have pain 
e.g. pain score of 6 which is over the acceptable level of pain. As such, a patient was 
considered stable once their pain was ≤4 on the 11-point pain scale for 3 continuous 
days.  
1.6 Funding of the study, e.g. for research nurses and sample  
analysis.  
Many discussions arose concerning the funding of the pilot study. As the research 
was part-funded by Randox and Bournemouth University the necessary drug 
standards and reagents for toxicological and genetic analysis were funded by them. 
One of the major concerns was who would collect the data from patients, including 
their demographic details and responses to questionnaires. It was proposed that at 
the Bournemouth and Poole sites existing research nurses would take on this project 
in addition to any other work without any additional pay. However for ease, all the 
data collection was the responsibility of the PhD researcher.   
1.7 Statistician  
The Royal Marsden group are very experienced in carrying out pharmacogenetic 
studies so the initial thought was to use their statistician to help interpret the data. 
However the statistician had to be associated with the study sponsor so Professor 
Peter Thomas was approached instead.  
2.0 Delays encountered obtaining approval from the ethical 
committee Ethic delays  
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The second hurdle arose trying to complete the online ethics submission as this was 
a time consuming endeavour. Careful attention had to be made to the phrasing of 
each answer to ensure clarity. Despite having assistance from staff at Bournemouth 
Hospital who were experienced with ethics applications and the time taken to 
complete the protocol and ethics application the South Berkshire Ethics Committee 
expressed a number of concerns with the original proposal. The first ethics 
application was submitted, and was heard on 10th October 2011 but obtained an 
unfavourable opinion.  
The concerns of South Berkshire B Ethics Committee are detailed below.  
2.1 Aims and objectives of the study.  
There was a lot of confusion as to what the study was supposed to achieve. The PhD 
proposal was to create an algorithm to allow clinicians to calculate which opioid to 
use and at what dose based on a patients phenotype and personal data. However, 
previous research demonstrated that large populations were needed to obtain 
associations between pain relief response and genetic variations. To obtain a 
statistically meaningful population a number of hospitals would have to be involved 
which would lead to issues including who would fund the research nurses and how 
would the large volume of samples be analysed. As such, it was decided that this 
project would be a pilot study so the main aim became to determine the feasibility of 
carrying out a pharmacogenetic study and secondary aims would be to find genetic 
variations indicative of affecting patient pain relief response.  
2.2 Population size.  
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A small patient population could be used to achieve the primary aim as the 
recruitment rate and compliance with the study could easily be calculated and 
multiplied up to determine the number of patients that need to be approached in the 
larger study to obtain meaningful samples and data. However, to find genetic 
associations to pain relief response a larger population was needed to obtain 
significant results as there are many variables that may affect the patient response. 
These variables include the patient’s age, ethnicity, gender, cancer type, 
concomitant medication and lifestyle. A larger population would allow the patients 
to be separated into more comparable categories but a sample size of 200 would 
give an indication of genetic variations that may be of interest.  
2.3 Number of samples to be collected and what samples.  
At the beginning of this PhD samples were going to be collected from the cancer 
patients’ post-mortem. However, the Royal Marsden group looked unfavourably 
upon collecting samples post-mortem and this opinion was later mirrored by the 
Ethics Committee despite a Patient Participant Panel approving of the post-mortem 
sample collection. Eventually it was agreed by the participating researchers that only 
antemortem samples would be collected. Blood and oral fluid samples were to be 
collected once patients were stable on an opioid or switched to an alternative opioid. 
Ideally a blood and oral fluid sample would have also been collected following the 
first dose of Step III opioid. However the collection of these samples within a 24 
hour time frame would have proved difficult so this sample collection was removed.  
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2.4 Patient information sheet  
Similarly to the protocol, a number of amendments were made to the protocol 
support documents. The document with the most revisions was the patient 
information sheet as the Ethics Committee felt it did not portray the main aim of the 
study effectively and was not written in a sensitive enough manner for this sick 
study population. The Ethics Committee also required additional information to be 
added to the patient information sheet, the newly added information is shown in 
Figure 1-1.  
“What will happen to the results of the research study? Results of this study 
are likely to be available in 2014 / 2015.  They will be presented in a range of 
publications.”  
“What if I have any concerns? If you have any concerns or other questions about 
this study or the way it has been carried out, you should contact your study doctor 
(see below) on telephone number (see below), or you may contact the hospital 
complaints department. Any complaints will be assessed on a case by case basis 
and will be dealt with or forwarded on to the relevant regulatory bodies as 
required. We  
Figure 1-1. Additional information added to the Patient Information Sheet  
Once the changes had been made, the ethics application was resubmitted and heard 
on  
17th January 2012. A favourable ethical opinion subject to changes was obtained. 
The Ethics Committee however wanted considerable changes to the protocol, either 
emphasising the primary objective relating to feasibility of monitoring patients over 
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a 28 day period, or changing the aim of the protocol completely. The primary 
objective was emphasised in the protocol along with other minor amendments by 
Dr. Tamas Hickish (chief investigator and PhD supervisor) and favourable ethical 
opinion was given on 17th February 2012.   
2.5 Minor and major amendments  
Following favourable ethical opinion to undertake a study no changes can be made 
to the protocol and supporting documents without the approval of either the main 
Ethics Committee or the study sponsor. Minor amendments only have to be 
reviewed by the study sponsor. Within 2 months of obtaining ethical approval to 
undertake the study minor amendments were made to the existing documents and 
additional supporting documents were created. As these changes did not impact the 
study protocol or influence the patients the proposed changes were sent to, and 
approved by, the Royal Bournemouth Hospital acting as study sponsor (Table 1-1).  
Table 1-1. Changes made to existing protocol documents or newly created supporting 
documents  
Document  Changes  
Patient Information Sheet  Contact details for Dr Hickish updated  
GP Letter  Contact details for Dr Hickish updated  
Information for Staff  
Contact details for Dr Hickish updated and document renamed 
“Information for staff” from “Nurse Information”.  
Initial Assessment  
Biochemistry information collated reduced down to test results 
that may have an impact on study outcome.  
Reminder Card  Newly created  
Patient Reminder Cards  Newly created  
Patient Sample Stickers  Newly created  
  
The main Ethics Committee has to approve any substantial protocol amendments; 
these include changes to the study methodology or significant changes to study 
documentation. Throughout the initial months of undertaking the study it was 
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noticed that cancer outpatients requiring either morphine or oxycodone were being 
missed during the recruitment process. The outpatients could be given a patient 
information sheet during their visit with the oncologist but a 24 hour period was 
required between providing the patient information sheet and signing the consent 
form. Therefore it was necessary for the patient to return to the hospital the 
following day to provide consent which is an inconvenience to the patient and would 
make their participation less likely. As such a major amendment was made to the 
protocol that allowed for a member of the research team to visit the patient at their 
home, with the patient’s consent. During the patient’s appointment with the 
oncologist, the patient would be provided with a brief overview of the study and a 
patient information sheet. If the patient was interested in the study and did not object 
to a member of the research team visiting their home they were asked to sign a 
“Home visit permission form”. The oncologist would then contact the PhD 
researcher who would contact and visit the patient 24 hours after the consent form 
was provided. Signing the home visit permission form did not mean the patient was 
obliged to participate in the study. The change to the protocol is underlined and in 
bold in Figure 1-2.   
5.6.1  Consent may be obtained from the patient during routine hospital visits; 
alternatively the patient will be visited by a member of the research team at their 
home address subject to the patient’s consent. Visits to patients’ homes will only 
occur if the patient has given verbal permission for home visits to take place. 
The patient’s verbal agreement to allow home visits will be recorded in the 
patient’s  
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Figure 1-2. Additions made to the protocol  
  
An additional sentence was added to the patient information sheet so patients would 
be aware that a member of the research team may visit them at their home (Figure 
13).  
What now?  
If you decide to voluntarily take part in this study, then you’ll be asked to sign a 
consent form. You will be given not less than 24 hours to make your decision as 
to whether you wish to take part. With your permission you may be visited at 
your home by a member of the research team who will go through the study 
process thoroughly with you and obtain consent. Ideally we would like to see 
you before you start the new pain killers as we would like to gather some 
baseline information. However, if you agree to participate and the initial … 
questionnaires  
Figure 1-3. Additional changes made to the Patient Information Sheet (bold text)  
The amended protocol, patient information sheet and home visit permission form 
were given a favourable opinion by the main Ethics Committee on 11th February 
2013 and resulted in a marked increase in patient recruitment (Figure 1-4).  
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Figure 1-4. Recruitment rate of cancer patients into pharmacogenetic study  
2.6 Extension of study period and annual reviews  
The PhD commenced in October 2010 due to be completed by September 2013; 
therefore the original ethical approval to undertake the pharmacogenetic study 
expired on 2nd October 2013. However as ethical approval was not obtained until 
February  
2012 due to difficulties writing the protocol and ethics application, Bournemouth 
University granted a one year extension onto the PhD. To enable a greater patient 
population to be recruited an extension to ethics was applied for. Approval to 
continue the study until October 2014 was sought with the aim of recruiting a more 
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realistic patient group of 50. South Berkshire B approved the ethics application 
extension.  
From the date ethical approval was obtained to undertake the study, annual reports 
had to be completed. These forms check the progress of the study and ask for details 
on any protocol changes or breaches. Once completed the forms are sent to the R&D 
departments of each participating site as well as the main Ethics Committee.   
2.7 Patient recruitment issues  
Patient recruitment was much slower than anticipated considering the number of 
cancer patients diagnosed each week that may require an opioid analgesic to 
alleviate cancer pain. Initially the recruitment rate was slow as for the first 6 months 
only one oncologist was recruiting patients so that any flaws in the recruitment 
process could be ironed out before additional personnel were involved. In those 6 
months three patients were successfully recruited but obtaining consent in a 
timeframe convenient for the patient proved to be difficult. Following approval from 
South Berkshire B Ethics Committee to visit patients at their homes the study was 
re-presented to clinicians and nurses at each participating NHS site. The study was 
received with enthusiasm by the oncology teams with a good intake of patients over 
the first 4 months (Figure 1-4). A lull in patient recruitment occurred over summer 
2013 as participating clinicians took annual leave and covering clinicians were 
unaware of whether the patient had or had not been informed of the study.   
To encourage patient recruitment following the summer period Multidisciplinary 
Team meetings (MDTs) were attended at each participating NHS site by the PhD 
researcher. The presence of the PhD researcher at the meetings acted as a visual 
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reminder of the study being undertaken and also meant that any patients being 
discussed at the meetings could be flagged by the researcher as a potential 
participant.  
Attendance at these meetings did help identify patients, however the meetings were 
held on Tuesday afternoon in Poole and Thursday mornings in Christchurch, each 
lasting up to 3 hours on a weekly basis. With attendance to the meetings as well as 
the time spent travelling to and from the MDT meetings, valuable experiment time 
was being lost. Therefore, meetings were attended on a fortnightly basis when 
possible. Unfortunately often within the two week period potential participants were 
prescribed either morphine or oxycodone but not considered for the trial (Figure 1-
5). If less than 48 hours had passed since the initial opioid dose and the clinician 
thought the patient had the capacity to provide retrospective answers to the 
questionnaires then the patient could be recruited into the study. More often than not 
the time period was longer than 48 hours.  
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Figure 1-5. Pie chart showing the number of, and reason for, patients not being included in the 
pharmacogenetic study over a six week period.  
The second most common reason for patients not being approached to participate in 
the study was their lack of capacity to complete the questionnaires, as assessed by 
their clinicians. Patients who were thought to lack capacity had diseases such as 
dementia and Alzheimer’s or suffered from confusion and short term memory loss 
that would result in inaccurate answers. In addition, patients who were hard of 
hearing were not approached to participate in the study as it would be difficult for 
the researcher to conduct the necessary questionnaires over the phone.   
Alongside missed participants, some patients could not participate in the study as 
they did not comply with the eligibility criteria. For example, patients who could not 
speak or understand written English were not included in the study.  
The majority of patients who were approached to participate were happy to 
contribute to the study. However, two people did not want to participate. Although it 
  
19 % 
38 % 
19 % 
10 % 
14 % 
> 48 hours since initial opioid use 
Inability to complete questionnaires 
Did not speak English 
Refused to participate 
Did not start opioid within PhD time frame 
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was not necessary for them to provide a reason for refusing the study they both 
volunteered their opinions. The first patient to reject the offer to participate in the 
study did not want anything extra to think about on top of their terminal cancer 
diagnosis. The second patient said they did not want to “feel like a guinea pig”.  
Three patients who agreed to participate in the study, signed the consent forms and 
completed the initial questionnaires did not see the study through to completion as 
they did not require the escalation to morphine or oxycodone for pain relief in the 
time frame of the PhD.   
  
